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ABSTRACT 
Exploring the role of Rapgef6 in neuropsychiatric disorders 
Rebecca Jeannette Levy 
Schizophrenia is highly heritable yet there are few confirmed, causal mutations. In human 
genetic studies, we discovered CNVs impacting RAPGEF6 and RAPGEF2. Behavioral analysis 
of a mouse modeling Rapgef6 deletion determined that amygdala function was the most impaired 
behavioral domain as measured by reduced fear conditioning and anxiolysis. More disseminated 
behavioral functions such as startle and prepulse inhibition were also reduced, while locomotion 
was increased. Hippocampal-dependent spatial memory was intact, as was prefrontal cortex 
function on a working memory task. Neural activation as measured by cFOS levels demonstrated 
a reduction in hippocampal and amygdala activation after fear conditioning. In vivo neural 
morphology assessment found CA3 spine density and primary dendrite number were reduced in 
knock out animals but additional hippocampal measurements were unaffected. Furthermore, 
amygdala spine density and prefrontal cortex dendrites were not changed. Considering all levels 
of analysis, the Rapgef6 mouse was most impaired in hippocampal and amygdala function, brain 
regions implicated in schizophrenia pathophysiology at a variety of levels. The exact cause of 
Rapgef6 pathology has not yet been determined, but the dysfunction appears to be due to subtle 
spine density changes as well as synaptic hypoactivity. Continued investigation may yield a 
deeper understanding of amygdala and hippocampal pathophysiology, particularly contributing 
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Chapter 1: Introduction 
1.1 Clinical introduction to schizophrenia 
 Around the turn of the last century, neuropsychiatrists such as Eugen Bleuler and Emil 
Kraepelin attempted to refine both the nosology and diagnosis of mental disorders. In 1911, 
Bleuler first used schizophrenia as a diagnostic term when he described a group of psychotic 
disorders that shared the four A’s: loosened association, incongruous affect, ambivalence, and 
autism (McGlashan 2011). His concern was accurate diagnosis on the basis of clinical 
symptoms. Bleuler believed the course and outcome for these patients varied, which was an 
ideological departure from Kraepelin’s theory of psychosis. Kraepelin distinguished folie 
circulaire (repetitive madness, now bipolar disorder) from dementia praecox (early dementia, 
today diagnosed as schizophrenia) because he felt those with schizophrenia had an early adult 
onset with gradual and eventual demise into premature dementia (Tandon et al. 2009). He 
emphasized the cognitive decline and poor functional outcome as the hallmarks of disease 
diagnosis and prognosis, instead of clinical symptoms early in the disease process. 
Whereas this divide of symptomatology as opposed to outcomes would separate 
American and European diagnostic approaches for decades, today both doctors’ opinions are 
represented in the diagnosis of schizophrenia. A patient must present with at least two of the 
following symptoms for at least one month: delusions, hallucinations, disorganized speech, 
disorganized or catatonic behavior, or negative symptoms (such as affective flattening, alogia, or 
avolition) (Association 2000). These symptoms must not be dominated by depressive or manic 
features, nor due to any substance or medical condition. In research, the official diagnostic 
criteria are often regrouped into the positive, negative, and cognitive symptoms of schizophrenia 




Figure 1.1 Categories of schizophrenia symptoms 
auditory phenomena such as voices, and delusions or bizarre thoughts and beliefs. The negative 
symptoms listed above indicate social withdrawal from emotion, language, and motivation. 
Finally the cognitive symptoms, so key to Kraepelin’s formulation of the disease, are garnering 
more research interest since they include deficits in verbal fluency and episodic and working 
memory.  
Due to the multifaceted diagnostic criteria, patients with the same diagnosis can be highly 
heterogeneous in their symptoms, presenting a challenge for research. Moreover, there are no 
biomarkers or physical signs that are diagnostic or prognostic with a high degree of certainty. 
Fortunately, diagnostic criteria in the United States and Europe yield over 70% concordance and 
high diagnostic agreement so clinical assessment is usually correct (Jakobsen et al. 2006). Thus 
clinical research in schizophrenia is complicated because diagnosis can never be biologically 
validated and the diagnostic criteria encompass a spectrum of symptoms.  




symptoms such as depression or mania are a consistent component along with positive, negative, 
and cognitive symptoms, the diagnosis of schizoaffective disorder applies. This diagnosis 
represents some of the clinical and genetic overlap between schizophrenia and affective disorders 
discussed below. Second, schizotypal personality disorder shares some clinical aspects with 
schizophrenia, such as strange thoughts and behavior and a lack of social interaction; however 
these symptoms are never as severe as the positive or negative symptoms in schizophrenia. 
Disease incidence is 15.2 cases per 100,000 individuals per year, which yields a lifetime 
risk of 0.7% (McGrath et al. 2004; Tandon et al. 2008). While incidence is equivalent across 
dozens of countries and is not affected by national affluence as measured by gross national 
product, there are slightly higher rates of schizophrenia diagnosis in urban populations and in 
people who have migrated (McGrath et al. 2004; Saha et al. 2006). Men have an onset about 5 
years before women (Hafner et al. 1998). Moreover, the ratio of male to female patients is 1.42:1 
on meta-analysis of epidemiologic data, further indicating the possibility of estrogen or lifestyle 
influence (Aleman et al. 2003).  
Disease onset is typically in young adults in their 20s and 30s, however many prospective 
and retrospective studies have identified a prodromal or premorbid period marked by milder 
symptoms in the years before the first psychotic episode. Analysis of 13 studies following 
prodromal patients found that prodromal diagnosis has on average 81-97% sensitivity (correct 
predictions of prodromal conversion to schizophrenia) and 59-67% specificity (accurate 
predictions of no prodrome remaining psychosis-free), depending on the type of diagnostic 
criteria (Chuma and Mahadun 2011). These results demonstrate that individuals at risk can be 
identified with accuracy; whether intervention with psychological or pharmacological treatment 




The discovery of antipsychotic drugs in the 1960s put an end to earlier “treatments” 
including lifetime institutionalization, insulin coma, and prefrontal leucotomy. Antipsychotics 
are typically classed into first and second generation drugs, with first generation drugs sharing 
dopamine receptor-specific antagonism and second generation medications having more 
widespread neurochemical effects. Yet drug efficacy is proportional to dopamine D2 receptor 
antagonism among both first and second generation antipsychotic medications, and all 
antipsychotic drugs are more effective than placebo in treating positive symptoms of 
schizophrenia (Tandon et al. 2010). Multiple studies have demonstrated that newer drugs are no 
more efficacious for cognitive outcomes, quality of life, or first psychotic breaks than older, less 
expensive drugs (Davidson et al. 2009; Keefe et al. 2007; Swartz et al. 2007). While second 
generation drugs carry lower risk of motor side effects such as extrapyramidal symptoms and 
tardive dyskinesia, they carry metabolic side effects. Since negative and cognitive symptoms are 
poorly treated with available medications, it is critical to come to an understanding of the 
underlying biology of these symptoms so that targeted treatments can be developed with the 
potential to greatly reduce the burden of illness. Potential neurobiological targets for treating 
cognitive and negative symptoms include other dopamine, serotonin, glutamate, and 
acetylcholine receptors. 
 Thanks to modern treatment, the dire downward spiral described by Kraepelin is no 
longer the usual course of schizophrenia, however it is still a devastating lifetime disease. 
Approximately one quarter of patients have full remission and around 50% have partial recovery 
of quality of life (Harrison et al. 2001). Unfortunately, individuals with schizophrenia have a 2.5-
fold mortality hazard compared with unaffected people (Saha et al. 2007). Part of the excess 




increased medical and psychiatric comorbidities. Homelessness, incarceration, and reduced 
productivity or unemployment are all more common among patients with schizophrenia (Tandon 
et al. 2009). Having a family member with schizophrenia was rated as more challenging than any 
other medical diagnosis queried (Magliano et al. 2005). When patient care, medical and legal 
fees, and lost productivity are taken into account, schizophrenia was estimated to cost $62.7 
billion in 2002 in the United States (McEvoy 2007). The financial and emotional costs of 
schizophrenia are staggering. While there is reason for optimism, there is still great concern for 
the welfare of patients and their families that urgently drives research. 
1.2 Schizophrenia etiology 
 The etiology of schizophrenia remains unknown. This hampers the development of novel 
diagnostic tests, therapies, and prevention since neurobiological targets and risk factors are as yet 
unidentified. Analysis of epidemiological, morphological, and behavioral data from individuals 
with schizophrenia as well as animal models have yielded many theories concerning 
schizophrenia etiology, several of which are discussed here. 
1.2.1 Neurotransmitter theories of schizophrenia  
 Changes in neurotransmission are a major area of schizophrenia research due to the 
known drug mechanisms on neurotransmitters. Dopamine is an excitatory neurotransmitter 
released from the ventral tegmental area in several pathways throughout the brain, notably into 
the prefrontal cortex in the mesocortical pathway and via the mesolimbic pathway into the 
nucleus accumbens and amygdala. Since all antipsychotic drugs are dopamine receptor 
antagonists, dopamine dysregulation is clearly important. Moreover, in vivo imaging showed that 
amphetamine given to patients with schizophrenia caused increased psychotic symptoms and 




of D1 receptor occupancy, however, found less dopamine binding in the dorsolateral prefrontal 
cortex that correlated with working memory impairments in patients (Abi-Dargham et al. 2002). 
This pattern of altered dopamine function is supported by animal models such as overexpression 
of the D2 receptor in the striatum that caused increased cortical D1 receptor activation, leading to 
behavioral deficits in prefrontal tasks (Kellendonk et al. 2006). Based on these findings, the 
modern dopamine theory of schizophrenia posits that there is an increase in mesolimbic 
dopamine release onto D2 receptors leading to positive symptoms and a decrease in mesocortical 
dopamine onto D1 receptors causing negative and cognitive symptoms (Simpson et al. 2010). 
Glutamate is the major excitatory neurotransmitter of the central nervous system and its 
release is widespread, unlike dopamine. Glutamate NMDA receptor antagonists such as 
phencyclidine and ketamine can induce psychotic states in individuals with and without 
schizophrenia (Javitt and Zukin 1991; Lahti et al. 2001). Ketamine induced effects on episodic 
memory and psychosis may be localized to the cingulate cortex (Northoff et al. 2005). These 
results suggest both that these drugs can be used to model psychosis and that NMDA receptors 
are potential novel therapeutic targets. A mouse model with 90% reduced NMDA receptor 
subunit 1 expression demonstrated reduced sensorimotor gating, anxiety, and social interaction, 
suggestive of negative symptoms and diminished neural inhibition (Halene et al. 2009). One 
hypothesized relationship between glutamate and dopamine is that reduced glutamate in the 
corticostriatal system causes increased thalamic output, leading to elevated dopamine and 
sensory signal transmission that may fuel positive symptoms (Lang et al. 2007).  
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the brain 
secreted by inhibitory interneurons. Several studies suggest GABA function is diminished in 




anterior cingulate, and superior temporal cortex, as well as striatum and thalamus (Thompson et 
al. 2009). Careful analysis of GABAergic interneurons in postmortem tissue across multiple 
studies found that interneurons are reduced in more superficial layers and increased in deeper 
cortical layers, implicating impaired interneuron migration in prenatal development (Benes 
2012). In a GABA theory of schizophrenia, a loss of cortical inhibition could lead to positive 
symptoms mediated by altered dopamine and glutamate neurotransmission. 
While almost every other neurotransmitter or neuropeptide has been implicated in at least 
one study of schizophrenia, the most significant and validated findings converge on 
dysregulation of dopamine, glutamate, and GABA. Despite much effort, there is still no theory to 
link these neurochemical findings together with environmental, genetic, and animal model 
results to yield one unifying explanation of the etiology of schizophrenia. In light of the 
heterogeneity found in genetic studies, it is unlikely that a single neurotransmitter underlies 
schizophrenia. Instead, it is more likely that a myriad of disruptions, from genetic and 
environmental sources, affect particular circuits, leading to pathophysiology. 
1.2.2 Environmental factors in schizophrenia 
 While schizophrenia is highly heritable (Sullivan et al. 2003), indicating that genetic 
factors (described below) play a significant role in disease etiology, there is substantial risk 
attributable to environmental exposure. These exposures are typically divided into prenatal and 
childhood risk factors. 
 Prenatal risk factors associated with increased schizophrenia diagnosis include maternal 
infection, most notably with influenza, malnutrition in general and specifically deficiency of 
micronutrients such as vitamin D, advanced paternal age, and obstetric complications especially 




reliably generate neurobiological changes and behavioral deficits considered endophenotypes of 
schizophrenia (Brown 2011). These factors seem to converge onto oxidative stress, apoptosis, 
and inflammation pathways that could endanger fetal neurodevelopment. This negative impact 
on neurodevelopment may lead to the changes in brain volume found in adult patients, discussed 
further in Chapter 4 (Figure 1.2). Prenatal rodent models demonstrate that early life insults can 
cause adult behavioral and anatomical deficits, therefore it is possible that a similar timeline of 
pathophysiology may also occur in humans with regard to schizophrenia pathophysiology. 
 
Figure 1.2 Brain regions affected in schizophrenia 
As mentioned above, both urban living and migration appear to be childhood risk factors 
for developing schizophrenia (McGrath et al. 2004). Both of these may cause socioeconomic 
challenges or hypothalamus-pituitary-adrenal stress axis overactivity that could negatively 
impact development and puberty. Another risk exposure is cannabis, the use of which correlated 




prodromal symptoms to rule out self-medication (Brown 2011). Cannabinoid receptors might 
alter dopamine release from the ventral tegmental area to the striatum, thereby worsening 
neurotransmitter imbalances (Dean et al. 2001). 
Environmental factors are an important consideration because they may represent 
possible inroads to disease prevention that are safe and uncontroversial, as opposed to premorbid 
treatment. For example, maternal immunization against influenza and other viruses and prenatal 
education may represent feasible, safe, effective ways to limit schizophrenia risk slightly. 
Furthermore, environmental exposures may interact with genetic factors in determining risk.  
1.3 Genetics of schizophrenia  
Twin studies yielded an estimate of 81% heritability for schizophrenia based on meta-
analysis of the difference between dizygotic twin diagnostic concordance (10-15%) and 
monozygotic twin concordance (40-55%) (Sullivan et al. 2003). This means that a major fraction 
of the predisposition to schizophrenia is attributable to genetic factors as opposed to 
environmental exposure; yet in most families schizophrenia is not a Mendelian disease with 
recessive or dominant inheritance patterns. To add to the complexity, only about one third of 
individuals with schizophrenia have family members with schizophrenia, meaning up to two 
thirds of cases are sporadic, implying the genetic contribution is of low penetrance or due to 
novel mutations (Tandon et al. 2008). Therefore the genetics of schizophrenia are quite complex 
and until recent advances in technology permitted assessment of newly discovered forms of 
genetic variation such as single nucleotide polymorphisms (SNPs) and copy number variants 
(CNVs) there was little agreement on the genetic factors contributing to schizophrenia. 
1.3.1 Common vs. rare variants (adapted from (Levy et al. 2012)) 




Both risk allele frequency and penetrance contribute to disease susceptibility. The common 
disease-common variant (CDCV) hypothesis emphasizes the importance of relatively common or 
high frequency alleles, each of small effect, acting together to increase disease risk. The common 
disease-rare variant (CDRV) hypothesis, conversely, stresses the impact of individually rare yet 
highly penetrant alleles (Figure 1.3). Schizophrenia is undoubtedly caused by both common and 
rare alleles, yet the relative contribution of each hypothesis remains debatable. 
 
Figure 1.3 Comparison of rare and common variants 
Association studies to examine the CDCV hypothesis can either investigate candidate 
genes based on a priori functional or positional evidence or identify candidates using unbiased 
genome wide association studies (GWAS) (Altshuler et al. 2008). Some of the more recent 
GWAS identified additional putative loci for schizophrenia, as well as bipolar disorder and 
autism (Ferreira et al. 2008; O'Donovan et al. 2008; Wang et al. 2009). It is interesting to note 
that the implicated loci do not include any of the previous top candidate genes. After nearly 
1,500 association studies on almost 800 candidate genes for schizophrenia (www.szgene.org), no 




et al. 2008; Need and Goldstein 2009; Sanders et al. 2008). The most recent GWAS meta-
analysis, with almost 10,000 cases and nearly 1 million SNPs, did not identify any individual risk 
loci, but did calculate that a minimum of 23% of schizophrenia risk is due to common variants 
(Lee et al. 2012). When the largest schizophrenia group to date (almost 18,000 cases) was 
analyzed by GWAS, seven loci reached genome-wide significance, but only two of those loci 
had been previously reported, indicating that greater power yields results but minimal replication 
(Schizophrenia Psychiatric Genome-Wide Association Study 2011). Thus common variant 
approaches have not been highly successful in defining specific predisposing genetic factors. 
 Because few families transmit psychiatric disorders in a Mendelian pattern and 
technology was inefficient to recognize rare alleles, until recently, the CDRV hypothesis had not 
received much attention. As technology to detect rare mutations improves, it is becoming 
increasingly clear that rare alleles may contribute substantially to both familial and sporadic 
cases of schizophrenia (Bodmer and Bonilla 2008; ISC 2008; Xu et al. 2008). Ironically, while 
the limitations of linkage studies spurred GWAS to elucidate common risk alleles, it was the 
unintended repurposing of GWAS data for copy number variation detection that provided strong 
supporting evidence for the rare variant hypothesis. With the discovery of copy number variants 
(CNVs) as a form of rare genetic variation, there has been a wave of research demonstrating that 
rare, occasionally recurrent, CNVs contribute to schizophrenia genetic heterogeneity and 
etiology. Plummeting sequencing costs and new arrays containing all known polymorphic exonic 
coding variants will result in many additional studies of rare mutations. This represents a 
conceptual shift in our understanding of the genetic architecture of schizophrenia.  
 Rare variants also help to explain how schizophrenia and other disorders can persist as 




transmission of inherited causal variants (Laursen and Munk-Olsen 2010). This natural selection 
should reduce the incidence of schizophrenia, yet as discussed above the incidence remains 
stable. The evidence for rare mutations, especially de novo germline mutations, provides a 
constant source of new risk (Rees et al. 2012; Xu et al. 2012; Xu et al. 2008). 
1.3.2 Copy number variant results in schizophrenia (adapted from (Levy et al. 2012)) 
Microdeletion of 22q11.2 was one of the first CNV described in schizophrenia 
(Karayiorgou et al. 1995). Since its initial discovery a strong and specific relationship has been 
established between 22q11.2 microdeletion and psychosis; as patients enter adulthood up to one-
third of all individuals carrying this deletion developed either schizophrenia or schizoaffective 
disorder (Gothelf et al. 2007; Murphy et al. 1999; Pulver et al. 1994). A number of studies, 
including those using CNV arrays, indicated that 22q11.2 deletions account for as many as 1–2% 
of sporadic (non-familial) schizophrenia cases (ISC 2008; Karayiorgou et al. 1995; Stefansson et 
al. 2009; Xu et al. 2008). There were initial reports of an association of autism with both 
deletions and duplications at this locus, however a recent meta-analysis demonstrated that 22q11 
duplication is significantly associated with autism and 22q11 deletion with schizophrenia, but 
there is no significant overlap between diagnostic categories and risk variants (Crespi and Crofts 
2012). Thus 22q11 deletion represents the only confirmed, recurrent structural mutation 
responsible for introducing new, sporadic cases of schizophrenia specifically. 
Following rapid developments in high-density microarray technologies designed to 
screen for structural variants throughout the whole genome and advancements in statistical 
analysis methods, several groups in rapid succession provided evidence that rare CNVs 
contribute to the genetic etiology of schizophrenia (Figure 1.4). A high resolution SNP array 




biological parents) determined that de novo or non-inherited CNVs are significantly more 
common in sporadic schizophrenia cases than controls, a 10% rate compared to 1.3%, 
respectively (Xu et al. 2008). In contrast with de novo CNVs, inherited rare CNVs were only 1.5 
times more common in sporadic cases than controls, representing a smaller but significant 
increase from 20% to 30%. Analysis of the genes affected by the de novo CNVs demonstrated 
enrichment for pathways participating in neural development and RNA processing. Conversely, 
a parallel scan that focused on familial schizophrenia (cases with at least one first- or second- 
degree relative with schizophrenia) showed that rare inherited CNVs had a prominent role, being 
almost twice as common in familial cases of schizophrenia compared to sporadic cases or 
controls (Xu et al. 2009), while there was no enrichment of de novo CNVs. Nine of 12 families 
with inherited CNVs showed evidence of CNV and disease co-segregation, increasing the 
likelihood of pathogenicity.  
The role of de novo as compared to inherited CNVs was investigated by several studies 
with similar family-based patient populations. Among 662 schizophrenia trios, the rate of de 
novo CNVs was 5.5% in sporadic cases as opposed to 5.1% in familial cases and 2.2% in 
controls (Kirov et al. 2012). In a smaller study of 177 schizophrenia trios, the de novo CNV rate 
was significantly increased over controls to an odds ratio of 5.0, although de novo CNVs were 
not more common in sporadic compared to familial cases (Malhotra et al. 2011). Alternatively, 
in a study of 631 families with multiple individuals with schizophrenia, the CNV rate was similar 
to nonfamily studies (Levinson et al. 2012). These studies present empirical evidence supporting 
the hypothesis that multiple rare CNVs contribute to the genetic risk of schizophrenia, including 
mutations unique to a family termed “private” CNVs that affect diverse genes. The results also 





Figure 1.4 Diversity of schizophrenia rare risk mutations 
schizophrenia (Figure 1.5). While the overall frequency of rare structural variants is equivalent 
between the familial and sporadic cases (~40%), the heritable nature of variants is markedly 
different. Sporadic schizophrenia is characterized by a significant enrichment of rare de novo 
mutations and only a modest increase in the rate of rare inherited CNVs that do not appear to 
preferentially affect genes. By contrast, familial schizophrenia is characterized by enrichment in 
rare inherited genic CNVs that hypothetically have higher penetrance, while de novo mutations 





Figure 1.5 Divergence in the genetic architecture of familial and non-familial schizophrenia 
Three initial case/control studies (ISC 2008; Stefansson et al. 2009; Walsh et al. 2008) 
also provided evidence for a collective enrichment of rare CNVs in schizophrenia, although they 
could not confirm the importance of CNV heritability or familial as opposed to sporadic 
schizophrenia on mutation rates. Initially, Walsh and colleagues used ROMA on 150 
schizophrenia cases plus controls (Walsh et al. 2008). They reported a significant 3-fold increase 
in the frequency of rare genic CNVs among cases (15% compared to 5% in controls), and a 4-
fold increase when only early-onset cases were considered (20% compared to 5% in controls). In 
an independent sample of 83 early-onset trios, they determined that rare genic CNVs were 
present in 28% of cases compared to 13% of non-transmitted parental chromosomes, a 
significant increase. One recurrent CNV was identified at 16p11.2. Genes affected in the cases 
were mostly involved in brain development and neural function and included ERBB4 and 
Neurexin1 (NRXN1).  
The International Schizophrenia Consortium (ISC) analyzed 3,391 European 




considered, cases had 1.15 times as many CNVs as controls. Furthermore, cases had 1.41 times 
as many genes affected by CNVs. This study confirmed that 22q11.2 deletions were significantly 
associated with schizophrenia and identified two other recurrent CNVs at 15q13.3 and 1q21.1 
that had significantly increased frequency among cases.  
Additionally, Stefansson et al. employed a three-step strategy that partially took 
advantage of family structure to provide additional evidence for the role of rare CNVs in 
schizophrenia (Stefansson et al. 2009). First, they identified 66 de novo CNVs in over 7,500 
control families. Next, they tested these 66 CNVs for association with schizophrenia in 1,433 
cases and over 33,000 controls. Three recurrent deletions at 1q21.1, 15q11.2, and 15q13.3 were 
nominally significant among cases with schizophrenia or psychosis, two of which were also 
reported in the ISC scan (ISC 2008). Finally, they performed association analysis in 3,285 
additional cases and controls, and reported that all three CNVs, but not SNPs within these 
regions, were significantly associated with psychosis with high odds ratios. Moreover, the 
controls included individuals with other psychiatric disorders, thus possibly masking non-
psychotic neuropsychiatric phenotypes associated with these CNVs.  
Next, Need et al. performed both a GWAS and a CNV scan in 871 cases plus controls, 
followed by independent replication (Need et al. 2009). The GWAS yielded no significant 
results. CNV analysis, however, indicated an enrichment of large structural variants (>2 Mb) in 
the cases. CNVs within NRXN1, as well as at 1q21.1 and 22q11.2, replicated earlier findings. 
Three smaller-scale studies also investigated the importance of rare CNVs in the etiology 
of schizophrenia. A scan of schizophrenia trios identified 13 rare CNVs in cases that were absent 
from controls or the CNV database (Kirov et al. 2008). The most interesting findings in light of 




siblings from their unaffected mother, a de novo duplication at 15q13.1, and a deletion at 
16p12.2 inherited from a parent with a non-psychotic affective disorder. Another SNP array 
analysis of 54 Dutch cases discovered CNVs affecting NRXN1, as well as 3 other candidate 
genes (Vrijenhoek et al. 2008). A study in 471 UK schizophrenia cases investigated how CNV 
frequency, size, and copy number were associated with schizophrenia (Kirov et al. 2009). It was 
determined that CNVs with frequency <1% and length >1 Mb were 2.3 times more frequent in 
cases than controls. After combining their data with the Stefansson et al. (2008) and ISC (2008) 
studies in a preliminary meta-analysis, 1q21.1, 15q11.2, 15q13.3, and 17p12 demonstrated 
significant association with a broad schizophrenia diagnosis.  
Subsequent to these initial reports, there have been dozens of additional studies and meta-
analyses confirming the importance of rare CNVs in schizophrenia and other neuropsychiatric 
disorders, some of which are noted in Tables 1.1 and 1.2. Of note, several studies found an 
enrichment of synaptic genes affected by rare CNVs (Glessner et al. 2010; Kirov et al. 2012). 
While all the studies described here were based on blood samples, one study used postmortem 
brain tissue from a variety of neuropsychiatric disorders and, though underpowered to detect a 
change in CNVs in cases, replicated prior findings at 1q21.1 11q25, 15q11.2 and 22q11 in 
individuals with schizophrenia (Ye et al. 2012). Interestingly, a parallel expression microarray 
analysis found that CNVs have variable penetrance on gene expression.  
There are parallel copy number findings in autism spectrum disorder. De novo CNVs are 
enriched in individuals with autism, especially in sporadic cases which had rates ten-fold higher 
than controls and three times higher than familial cases (Sebat et al. 2007). This finding of 
increased overall CNV burden especially de novo CNVs in sporadic cases has been repeated 




CNV analysis in consanguineous families identified fewer de novo and more inherited CNVs 
compared to other autism populations, confirming that de novo CNVs contribute less when there 
is an increased recessive risk burden (Morrow et al. 2008). 
Overall, these studies suggest that rare structural rearrangements collectively contribute 
significantly to schizophrenia risk. De novo mutations appear to contribute more to sporadic than 
to familial schizophrenia. Several loci were discovered in multiple studies, indicating risk loci as 
well as specific genes (Tables 1.1 and 1.2). Thus, rare CNVs represent an important source of 
genetic heterogeneity in the etiology of complex psychiatric diseases such as schizophrenia. 
Table 1.1: Loci Overlapping in CNV Reports  
Locus of 
interest 
Study Candidate genes Odds Ratio 
(95%CI)* 
1q21.1 (ISC 2008);(Stefansson et al. 
2008);(Kirov et al. 2009);(Need et 
al. 2009) 
GJP8 9.1 (4.2–19.4) 
2p16.3 (Kirov et al. 2008);(Walsh et al. 
2008);(ISC 2008);(Vrijenhoek et al. 




15q11.2 (Stefansson et al. 2008);(Kirov et al. 
2009) 
CYFIP1  2.8 (2.0–3.9) 
15q13.1-q13.3 (ISC 2008);(Stefansson et al. 










16p12.2-p12.1 (Kirov et al. 2008);(ISC 2008)  EEF2K, CDR2  






22q11.2 (Xu et al. 2008);(ISC 
2008);(Stefansson et al. 2008);(Need 














Table 1.2: Candidate Genes from CNV Reports 
Study Genes of Interest Pathways of Interest 
(Walsh et al. 
2008) 
ERBB4, NRXN1, SLC1A3, GRM7, 
PRKCD, SKP2, MAGI2, CAV1, 
PRKAG2, PTK2, DLG2, LAMA1, 
PTPRM  
Cell adhesion, glutamate receptors, cell 
cycle, cell growth and extension 
(Kirov et al. 
2008) 
NRXN1, APBA2, NDNL2, TJP1, 
EEF2K, CDR2 
Cell adhesion, amyloid processing, 
calmodulin signaling 
(ISC 2008) CHRNA7, NRXN1, CNTNAP2, 
NOTCH1, PAK7, GJA8 
Cell adhesion, gap junctions, 
acetylcholine receptors 
(Xu et al. 
2008) 








NRXN1, MYT1L, ASTN2 cell/synaptic adhesion 
(Kirov et al. 
2009) 
PMP22, NDE1, NXPH2, GJA8, 
CYFIP1, CHRNA7 
Myelin sheath, cell adhesion 
(Xu et al. 
2009) 
NRG3, RAPGEF2, PEX13, 
KIAA1841, AHSA2, USP34, 
C4orf45, PTPRN2, CSMD1, 
MACROD2, A26B3, LOC441956 
Neural differentiation, peroxisomal 
targeting, ubiquitination 
(Ingason et al. 
2011) 
NTAN1, NDE1 Disc1 signaling, neuronal proliferation, 
memory regulation 
 
1.3.3 Sequencing results in schizophrenia 
 As the costs of exon chip array and whole exome and genome sequencing are driven 
down by new technology, researchers are hopeful to discover some of the missing risk alleles for 
schizophrenia and other disorders. Sequencing the entire genome is more informative as it 
provides data on regulatory domains and as yet unidentified genes, however the cost and data 
informatics burden are currently prohibitive for large studies. To date there have been 3 whole 
exome studies of schizophrenia. Our laboratory reported the results of whole exome sequencing  
of 53 trios with a sporadic case of schizophrenia plus 22 control trios, then on a larger sample of 




schizoaffective disorder plus 34 control trios (Xu et al. 2012; Xu et al. 2011). When the entire 
cohort of Afrikaner cases was considered, 73 out of 146 individuals had at least one de novo 
mutation predicted to be functionally disruptive. This mutation rate was not different from 
controls or statistical expectations, but the ratio of nonsynonymous to synonymous de novo 
mutations, 6.15:1, was significantly higher than the control ratio of 2.2:1 and the expected ratio 
of 2.23:1. This ratio was not affected among inherited mutations, suggesting a specific, 
deleterious accumulation of novel but not inherited mutations in sporadic cases, analogous to 
CNV findings (Xu et al. 2008). Moreover, four genes were affected by two de novo mutations 
each among cases, demonstrating that even rare mutations can cluster in novel candidate genes. 
Individuals with CNVs were excluded from the sequencing study. Thus in the Afrikaner 
schizophrenia population 9.9% of sporadic cases carry de novo CNVs while 17.6% harbor rare 
mutations, yielding an estimate that about a quarter of sporadic cases are due to de novo 
mutations. 
 In a smaller scale study of 14 trios with moderate exome coverage, there was an increase 
in the number of both de novo mutations and nonsense mutations in cases compared to controls 
(Girard et al. 2011). Although this sample was underpowered, the findings are consistent with 
our results. 
 Finally, a study of 166 individuals with schizophrenia or schizoaffective disorder who 
were treatment resistant or had a strong family history of schizophrenia found no significant 
enrichment of rare mutations (Need et al. 2012). They selected the 5155 variants that had a P 
value <0.05 and genotyped these in additional cases and controls, but no loci were significantly 
associated with schizophrenia after correction for multiple comparisons. The authors calculated 




risk of 2-6 but failed to do so, the missing variation in schizophrenia must reside in very rare 
(<1%) mutations. 
 The coming months will surely bring additional sequencing data, especially since 
psychiatric genetics experts have recommended a focus on rare, penetrant mutations such as 
those that result from sequencing (Karayiorgou et al. 2012). It is probable that future sequencing 
results will confirm CNV findings in establishing the importance of rare mutations as causes of 
schizophrenia. 
1.3.4 Interactions among rare and common variants 
 There are several pathways through which common and rare variants may interact in 
determining schizophrenia risk. First, common variants may identify loci affected by rare 
variants, or vice versa. Common variants discovered through SNP association studies are not 
usually deleterious, therefore they are presumed to be in linkage disequilibrium with rare variants 
that are causal (Bodmer and Bonilla 2008). Thus common variants might predict the location of 
rare variants for targeted sequencing of candidate regions. Alternatively, genes carrying rare 
variants may also carry common variants as well, as is the case with DISC1. While DISC1 
mutation was identified as a cause of neuropsychiatric disease including schizophrenia due to a 
truncating translocation in one family, there are many studies of common SNPs within the gene 
that are associated with schizophrenia as well (i.e. (Saetre et al. 2008)). 
Next, common variants might modify rare variants within the same gene or in gene-gene 
interactions. In schizophrenia, such an interaction has been suggested between common CNVs 
affecting glutathione transferases GSTM1 and GSTT2 and rare CNVs elsewhere in the genome 
that also contribute to risk (Rodriguez-Santiago et al. 2010). In hereditary non-polyposis colon 




alleles affecting the same family of glutathione transferases may also modify the severity of 
disease symptoms and onset (Felix et al. 2006; Pande et al. 2008). Common variant risk 
modifiers have also been identified in β-thalassemia (Nuinoon et al. 2010).  
The common variant hypothesis assumes that common alleles interact with each other, 
but there is also growing evidence for interactions among rare variants as well. For example, the 
rare CNV of 16p12.1 deletion was associated with developmental delay, but carrying additional 
CNVs in addition to 16p12.1 deletion predicted worse symptoms (Girirajan et al. 2010). This 
phenomenon has been termed the two hit hypothesis or oligogenic model of rare mutations 
interacting to affect disease phenotype (Coe et al. 2012; Girirajan et al. 2012). This suggests rare 
variants do not need to be 100% penetrant therefore explaining why identified CNVs occur at 
low levels in control populations. Such interactions may also help explain phenotypic variation, 
or the association of one primary CNV with multiple diagnoses. While this primary CNV 
increases neurodevelopmental disease sensitivity, differing secondary rare variants in each 
individual’s genetic background may predispose to one particular disorder over another. These 
secondary variants could be CNVs or smaller mutations that presumably disable disorder-
specific circuitry and molecular pathways that interact with genes altered by the primary CNV. 
As the spectrum of identified risk factors expands, understanding the relationships between 
variants will become an exciting new field. 
1.3.5 Rare variants affect circuitry  
 Rare mutations that have been reported in schizophrenia do not frequently implicate the 
same genes, but they do converge on similar pathways. As mentioned, several CNV studies 
found that affected genes were significantly enriched for synaptic pathways (Glessner et al. 




schizophrenia, bipolar disorder, and autism that genetic findings implicate synaptic and axonal 
pathways (Arguello and Gogos 2012). Moreover, sequence results from our laboratory 
determined that affected genes were more likely to be expressed during fetal development, 
indicating a temporal specificity for neurodevelopment (Xu et al. 2012). This convergence onto 
synaptic function and neurodevelopment could help explain how such a disparate mutational 
load can yield the same clinical disorder and informs our understanding of the neurobiological 
etiology. Given that several neurodevelopmental diseases are inter-related by the same pathways, 
however, this avenue of research does not help differentiate between pathophysiology 
mechanisms. It remains to be proven how these genes affect synaptic function, how disease 
variants compromise this function, and how changes at the cellular level can contribute to the 
complicated clinical spectrum of dysfunction.  
In contrast to temporal and functional approaches, studying brain circuitry via animal 
models may be a faster and more specific way to investigate pathophysiology. Analysis of the 
22q11 mouse model found altered hippocampal-prefrontal cortex connectivity during working 
memory performance (Sigurdsson et al. 2010). Careful assessment of animal models based on 
rare mutations with disease specificity will determine if there are other circuitry phenotypes that 
are unique to particular diagnoses. Future studies could assess circuitry via optogenetics 
approaches or in vivo recordings (Kvajo et al. 2012). Circuit analysis has the added benefit of 
directly explaining pathophysiology on a functional level.  
1.4 Comorbidity and coheritability of schizophrenia with affective and anxiety disorders 
 There is much clinical overlap among patients with schizophrenia, mood, and anxiety 
disorders. The Diagnostic and Statistical Manual requires that for multiple diagnoses to be valid, 




patients with schizoaffective disorder and 17% of those with schizophrenia also have anxiety 
disorder diagnoses (Young et al. 2012). A meta-analysis of anxiety disorder comorbidity 
published prior to the release of that study found that among individuals with schizophrenia 12% 
were also diagnosed with obsessive compulsive disorder, 15% with social phobia, 11% with 
generalized anxiety disorder, 10% with panic disorder, and 12.4% with post-traumatic stress 
disorder (Achim et al. 2011). While some of this prevalence may be overlapping, a conservative 
estimate is that 30-40% of patients have a coexisting anxiety disorder. Among affective 
disorders, the comorbidity of depression is estimated at half of all patients with schizophrenia 
(Buckley et al. 2009). Patients with schizophrenia have 20 times higher risk of being diagnosed 
with bipolar disorder and those with schizoaffective disorder carry over 100 fold increased risk 
of bipolar comorbidity (Laursen et al. 2009). Having a comorbid diagnosis is associated with 
more severe symptoms and worse outcome.  
This high degree of comorbidity may be due to a shared genetic etiology of 
neuropsychiatric disorders or a lack of diagnostic specificity. Genetic studies demonstrate 
overlap among risk loci for schizophrenia, bipolar, and autism spectrum disorders (Carroll and 
Owen 2009). Additionally, relatives of patients with either bipolar disorder or schizophrenia 
have an increased risk of having the other diagnosis (Van Snellenberg and de Candia 2009). 
While genetic overlap between schizophrenia and anxiety disorders is less prevalent, there are 
reports of variants in schizophrenia or anxiety candidate genes such as DTNBP1, GRM1, and the 
serotonin transporter being associated with anxiety diagnosis as well (Ayoub et al. 2012; 
Haddley et al. 2012; Voisey et al. 2010). Some researchers believe there may be a clinical and 
genetic spectrum connecting schizophrenia with affective disorders. This shared genetic risk may 




these diagnoses may predispose patients to other diseases, for example schizophrenia may 
increase the risk of traumatic events occurring and therefore the rate of post-traumatic stress 
disorder. The data suggest that any clinical or animal model should consider assessment of 
affective and anxiety symptoms as well as the core symptoms of schizophrenia. 
1.5 Animal modeling of neuropsychiatric disease 
1.5.1 Animal model validity 
 While epidemiology, in vivo imaging, and treatment outcome studies have greatly 
contributed to our understanding of schizophrenia, there are a multitude of questions remaining 
that can only be answered through experimentation. Animal models provide an ethical way to 
explore questions of disease etiology, pathophysiology, and treatment. In order to gauge whether 
an animal represents an accurate and useful model, there are three criteria to be met: face 
validity, construct validity, and predictive validity (Robbins and Sahakian 1979). Face validity 
requires that a model recapitulates disease symptoms especially behavioral symptoms and 
pathology. Construct or etiological validity means the animal model shares either the genetic or 
environmental etiology of the disease and therefore the ensuing neurobiological mechanisms are 
affected. Predictive validity is when animal models respond the same way humans do to 
treatments or interventions. The goal is to create models that are valid at as many levels as 
possible. 
 Schizophrenia is not an easy disease to model in rodents. Many of the clinical symptoms 
do not apply to rodent behavior making it challenging to prove face validity or to treat those 
symptoms with antipsychotic drugs to establish predictive validity. Moreover, as there are no 
genetic loci or environmental risks that have 100% penetrance for schizophrenia in humans, it is 




some mutations that are amenable to modeling. 
 Several schizophrenia symptoms can be modeled and measured in rodents (Powell and 
Miyakawa 2006). Amphetamine induced hyperactivity in animals is similar to clinical findings 
of increased positive symptoms following the administration of amphetamines and other 
psychostimulant drugs. Social interaction deficits are analogous to the negative symptom of 
social withdrawal. Cognitive symptoms such as reduced working memory and attention are 
analogous to impairments on maze tasks with delays such as the T maze. Finally, sensorimotor 
gating deficits, a specific neurological phenomenon found in patients with schizophrenia, can be 
modeled in rodents as prepulse inhibition. A strong model should find converging evidence of 
deficits in several of these tests (Arguello and Gogos 2006). All of these behavioral domains will 
be discussed in detail and many of them experimentally tested in Chapter 3. 
1.5.2 Rare mutation models of schizophrenia 
 Rare mutations are considered by some, including our laboratory, to be the most 
etiologically valid type of animal model (Arguello et al. 2010). Rare mutations are more likely to 
be causal because they are more likely to be deleterious; common variants are less damaging 
because they persist at high frequencies under natural selection. This is validated by the higher 
penetrance and risk of rare as opposed to common variants (Bodmer and Bonilla 2008). Due to 
high homology and synteny between the human and mouse genome, gene mutations or entire 
CNVs can be faithfully mimicked across species (Kas et al. 2009). Thus the ability to accurately 
model a pathologic mutation holds much promise for understanding the neurobiology and 
pathophysiology. 
 There are several well characterized models of rare mutations in schizophrenia including 




human deletion to varying extends and many of the  findings concur (Kvajo et al. 2012). Our 
laboratory developed the Df(16)A
+/-
 mouse that faithfully models the 1.5Mb 22q11 deletion 
(Stark et al. 2008). Behaviorally, the heterozygous deletion mouse was hyperactive and anxious 
with impaired prepulse inhibition, fear conditioning, and working memory acquisition on the T 
maze but not the Morris water maze (Drew et al. 2011; Stark et al. 2008). In vivo and in vitro, 
hippocampal neurons had decreased dendritic arbors and reduced mushroom spine density and 
width (Mukai et al. 2008). On electrophysiology analysis, there was a reduction in inhibition in 
hippocampal area CA1, diminished long term potentiation, and decreased CA3 neural activation 
(Drew et al. 2011). Many of these findings were phenocopied by heterozygous deletion of 
Dgcr8, a microRNA processing gene within the deleted locus. Dgcr8
+/-
 mice had deficits in 
prepulse inhibition and working memory, but locomotion and fear conditioning were normal 
(Stark et al. 2008). On analysis, these mice shared a reduction in the hippocampal CA1 dendritic 
arbor and mushroom spine width, although spine density was unaffected, while in the medial 
prefrontal cortex there was a reduction in neuron density and spine area (Fenelon et al. 2011; 
Stark et al. 2008). Multiple other genes within the homologous region on mouse chromosome 16 
have also been explored via knock out models. The results indicate that hippocampal 
morphology and electrophysiology are affected by several genes, revealing a shared phenotype 
of pathology. 
 Truncation of DISC1 in one family with high incidence of neuropsychiatric diagnoses 
drew attention to this gene as a rare cause of schizophrenia and other disorders (Millar et al. 
2000). There are multiple models affecting this gene, varying from deletions to dominant 
negative knock in mice, but our laboratory generated a model that most accurately represents the 




tests of working memory (Koike et al. 2006; Kvajo et al. 2008). Morphologically, Disc1 animals 
had reduced cortex volume and apical dendritic arbor length in the prefrontal cortex, as well as 
increased migration and diminished, misoriented dendritic arbors of adult born neurons in the 
dentate gyrus subregion of the hippocampus. When compared with the 22q11 and Dgcr8 models, 
both genetic manipulations converged on altered working memory and changes in the prefrontal 
cortex and hippocampus, the brain regions responsible for generating working memory. This 
highlights the importance of cognitive symptoms, especially working memory, in animal 
modeling. 
 As noted above, multiple CNV studies found deletions affecting NRXN1 in schizophrenia 
as well as autism. When deleted in mice, the homologous gene Neurexin1a was proven to be 
important in hippocampal function. Deletion mice had decreased spontaneous excitatory post-
synaptic current frequency and input/output ratios but inhibitory neurotransmission was 
unchanged, indicating a specific reduction in CA1 hippocampal excitatory synaptic strength 
(Etherton et al. 2009). On behavioral testing, these animals had reduced prepulse inhibition and 
nest building, increased grooming and motor learning on the rotarod, and no changes in social 
interaction, anxiety, or spatial memory. While the hippocampal deficits are in line with other rare 
schizophrenia models, the behavior phenotype is more suggestive of autism symptoms than of 
schizophrenia. This model highlights the issue of pleiotropy in genetics since rare mutations can 
be associated with multiple diagnoses. Although this mouse model is certainly valuable in terms 
of understanding similarities between schizophrenia and autism and the role of Neurexin1 in 
neural function, it does not advance our understanding of schizophrenia-specific 
pathophysiology. The same concern applies to animal models of CNTNAP2 deletion and 16p11.2 




autism (Horev et al. 2011; Penagarikano et al. 2011). In order to generate useful animal models 
of schizophrenia pathophysiology, we should focus on non-promiscuous, disease-specific 
mutations. 
 Although there are many animal models exploring genetic, pharmacologic, and 
environmental contributions to schizophrenia risk, there are very few animal models that target 
rare genetic mutations known to increase the risk of schizophrenia specifically. 
1.6 Statement of hypothesis 
We aim to understand the genetic etiology of schizophrenia by assessing rare mutations 
that are specific to schizophrenia and amenable to animal modeling. We identified RAPGEF6 as 
a putative causal gene in a de novo case of schizophrenia; consequently we speculated that it 
contributes to neuropsychiatric development and function in both humans and rodents. We 
hypothesized that a mouse model knocking out Rapgef6 will have neural and behavioral 
phenotypes associated with schizophrenia. We tested these hypotheses via the following 
experiments: 
1) CNV and whole exome sequencing of schizophrenia cases as described in Chapter 2 
2) Behavioral characterization of a mouse with Rapgef6 deleted, including assessment of 
schizophrenia endophenotypes and amygdala and hippocampal activation, as 
described in Chapter 3 
3) Morphological analysis of neurons in vivo and in vitro from the hippocampus, 
prefrontal cortex, and amygdala, regions associated with both the altered behavioral 
domains and clinical findings in schizophrenia, as described in Chapter 4 
1.7 In the next chapter  




these results to explore the genetic convergence onto chromosome 5q and the RAPGEF6 locus. 
A variety of genetic techniques discussed above identified RAPGEF6 as a potential candidate 





Chapter 2: RAPGEF6 Genetic Findings 
2.0 My role 
 I contributed to some of the probe design and execution of multiplex ligation-dependent 
probe amplification (MLPA) to validate inherited CNVs. I also designed primers and performed 
sequencing to confirm the mutation found via sequencing in RAPGEF2. 
2.1 Introduction: 5q genetic results in schizophrenia 
Prior genetic research in schizophrenia pointed to the RAPGEF6 locus, including 
cytogenetics, linkage, and association studies (Figure 2.1). Early karyotype studies drew 
neuropsychiatric attention to chromosome 5q. An uncle and a nephew concordant for 
schizophrenia as well as facial abnormalities were found to carry, along with the proband’s 
unaffected mother, a trisomy of chr5q11.2-q13.3 (Bassett et al. 1988). Another duplication of 
chr5q35.2-q35.3 was found in a child with microcephaly, mental and motor retardation, and 
facial abnormalities (Chen et al. 2006a). Neither of these duplications covered the RAPGEF6 
locus directly, but this gene was influenced by a 5q deletion (remapped in the current genome) in 
a woman with schizophrenia, mental retardation, and facial abnormalities (Bennett et al. 1997) 
and an insertion of 5q22.1-q31.1 in 10 family members leading to duplications and deletions of 
RAPGEF6 and other genes, both of which led to developmental and anatomic abnormalities but 
not schizophrenia (Arens et al. 2004). 
Linkage results for schizophrenia on chromosome 5 originated with associations at 5q11-
q13 (Sherrington et al. 1988) and 5p14.1-p13 (Silverman et al. 1996). Assessment of specific 
European high risk families drew attention to the RAPGEF6 locus on 5q31.1. Irish schizophrenia 





Figure 2.1 Genetic convergence onto chr5q 
and Israeli sibling pairs revealed linkage to 5q31.1-q31.2 with a combined LOD 1.27 (Schwab et 
al. 1997); Finnish families displayed linkage to 5q31.2-33.1 with LOD 3.16 (Paunio et al. 2001); 
and mixed families were found to be linked to 5q33.2 with LOD 3.6 (Gurling et al. 2001). Two 
studies of isolated cases of schizophrenia also showed linkage to 5q32 and 5q35 in Palau natives 
(Devlin et al. 2002) and 5q 166-176.6cM in European Costa Ricans (DeLisi et al. 2002). After 
these findings, a genome-wide meta-analysis of linkage results found that 5q21-q31 was the 
fourth most important linkage peak in schizophrenia although it did not reach genome-wide 
significance (Lewis et al. 2003). Subsequent to that meta-analysis, one final linkage study was 
published linking 5q31-q35 to schizophrenia, psychosis in schizophrenia, and bipolar disorder 




With the advent of single nucleotide polymorphism (SNP) genotyping, researchers began 
to explore genome-wide association (GWA) with schizophrenia. Assessment of Irish pedigrees 
demonstrated association with 5q31.1 including SPEC2, RAPGEF6, and ACSL6; this finding was 
replicated in an independent sample, but the linkage disequilibrium between these genes was too 
strong to narrow the locus (Chen et al. 2006b). The region encompassing these three genes also 
was implicated in a Han Chinese population analyzing 8 SNPs representing a haplotype block 
across the locus (Luo et al. 2008). The researchers also determined that there was significant 
evidence for positive selection (reduced mutation) on RAPGEF6 across animal species. A 
focused analysis of 5q31-q32 in family trios found a moderate association with Neuregulin2, 
protocadherins, and IL9 (Zaharieva et al. 2008). Disequilibrium testing limited to 8 genes of 
interest within the Irish sample did not find a significant association for RAPGEF6 (Edwards et 
al. 2008). Finally, a genome-wide study performed by grouping SNPs into regional loci using 
genotypes from 4 public data sets found association with schizophrenia at 5q23.3-q31.1 
(Gladwin et al. 2012). Figure 2.1 clearly demonstrates that there was convergence of genetic data 
from a variety of studies onto the RAPGEF6 locus prior to our copy number variation (CNV) and 
sequencing analysis. 
2.2 Methods 
2.2.1 Patient collection (adapted from (Xu et al. 2008)) 
Patient collection methods were described in (Abecasis et al. 2004). Both affected and 
control families were recruited from the Afrikaner population in South Africa. Afrikaner heritage 
was established by surname and by having Afrikaans-speaking grandparents. Diagnostic 
evaluations were done in person by trained clinicians using the Diagnostic Instrument for 




completion of the DIGS, the interviewers assigned DSM-IV diagnoses and completed a detailed 
narrative report. All narratives and DIGS were independently evaluated by trained clinicians in 
New York City. Family history was obtained by a nursing sister, who recorded detailed pedigree 
information, and by the clinical interviewer, who inquired in detail about family history during 
the clinical interview.  
The cohort of 152 sporadic cases consisted of all probands collected from this population 
who satisfied two criteria: i) both biological parents were available for genotyping, and ii) there 
was no history of schizophrenia in first- or second-degree relatives. Similarly, our cohort of 48 
familial cases consisted of all probands collected from this population who satisfied two criteria: 
i) both biological parents were available for genotyping, and ii) there was a positive history of 
schizophrenia in first or second-degree relatives. Finally, the control cohort consisted of 159 
families (triads) recruited from the Afrikaner community. A subset of the control families 
completed a detailed self-report questionnaire that inquired about several mental conditions, 
including phobias, anxiety, depression and history of treatment for any of these conditions. Also, 
family history of any mental illness up to three generations was excluded. Families were 
excluded only if sample failures occurred at the quality control and CNV identification step. 
Even if one of the three DNA samples included in each triad failed, the entire triad was excluded 
from analysis, as the de novo nature of CNV could not be established.  
2.2.2 Copy number variant scan (adapted from (Xu et al. 2008; Xu et al. 2009)) 
We genotyped subjects using the Human Genome-Wide SNP Array 5.0 (Affymetrix), 
which contains 500,568 SNPs, as well as 420,000 additional nonpolymorphic probes that can 
assess copy number (CN) variation across the human genome. All sample processing was 




Following hybridization, we used the GeneChip Command Console (Affymetrix) to acquire raw 
genotyping data. Raw data in the form of CEL files was imported into the Genotyping Console 
(Affymetrix) for quality control analysis and genotype calling using the BRLMM-P algorithm 
(Affymetrix). Average call rate on arrays used in this study was 99.43%.  
We analyzed CEL files from all chips using two software packages, DNA-Chip Analyzer 
(dChip) and Partek Genomics Suite (Partek software, version 6.3 Beta, build #6.07.1127), which 
enable detection of CNVs by performing scaling, normalization, and feature extraction of 
hybridization signal intensities, as well as hidden Markov model (HMM) analysis for inferring 
locus specific CNV status. The entire procedure included five steps: (i) quality control; (ii) CNV 
identification; (iii) de novo CNV detection; (iv) de novo CNV verification by intensity and 
genotyping filters, and (v) de novo CNV confirmation by duplex Taqman quantitative real time 
PCR (qPCR) or inherited CNV confirmation by multiplex ligation-dependent probe 
amplification (MLPA). 
We considered a CNV as inherited only if there was 50% or more overlap in size with a 
variant in its biological parental chromosomes. Inherited rare CNVs detected in subjects and 
their parents were considered only if they involved at least ten consecutive probe sets and did not 
show 50% overlap with a CNV detected in any parental chromosome other than those of the 
biological parents. An alternative criterion (CNVs not showing >50% overlap with the CNV 
collection downloaded from Database of Genomic Variants [hg18 version 3]) was also applied 
with almost identical results.  
A number of rules were applied to determine whether a candidate CNV in a child is a true 
inherited CNV. 1) Average inferred CN of the normal parent should be close to two for an 




be at least 20% greater (for duplication) or less (for deletion) than the normal parent; 2) if a 
stretch of homozygosity was observed within a candidate deletion CNV, the latter was 
considered to be a true positive call. Moreover, observation of the same homozygosity in a child 
and mutation-carrying parent, when the normal parent maintains proper heterozygosity, was 
considered a strong indication of an inherited CNV; and 3) presence of Mendelian 
inconsistencies between the genotype of a child and the normal parent was considered a good 
indicator of the existence of an inherited CNV in the child.  
2.2.3 CNV validation by qPCR and MLPA (adapted from (Xu et al. 2008; Xu et al. 2009)) 
 Real-time quantitative PCR validation was performed using the ABI Prism 7900HT 
System (Applied Biosystems) to confirm candidate de novo CNVs. The TaqMan method was 
used, according to the manufacturer’s guidelines. All PCR primers and probes were custom 
designed (Sigma-Aldrich). All target CNV probes were 5’ FAM and 3’ BHQ™-1 Dual labeled. 
For normalization, a 5’ JOE™ and 3’ BHQ™-1 dual labeled TaqMan probe to the VEGFA locus 
(vascular endothelial growth factor) was used as control. For each candidate de novo CNV, 
genomic DNA samples of the subject and his/her parents were tested simultaneously within one 
run. An aliquot of the genomic DNA from each triad was pooled as the template to obtain a 
qPCR standard curve for each run. For each CNV a duplex PCR reaction was set up containing a 
target gene primer probeset and a VEGFA primer probeset. We conducted 5 replicate PCR 
reactions for each CNV and each triad. The reactions were incubated in a 384-well plate at 95°C 
for 10 min, followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min on a 7900HT (Applied 
Biosystems). The relative levels of gene dosage were determined according to both comparative 
CT method and the standard curve methods described in the ABI company manual. All results 




For MLPA validation, two to three pairs of MLPA target-probes were designed based on 
unique sequences within each CNV region. Additionally, three pairs of MLPA control probes 
from the unique sequences of the VEGFA locus were included in each MLPA reaction. All 
probes were synthetic oligonucleotides. MLPA reagents were prepared according to the 
instructions (MRC-Holland). Final PCR products were analyzed on an ABI3730XL for peak 
identification and quantification. The peak profiles of all test samples were visualized and 
parameters (height and area) were extracted using Peak Scanner Software v1.0 (Applied 
Biosystems). For copy number quantification, peak area and height for each probe was 
normalized to the mean value for all control probes. The relative ratio of each peak was 
calculated by comparisons between the proband sample and the samples of his/her relatives. 
Deletion was identified as relative ratio <0.8 and duplication as relative ratio >1.2. 
2.2.4 Whole exome sequencing (adapted from (Xu et al. 2012)) 
For exome capture and sequencing, genomic DNA (~3 μg) was sheared to 200–300 bp in 
size using a Covaris Acoustic Adaptor. Fragments were then end repaired, polyA tailed and 
ligated to sequencing adaptor oligonucleotides (New England BioLab). Libraries were barcoded 
using the Illumina index read strategy, which uses 6-base sequences within the adaptor that are 
sequenced separately from the genomic DNA insert. Ligated products were size selected during 
purification steps. The DNA library was subsequently enriched for sequences with 5′ and 3′ 
adaptors by PCR amplification using primers complementary to the adaptor sequences (ligation-
mediated PCR, LM-PCR). Exonic DNA was captured using two hybridization systems: Agilent 
SureSelect v2 (n = 85 trios) and NimbleGen SeqCap EZ v2 (n = 180 trios). After capture, 
another round of LM-PCR was performed to generate the final libraries. Each library was 




the Agilent Bioanalyzer. Finally, the molar concentration of each library was measured using the 
size information from the Agilent Bioanalyzer and DNA quantitation information from an RT-
PCR assay (Kapa Biosystems). Each library was normalized to a 10 nM concentration and 
sequenced using an Illumina HiSeq 2000. 
In the exome data analysis pipeline, raw sequencing data were mapped to the human 
reference genome (hg19) using the Burrows-Wheeler Aligner (BWA v0.5.81536). The Genome 
Analysis Toolkit (GATK, version 5091) was used to remove duplicates, perform local 
realignment and map quality score recalibration to produce a cleaned BAM file and then make 
genotype calls for all trios jointly. The resulting variant call format (VCF, version 4.0) files were 
annotated using the GenomicAnnotator module in GATK to identify and label the called variants 
that were within the targeted coding regions and overlap with known and likely benign SNPs 
reported in dbSNP v132. The filtered genotype calls were further validated using the mpileup 
module in SAMtools. Indel calls were made by Dindel software using one cleaned BAM file per 
run. The resulting VCF files were further revalidated using the same SAMtools procedure as for 
the point mutations. To determine potential mutations at splice donor or acceptor sites, GATK 
variant calls were made in a batch fashion (90 samples per batch) that covered each target coding 
region and the 50-bp flanking segments on each side of it. The variants in the resulting VCF files 
were annotated according to refGene-big-table-hg19.txt. A variant was annotated as a 'canonical 
splice-site mutation' if it disrupted the largely invariable core canonical 2-bp acceptor (AG) or 
donor (GU) sites. De novo variants within 10 bp of the exon-intron boundary, included in the 
consensus sequence flanking core canonical splice sites and therefore likely to modulate splicing 
efficiency, were annotated as 'consensus splice-site mutations.' Candidate de novo variants were 




to validate the presence of each mutation in the proband and its absence in the parental genomes, 
using custom primers designed using Primer3 software. The total number of de novo single 
nucleotide variants (SNVs) found and validated in a given cohort was divided by the total 
number of bases analyzed to calculate the per-base rate of point mutation in the captured coding 
sequence. 
The two-sided exact binomial test was conducted using R. Fisher's exact test or the χ-
squared test with Yates' correction was used for the analysis of contingency tables, depending on 
the sample sizes, using R. 
2.3 Results 
2.3.1 Copy number variant scan 
 A whole genome CNV scan in the general population determined that even healthy 
individuals carry on average 11 large scale insertions or deletions (Sebat et al. 2004). We 
speculated that some of these CNVs, specifically de novo and rare inherited CNVs, contribute 
causally to schizophrenia and other psychiatric disorders. To assess the CNV burden in disease, 
we analyzed trios of an affected patient and his or her parents. The resulting CNV data were 
analyzed separately for familial (at least one first or second degree relative was also affected) 
and sporadic (no family history) schizophrenia to determine if they had differing large scale copy 
number burdens. The results and implications for understanding the genetic basis of 
schizophrenia etiology were discussed in Chapter 1.  
Because both de novo and rare inherited mutations have low allele frequency in the 
population, most genetic analysis will be under-powered if a specific mutation target is under 
investigation. Alternatively, we wanted to test the hypothesis that mutations affecting a specific 




A de novo deletion of RAPGEF6 occurred in a sporadic case of schizophrenia (Figure 
2.2A) (Xu et al. 2008). This deletion was 114.3kb long starting at chr5:130,863,839 (hg18) 
affecting exons 2 through 11 of the gene. This CNV was confirmed by qPCR (Figure 2.2B). 
 There was an inherited duplication of 4q32.1-q32.2 that included RAPGEF2, another 
member of the RAPGEF protein family, in two sisters concordant for schizophrenia (Figure 
2.2C,D) (Xu et al. 2009). The 716.4kb duplication spanned chr4:160104841-160821269 (hg18) 
and was confirmed by MLPA to be inherited from their mother, who was asymptomatic (Figure 
2.2C). The other duplicated gene, C4orf45, is a predicted open reading frame. 
2.3.2 Clinical history of patients 
 The patient carrying a de novo deletion on chromosome 5q, encompassing the RAPGEF6 
gene, was male, born in 1962. He had dropped out of school after 8
th
 grade due to intellectual 
difficulty and had no family history of schizophrenia. He first presented to medical services in 
his 30s with 8 months of psychotic symptoms including thought disturbances, flattened affect, 
suicidal ideation, and alcohol use, meeting full criteria for a diagnosis of schizophrenia, paranoid 
subtype. He had long periods of paranoid ideation and bouts of aggression, auditory 
hallucinations, as well as poverty of ideation and withdrawal. He was noncompliant with 
medication, experienced marked deterioration in his functioning and eventually committed 
suicide by overdose of medication and alcohol.  
The duplication on chromosome 4q that disrupts RAPGEF2 is shared by 2 sisters affected 
with schizophrenia and was inherited from their mother. The elder sister, ECL, was born in 1950. 
She started training as a nurse but could not cope and did not complete her training. At that time, 
she experienced confusion and exhibited obsessive-compulsive behavior; including asking the 









started experiencing persecutory delusions, auditory hallucinations, and decreased drive. In 
addition, several negative symptoms were present in the course of ECL’s disease, including 
apathy, alogia, flat affect, inappropriate affect, depersonalization and derealization. The patient 
was anxious and socially withdrawn as a child. The younger sister, ML, now deceased, was born 
in 1952. Following her graduation from high school she completed a 3 year degree in primary 
school education. During her second year of teaching she became psychotic and was admitted to 
a psychiatric hospital for 3 months. At that time she was 25 years old. She experienced several 
delusions and hallucinations, including olfactory and visual hallucinations, which are overall 
rare. She had problems with socialization from a young age that worsened with time. Both sisters 
were unable to hold a job due to their principal illness and received disability grants. They are 
both unmarried and living with their parents. There was no history of learning difficulties, 
developmental delays, or mental retardation. 
2.3.3 Whole exome sequencing  
 Our analysis demonstrated that de novo CNV rates were collectively increased in a 
schizophrenia cohort and can explain about 10% of sporadic case risk (Xu et al. 2008). 
Therefore, the purpose of whole exome sequencing was to assess whether our schizophrenia 
cohort had sources of genetic risk other than CNVs and if the pattern of risk found in CNVs, 
namely de novo mutations in sporadic cases and rare inherited mutations in familial cases, would 
also hold at the level of single base mutations. Individuals with CNVs as identified in prior 
studies were excluded from sequencing. Major findings concerning de novo mutations were 
discussed in Chapter 1.  
We did not detect any de novo mutations in the whole exome sequencing data. However 




chr4:160277184 V1450I (hg19), both localized to the C terminus of the protein. While the latter 
mutation of valine to isoleucine was predicted to be a tolerated mutation by SIFT software 
(sift.jcvi.org), the former mutation of serine to cysteine was predicted to be a damaging mutation. 
The serine site is conserved in Multiz Alignments of 46 vertebrates (UCSC genome browser) and 
the mutation had not been reported in the latest SNP database (dbSNP 135). Therefore, serine to 
cysteine conversion might have functional impact on the protein. 
2.4 Summary of findings 
Upon analysis of copy number variation in a genetically homogenous population, we 
discovered a de novo mutation in RAPGEF6 in a sporadic case of schizophrenia and an inherited 
mutation in RAPGEF2 in concordant familial cases, as well as two inherited exonic mutations in 
RAPGEF2. RAPGEF6 lies within the region of high linkage and association in schizophrenia 
studies of chromosome 5q (Figure 2.1). These results represent a striking convergence of human 
genetics onto the RAPGEF family and RAPGEF6 in particular. Moreover, the literature reviewed 
below demonstrates significant involvement of the Rapgef family in neural phenotypes in animal 
models, indicating that Rapgef6 is a plausible functional candidate in schizophrenia. 
2.5 Discussion 
 The human genetics results, from cytogenetics to copy number research, implicated 
RAPGEF6 in the genetic liability to schizophrenia. In order to understand the functional 
implications of RAPGEF6 deletion, we will review the relevant literature about this gene, its 
family, and its up- and downstream regulators, the Rap family. 
2.5.1 Role of Rapgef6 in cell adhesion  




study found that Rapgef6 was upregulated in mouse lines with higher adult gliogenesis and 
downregulated in mice with higher neurogenesis (Kempermann et al. 2006). Several in vitro 
experiments using a variety of cell model systems demonstrated that, in both mouse and human 
cells, Rapgef6 has a definite role in stimulating adhesion to both other cells and to the 
extracellular matrix (Figure 2.3). RAPGEF6 was initially cloned and characterized biochemically 
through its homology to other Rapgef members. In humans there are 3 major isoforms, the 
shortest of which lacks the PDZ domain and thus might affect localization (Kuiperij et al. 2003).  
Expression and activity assays proved that RAPGEF6 activated Rap2 more than Rap1 by 
exchanging its GDP for GTP (Figure 2.3A), and that unlike other family members its activity 
was independent of GTP binding (Gao et al. 2001). The same group found that active MRas-
GTP bound to the RA domain of RAPGEF6 and delivered it to the cell membrane to increase 
membrane concentrations of Rap1-GTP. MRas is therefore important for localization but not 
modulation of RAPGEF6 activity. 
In lymphocyte precursor cells, MRas directed Rapgef6-dependent adhesion of integrin LFA1 to 
ICAM (Yoshikawa et al. 2007). This process of adhesion was triggered by TNFα administration. 
The mouse model of Rapgef6 deletion, described further in Chapter 3, had no gross behavioral or 
anatomic abnormalities beyond splenomegaly (Yoshikawa et al. 2007). Knock out B cells taken 
from the spleen also demonstrated absent TNFα induced LFA1-ICAM adhesion, even though 
levels of LFA1, MRas, and TNFα receptor were unchanged and MRas and Rapgef6 levels were 
the same in B as well as unaffected T cells. Thus Rapgef6 is essential for specific forms of 





Figure 2.3 Rap and Rapgef6 pathways 




Human epithelial cells also rely on RAPGEF6 for cell adhesion. Knocking down 
RAPGEF6 or RAP1A led to immature Ecadherin containing adherens junctions between cells 
(Dube et al. 2008). Additionally, Ecadherin levels were reduced, suggesting RAPGEF6 affects 
its expression via RAP1, and F-actin was disorganized. The authors also repeated these findings 
in endothelial cells with VEcadherin junctions, which they successfully rescued by administering 
RAPGEF3/4 agonist 8CPT. Similar studies established that RAPGEF6 maintained β1-integrin 
tight junctions and cellular migration by regulating JAM-A and Afadin (AF6) as well as RAP1 
activity and integrin expression (Severson et al. 2009). JAM-A was coimmunoprecipitated with 
the PDZ domain of RAPGEF6. Jam-A was identified as a marker of NG2 glia, including NG2 
glia undergoing proliferation to generate oligodendrocytes (Stelzer et al. 2010). Its unpolarized 
expression did not suggest a role in cell fate determination. Afadin is important in remodeling of 
dentate gyrus to CA3 synapses in the hippocampus because its deletion resulted in decreased 
nectin, Ncadherin, and β-catenin-dependent puncta adherentia junctions at the mossy fiber to 
CA3 synapse in vivo (Majima et al. 2009) and also in hippocampal culture (Lim et al. 2008). 
Expression of human RAPGEF6 in Cos7 cells found a role for RAPGEF6 in BAG3-
mediated cell migration (Iwasaki et al. 2010). BAG3 and RAPGEF6 associated on a yeast two 
hybrid screen and coimmunoprecipitated via the PPDY motif, which is a putative Nedd4 
ubiquitination domain. Overexpressing RAPGEF6 increased integrin-fibronectin adhesion and 
knock down studies demonstrated RAPGEF6 was necessary for the adhesion effects of BAG3. 
The Allen Brain Atlas predicts very low BAG3 brain expression. 
miRNA binding prediction from TargetScan (release 6.2) identified only 4 potential 
binding sites with low preferential conservation. The predicted miRNA interactions are with 




Finally, there are two protein structure reports of potential binding partners for 
RAPGEF6. The structure of tyrosine phosphatase PTP1E (also known as FAP-1) was solved by 
complexing its second PDZ domain with the C terminus of RAPGEF6, which proved to be an 
unusually complicated and high affinity PDZ binding arrangement (Kozlov et al. 2002; Milev et 
al. 2007). PTP1E also bound the Fas receptor, ephrins, and APC in a variety of cancer models 
(Kozlov et al. 2002). PTP1E was expressed in CA1 and dentate gyrus neurons where it blocked 
apoptosis (Savaskan et al. 2005). Protein interaction predictions as well as 
coimmunoprecipitation verified Interleukin-16 as another binding partner of RAPGEF6 (Chang 
2010). In both human and mouse cell culture systems, Rapgef6 has a role in integrin and 
cadherin mediated cell adhesion. Although it is more effective at activating Rap2 in vitro, there 
are no published findings to date on cellular interactions between Rapgef6 and Rap2. Since 
integrin and cadherin signaling are crucial in neural migration and cell connectivity, these 
findings suggest Rapgef6 could have a role in neural development and function. 
2.5.2 Neural role of Rapgef family members  
 While Rapgef6 has never been studied in the brain, many other family members have 
strong neural phenotypes (Table 2.1). The Rapgefs are a family of 6 proteins, of which Rapgef3 
and Rapgef4 are highly homologous and cAMP-activated. Some family members, such as 
Rapgef1 and Rapgef2, are positively regulated by Rap1 activity. 
 In mice, deletion of Rapgef1 is embryonic lethal because it is essential for vascular 
development (Ohba et al. 2001). Fibroblasts from early embryos were highly motile and poorly 
adherent. This finding was extended by demonstration that Rapgef1 is necessary for paxillin and 
β1-integrin mediated focal adhesion (Voss et al. 2003). A hypomorph mouse model was created 




Table 2.1 Neural roles of Rapgef family members  
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nuclear β-catenin preventing precursor cells from exiting symmetric mitosis (Voss et al. 2006). 
Beyond regulating neural proliferation, Rapgef1 also proved to be essential for radial glia 
orientation that directs cortical migration (Voss et al. 2008). 
 Rapgef2 is ubiquitinated for degradation by Nedd4, suggesting this is a potential 
mechanism for Rapgef6 regulation as well (Pham and Rotin 2001). It mediates NGF trophic 
signaling in the downstream cascade from TrkA receptors, promoting neurite outgrowth (Hisata 
et al. 2007). Rapgef2 deletion limited to the forebrain resulted in grossly abnormal brain 
development with heterotopia and failure of white matter tracts (Bilasy et al. 2009). Upon more 




Rapgef2 in axon guidance (Bilasy et al. 2011). 
 RAPGEF3 and 4, also known as EPACs, have a variety of cellular roles and, due to their 
regulation by cAMP, share a specific activator 8-pCPT-2’-O-Me-cAMP (8CPT). Administration 
of 8CPT has a variety of effects, including increasing long term depression in CA1 of the 
hippocampus (Ster et al. 2009), stimulating integrin adhesion (Bos 2006), and increasing 
prepulse inhibition and improving fear conditioning memory in wild type mice (Kelly et al. 
2009; Ma et al. 2009). Initial neural culture experiments localized Rapgef4 to both sides of the 
synapse, including colocalization with AMPA receptors (Woolfrey et al. 2009). 8CPT reduced 
spine area but not spine density, while dominant negative Rapgef4 increased spine area, 
implying that Rapgef4, unlike Rapgef1 and 2, depresses synapses. Individual knock out of either 
Rapgef3 or 4 had no effect on behavior, but a double knock out led to reduced long term 
potentiation in the hippocampus as well as impairments in spatial memory and social interaction 
(Yang et al. 2012). Neither the single or double deletions caused a change in spine density in 
CA1, contradicting the knock down findings. Microarray and rescue experiments found that 
Rapgef3/4 activate Rap1 to inhibit miRNA124 expression, thereby derepressing Zif268. 
Sequence analysis of 9 autism candidate genes revealed 4 nonsynonymous cosegregating 
mutations in RAPGEF4 (Bacchelli et al. 2003), while RAPGEF3 SNPs were associated with 
anxiety and depression (Middeldorp et al. 2009).  
Little is known about Rapgef5 except that it is inhibited by MRas (Rebhun et al. 2000) 
and downregulated in neural differentiation (Bithell et al. 2003). 
Rapgefs are conserved back to fly and worm. In Drosophila, the Dizzy mutant is a 
deletion of the gene 50% homologous to Rapgef2 and Rapgef6 because it is a guanine nucleotide 




photoreceptors in the eye, proper wing structure, or ovaries. Overexpression of Dizzy in fly 
macrophages caused normal migration but abnormally long cell protrusions and morphology, 
probably as a result of enhanced integrin adhesion (Huelsmann et al. 2006). Rapgef1 homolog 
C3G is necessary for muscle adhesion via integrins and its deletion was also lethal (Shirinian et 
al. 2010). In C. elegans the homolog of Rapgef2 and Rapgef6 is Pxf-1 which is essential for 
proper epithelial attachment and cuticle development and molting (Pellis-van Berkel et al. 2005). 
Overall, the other Rapgefs have striking neural phenotypes when deleted and contribute 
to neural guidance, morphology, and electrophysiology. We hypothesized that Rapgef6 would 
have a moderate neural phenotype when deleted. 
2.5.3 Neural role of Rap family members  
 Rapgefs activate Rap1 and Rap2 by exchanging GDP for GTP (Figure 2.3A). Raps 
mediate a number of signal cascades, several of which have neural significance such as cadherin 
and integrin signaling (Bos 2005), and have been associated with neuropsychiatric diseases 
(Stornetta and Zhu 2011). Rap1 was implicated early on in ERK activation for neuronal 
differentiation (York et al. 1998). Rap1 also directs neural polarity since its localization to a 
neurite tip correlated with that neurite developing into the axon (Schwamborn and Puschel 
2004). When constitutively active in vitro, Rap1 recruited Afadin (a Rapgef6 binding partner) to 
spines resulting in thinner spines with fewer AMPA receptors (Xie et al. 2005). Dominant 
negative Rap1 reduced in vitro neural complexity whereas constitutively active Rap1 had the 
opposite effect, suggesting Rap1 supports neural growth (Chen et al. 2005), but another study 
found no effect of active Rap1 on neural morphology (Fu et al. 2007).  
In vivo deletion of Rap1 limited to the cortex resulted in reduced long-term potentiation 




connections in the setting of normal presynaptic function (Pan et al. 2008). This correlated with 
impaired cued and conditional fear conditioning but normal spatial memory. Electroporation of 
dominant negative Rap1 into developing neurons in vivo did not affect neural migration or 
neurite outgrowth but led to a loss of neural orientation with the axon misguided (Jossin and 
Cooper 2011). Additional rescue experiments implicated Ncadherin, Rac1, Cdc42, and Ra1 as 
the downstream effectors of Rap1 in neural polarity. Both this and an additional study found that 
Reelin was the upstream activator of Rap1 in directing early neural migration and orientation 
(Franco et al. 2011). 
In human postmortem studies, Rap1 was reduced in both expression and activation in the 
prefrontal cortex and hippocampus of suicidal, depressed individuals (Dwivedi et al. 2006). 
Moreover, protein analysis of frontal cortex for ERK pathway members determined that Rap1 
levels were reduced in individuals with schizophrenia or depression but not bipolar disorder, 
increasing support for the idea of neuropsychiatric disorders as synaptic dysfunction disorders 
(Yuan et al. 2010). 
Rap2 experiments show that it may counteract Rap1 in neural growth and synaptic 
transmission. Rap2 constitutive activation impaired the length and complexity of hippocampal 
neurons in culture by increasing retraction (Fu et al. 2007). This also caused reduced electrical 
activity due to diminished GluR2 subunits of the AMPA receptor, and while spine density was 
normal the total number of spines was reduced due to the shorter arbor. Other studies replicate 
the negative effect of Rap2 on glutamate transmission, finding that constitutively active Rap2 
reduces AMPA but not NMDA current through TNIK activation, which blocks long-term 
potentiation (Zhu et al. 2005). In vivo, knocking in a constitutively active Rap2 transcript to 




al. 2008). Behaviorally this correlated with impaired spatial learning on a water maze and 
decreased contextual fear extinction plus hyperactivity, the first two of which implicate the 
hippocampus. Thus Rap2 may counteract Rap1 by inhibiting spines and increasing synaptic 
depression. 
MRas is not as well studied as the Raps, but it was found to promote filopodia outgrowth 
and actin rearrangement, most likely via Rapgef6 binding partner Afadin (Matsumoto et al. 
1997; Quilliam et al. 1999). In neural-like PC12 cells, NGF activated MRas leading to neural 
differentiation, and constitutively active MRas increased neurite outgrowth (Sun et al. 2006). 
Surprisingly, deletion of MRas did not cause any morphology changes in the hippocampus or 
cortex, nor any behavior issues on fear conditioning or the water maze (Nunez Rodriguez et al. 
2006). The authors found MRas was expressed in astrocytes as well as neurons and that FGF and 
EGF signaling in astrocytes was disrupted. 
The importance of Raps and MRas in neural development further confirms that Rapgef6 
is both a plausible functional and genetic candidate for modeling schizophrenia. 
2.5.4 Rare genetic models 
The large and small scale mutations we defined in RAPGEF6 and RAPGEF2 were so rare 
they were private, affecting no control individuals nor aligning with any findings in dbSNP. Rare 
mutations such as these are considered important in developing animal models of disease. Not 
only are rare mutations an essential component of schizophrenia genetic risk, they are more 
likely to be deleterious and causal and therefore more etiologically valid for understanding the 
neurobiology affected in the disorder (Arguello et al. 2010). We use the rare mutation approach 
to dissect affected pathways in schizophrenia, in this case pathways affected by Rapgef6 deletion 




2.6 Future directions 
2.6.1 Genetics 
We plan to continue discovering the full spectrum of genetic risk associated with 
RAPGEF6 by extending our exome sequencing to include additional cases. Unfortunately we did 
not sequence any individuals with rare CNVs, so it would be useful to sequence the three cases 
of RAPGEF CNVs to determine if there are any interacting mutations in related genes that might 
worsen the phenotype, per the two hit hypothesis. We are also monitoring the literature for 
evidence of mutation or CNV findings in this gene family from other populations.  
Several of the genetic findings discussed above are SNP association studies pointing to 
RAPGEF6, but an association study of this population did not generate a genome-wide 
significant result at this locus (unpublished data). We could use imputed SNP genotype data 
from publically available data sets to query this gene family and associated genes. Such a 
focused analysis would greatly increase power by reducing the need to correct for multiple 
comparisons. Moreover, there are growing maps of expression quantitative trail loci (eQTLs), 
SNPs that correlate with gene expression (Cookson et al. 2009). eQTLs for Rapgef family 
members are already identified in public databases so we could run an association study to 
determine if individuals with schizophrenia are predicted to have altered expression of these 
genes. 
2.6.2 In the next chapter 
Next we will consider the generation of a Rapgef6 deletion mouse and its behavioral 






Chapter 3: Animal Behavior 
3.0 My Role 
 The Rapgef6 knock out mouse used in the experiments described in this thesis was 
provided by the Kataoka laboratory. I validated two additional knock out lines that were not 
included in this project. I controlled the breeding of the mouse line, executed all behavior 
paradigms contained in this chapter, and analyzed all the data, with the exception of the auditory 
evaluation performed by the Olson laboratory. While many of our behavior protocols were 
already established in the lab, I had to develop and assess new protocols for novel object 
recognition and T maze testing, as well as a novel immunohistochemistry protocol to study cFOS 
expression after our laboratory’s standard fear conditioning protocol.  
3.1 Introduction 
3.1.1 Validity and utility of rodent modeling  
 Animal models, especially genetically altered mice, are used extensively in neuroscience 
research. Animal behaviorists agree upon three core features to validate a strong model: face, 
construct, and predictive validity (Robbins and Sahakian 1979). Face validity questions whether 
there is behavioral analogy between the animal and human phenotypes and whether the animals 
reproduces key disease symptoms. Construct validity ensures that there is a shared basis of 
etiology, be it a genetic or environmental insult, that leads to analogous neurobiological pathway 
abnormalities. Predictive validity is demonstrated when animals have similar behavioral 
responses to agonists, antagonists, and other pharmacology interventions as human patients. 
 In neuropsychiatric disorders, there is an incomplete understanding of the underlying 




prove. As mentioned below, the clinical phenotypes available to generate face validity are 
similarly limited by the complexity of psychiatric symptoms (Nestler and Hyman 2010). Thus it 
is the opinion of our lab and others that construct validity is the most fruitful starting point to 
build a useful animal model (Arguello et al. 2010; Kas et al. 2009). By working from rare human 
genetic mutations that are more likely to be causal and highly penetrant, we intend to create 
models that more accurately reflect genetic dysfunction and thus lead toward better 
neurobiological understanding and pharmacological therapeutics that can be reapplied to patient 
care. 
3.1.2 Endophenotypes of schizophrenia amenable to modeling 
As described in Chapter 1, the core symptoms of schizophrenia are classified as positive 
(notably hallucinations and delusions), negative (such as flattened affect and catatonia), and 
cognitive deficits (attention and working memory impairments). On initial consideration, these 
symptoms appear to have no rodent correlate, nor would one expect a single mouse to 
recapitulate such a heterogeneous disorder. Fortunately, careful behavior assessments can be 
used to investigate some clinical phenotypes of schizophrenia.  
Endophenotypes are heritable, quantitative traits that are associated with a disease and 
may be present in unaffected relatives, thus representing experimentally approachable 
subphenotypes (Amann et al. 2010). Thus endophenotypes are considered useful targets for 
rodent behavior assessment. What endophenotypes of schizophrenia can be accurately modeled 
for face validity? Cognitive working memory impairments, prepulse inhibition (PPI) deficits, 
hyperlocomotion, and altered social interaction are paradigms currently considered to have the 
most analogy between rodents and humans (Powell and Miyakawa 2006).  




treatment, and exist in unaffected relatives (Elvevag and Goldberg 2000; Green and Nuechterlein 
2004), this is considered by some to be the most pressing area for schizophrenia research and 
novel therapeutics (Arguello and Gogos 2010). Patients have deficits in a variety of cognitive 
domains (Lee and Park 2005), but working memory and attention are most amenable to animal 
modeling as they can be tested through mazes and goal set-shifting tasks which rely upon 
executive control of information over temporal delays (Arguello and Gogos 2010). 
PPI deficit is so established in the human literature that this paradigm is part of the 
cognitive neuroscience treatment research to improve cognition in schizophrenia (CNTRICS) 
focus for schizophrenia research (Green et al. 2009). PPI impairment is thought to be a failure of 
top-down cortical suppression of irrelevant information and thus may represent a cognitive 
symptom (Arguello and Gogos 2006). Also known as sensorimotor gating, PPI involves a 
reflexive reduction in startle when a sound or tactile stimulus is closely preceded by a milder 
stimulus. PPI is diminished in individuals with schizophrenia and their unaffected relatives, 
making this failure to suppress startle an endophenotype; yet is also decreased in other 
neuropsychiatric disorders (Powell et al. 2009). As it has strong relevance to neuropsychiatric 
disease and is easy to evoke in both humans and animals, PPI is a commonly investigated 
phenotype. 
Positive symptoms have only been successfully modeled by hyperactivity, which is 
thought to represent psychomotor agitation. Quantified activity either by home cage observation 
or on open field exploration should be considered both at baseline and after challenge with 
dopaminergic and serotonergic psychostimulants, which may cause an inordinate increase in 
locomotion in schizophrenia models (Brookshire and Jones 2009).  




withdrawal (Powell and Miyakawa 2006). In animals this can be tested in a number of protocols 
that bring together two animals for quantitative observation of social interest and establishment 
of dominance (Crawley 2008). This behavioral paradigm is more controversial since human and 
rodent social behaviors are not especially analogous. 
Working memory, PPI, hyperlocomotion, and social interaction are 4 hypothetically 
important phenotypes in animal models of schizophrenia, but we have also tested additional 
domains. Clearly a hypothesis-driven approach to understanding mouse behavior phenotypes is 
the most focused approach, yet it is important in animal models to consider the divergent effects 
of pleiotropy (when one gene influences multiple phenotypes). Many behaviorists recommend 
systematic phenotyping of novel models since 96% of mutant models were found to have 
unexpected behavioral findings (Beckers et al. 2009).  
3.1.3 Rodent behavior domains explored 
 In our experiments, we explored both schizophrenia-associated phenotypes as well as 
more general domains (Crawley 2008). In the open field test, mice are placed in a well-lit 
chamber and their movement is assessed by a laser beam grid. The resulting data assesses 
locomotion and anxiety-like behavior. Animals naturally tend to avoid the center of the chamber 
since it is less protected, so an increase in anxiety-like behavior is indicated by more time and 
distance in the chamber margins and anxiolysis by more transit in the center (Prut and Belzung 
2003). Altered locomotion can complicate analysis of other behavior tests therefore it is an 
important component of basic behavioral screening. 
During novel object recognition, animals are habituated to two identical objects then re-
exposed to one familiar and one novel object at two later time points. The mice should indicate 




recognition is a type of spatial memory that can be altered by psychostimulants such as PCP and 
methamphetamine and rescued by antipsychotics, thus it is dopamine sensitive and has relevance 
to schizophrenia modeling (Amann et al. 2010). The other assessment of spatial memory we used 
was the Morris water maze, in which mice learn to swim to a visibly marked platform, then to a 
hidden platform, relying on extramaze cues (D'Hooge and De Deyn 2001). Water maze 
performance is affected after deletion of schizophrenia candidate genes dopamine D1 receptor, 
glutamate NMDA receptor 2B, and some Disc1 models therefore it is relevant to schizophrenia 
research (Arguello and Gogos 2010). 
On the T maze, animals are trained to run to the end of one open maze arm then on the 
next trial in the maze when both arms are available they must choose the opposite arm for a 
reward. Increasing the delay time between the two trials increases the working memory load and 
this learning paradigm is dependent on the prefrontal cortex (Sanchez-Santed et al. 1997). The 
importance of the T maze as a measure of schizophrenia endophenotype working memory was 
discussed above. 
Mice are exposed to auditory tones with or without a preceding quieter prepulse tone and 
their reactions are measured by a force sensitive restraining chamber during prepulse inhibition 
assessment. PPI assays measures auditory function, baseline startle, and top-down sensorimotor 
gating of the startle reflex (Powell et al. 2009). As discussed, sensorimotor gating is an 
endophenotype of schizophrenia. 
Fear conditioning assesses both baseline fear and learned fear by quantifying freezing 
behavior at baseline and on re-exposure to the same chamber (contextual conditioning) and tone 
(cued conditioning) associated with the animal receiving foot shocks. Contextual conditioning 




amygdala (Gerlai 2001; Maren 2008). Contextual fear is diminished in Gαs and Reelin deletion 
while Dntbp1 deletion causes cued fear sensitization thus mouse models of schizophrenia have 
varying fear impairments (Amann et al. 2010). There is growing interest in the amygdala in 
schizophrenia as the possible basis of emotional blunting since the NMDA receptor antagonist 
ketamine can block amygdala activation and fear conditioning and the atypical antipsychotic 
clozapine can reverse these effects (Pietersen et al. 2007). 
3.1.4 Role of Rapgef and Rap proteins in behavior 
 While several genes in the Rapgef and Rap families have been knocked out or into mouse 
models, only some are nonlethal and thus amenable to behavior assessment. For instance, there 
are several interesting findings regarding Rapgef3 and Rapgef4. In wild type animals, 
administration of Rapgef3/4 agonist 8CPT leads to an increase in PPI without a change in startle, 
as well as an enhancement in fear learning (Kelly et al. 2009). These findings are supported by 
results that 8CPT delivered to the hippocampus after fear conditioning increases contextual fear 
memory (Ma et al. 2009). Double knock out (KO) of both Rapgef3/4 causes deficits in social 
interaction and water maze acquisition and reversal impairments in both constitutive and 
inducible knock out animals, while single gene deletion mice were not affected (Yang et al. 
2012). This study also demonstrated that overexpression of miR124 or knock down of 
transcription factor Zif268 could recapitulate the phenotype, and that the opposite changes in 
these genes could rescue the phenotype, identifying a pathway downstream of Rapgef3/4. 
 Cortex specific KO of Rap1a and Rap1b caused fear conditioning impairments while 
water maze performance was unaffected (Pan et al. 2008). Specifically there was a reduction in 
KO freezing in both short and long term testing of cued fear and long term contextual fear, as 




lengthened to strengthen learning, the deficits were reversed, suggesting a limited role of the 
cortex in fear conditioning. This fear dysfunction correlated with electrophysiology showing 
reduced plasticity from the cortex to the lateral amygdala but increased basal cortical glutamate 
release onto the lateral amygdala. The authors hypothesized that Rap1 suppresses cortico-
amygdala synaptic transmission to permit amygdala plasticity underlying fear conditioning. 
Constitutively active Rap2 overexpressed in the cortex led to poor spatial performance on 
the water maze, normal fear conditioning but decreased fear extinction, and open field 
hyperactivity (Ryu et al. 2008). The authors also attempted to make a dominant negative Rap2 
knock in, but this mouse did not demonstrate altered Rap2 activity levels. They posit that Rap2 
may inhibit the Ras-ERK pathway signaling, thereby inhibiting spine growth to increase synaptic 
depression. 
Knock out of MRas led to no neural morphological or behavioral phenotype; animals had 
no change in water maze learning or fear conditioning (Nunez Rodriguez et al. 2006). MRas 
localizes Rapgef6 to the membrane but does not activate it in lymphocytes (Gao et al. 2001), 
however it is unknown if this is the major Rapgef6 regulator in the brain or if MRas can affect 
Raps through any other Rapgef protein. 
Predictions based on these findings would be that since Rapgef6 positively regulates 
Rap1/2 activity as do Rapgef3/4, Rapgef6 KO may lead to impaired social interaction, decreased 
spatial performance on the water maze, and a reduction in fear conditioning. If MRas is truly the 






3.2.1 Animal model generation and housing 
Rapgef6 animals were generated and shared by the Kataoka laboratory at Kobe 
University (Yoshikawa et al. 2007). Exon 21 (encoding the GEF enzymatic domain) was isolated 
from a BAC with restriction enzymes MfeI and BsgI, then ligated into the floxed position in a 
vector that also had a 3’ floxed, inverted TK-neo cassette. Large regions of Rapgef6 were added 
up and downstream of this cassette to direct homologous recombination. This vector was 
linearized and electroporated into 129/Ola embryonic stem cells. Positive Rapgef6
flox
 cells were 
confirmed via Southern blot, then injected into C57Bl/6 blastocysts to generate chimeras. 
Resulting Rapgef6
+/flox
 mice after a generation of backcrossing to C57Bl/6 were bred with CAG-
Cre mice to yield Rapgef6
+/-
 animals lacking the GEF domain.  
After shipment from RIKEN facility, Rapgef6
+/-
 mice were housed on a 12 hour light 
cycle in the Kolb animal facility with water and food ad libitum except as noted. Heterozygous 
animals were mated to generate litters of wild type, heterozygous, and homozygous deletions. Up 
to 5 littermates of the same gender were co-housed. All animal procedures were performed 
according to protocols approved by the Institutional Animal Care and Use Committees 
established by Columbia University under federal and state regulations.  
Genotyping was performed using the following primers: 
GAGCCTTGAGATACAGAAACTTG located 5’ to exon 21, CTTGACAACAGGGAAGAGTG 
within exon 21, and CTAGGGAGGTGTCAGCAAAG 3’ of exon 21. PCR was performed with 
2uL DNA extracted from tail clippings on PureTaq PCR beads (GE) with the protocol 94
o
C 






C 60s then 72
o
C 10m. On an agarose gel, this yielded 




At least one week prior to the initial behavior, animals were moved to the Rodent 
Neurobehavioral Analysis Core (RNAC) facility in NYSPI or a satellite testing facility in the 
Black Building (T maze and PPI cohort). Animals continued to be group housed, except the T 
maze cohort that was individually housed with plastic igloos and nesting squares for enrichment. 
There was at least 1 week in between behavioral assessments. The first cohort (14 WT, 12 HET, 
7 HOM) underwent open field, novel object recognition, water maze, then fear conditioning. The 
second cohort (12 WT, 12 HET, 9 HOM) was tested on open field, novel object recognition 
(novel paradigm), and fear conditioning. The third cohort experienced T maze then PPI. The 
fourth cohort was used for fear conditioning followed immediately by sacrifice for cFOS 
staining. 
In an attempt to generate a different knock out mouse, ES cells were purchased with a 
trap inserted into intron 1 (CF0294) or 8 (AY0426) (Wellcome Sanger Institute). Trap insertion 
was validated by PCR and sequencing. The ES cells trapped in intron 1 were sent for 129 
blastocyst injections (MMRRC). The resulting chimera was shipped to Columbia University, 
where it was bred and the offspring backcrossed to C57Bl/6 for 5 generations using 
microsatellite-assisted speed congenics (Taconic) to select the most backcrossed mice from each 
generation to continue breeding. These HET mice were then mated together, but as mentioned 
above, no HOM offspring were ever recovered. 
3.2.2 Open field 
Animals were identified and habituated individually in cages for 30-60 minutes, then 
placed into transparent open field chambers (25cm square) with infrared motion detection beams 
(Coulbourn) for 1 hour on day 1 and 30 minutes on day 2, exactly 24 hours later. Locomotion in 




TruScan software as distance traveled or time in the margins (<2.5 beams from wall) and center 
(rest of chamber) as well as rearing. The time spent and distance traveled in center vs. margin 
zones was extrapolated using separate formulae from individual animal coordinates taken at 1s 
intervals. Due to reduced sampling frequency, this extrapolation formula yielded a discrepancy 
between zone distances and total distance, but no such discrepancy for time measurements. 
3.2.3 Novel object recognition 
The initial cohort of animals was tested using a protocol that failed to demonstrate 
accurate spatial memory for identical object placement. A new protocol was then executed with 
the second cohort of animals. On the first two days, animals were habituated to a 9x18in empty 
cage for 10 minutes. On the third day, they were returned to that cage with two identical green 
plastic toys affixed at either end and videotaped for 5 minutes. One hour later, they were returned 
to the cage except one green toy was replaced with a yellow plastic toy, balanced across 
genotypes for left and right sides, and videotaped for 5 minutes. Three hours later, the novel toy 
was replaced again with a red plastic toy. All toys were distinct in texture, shape, and color. 
Videotape was hand-scored by a blind observer for the time spent in direct contact sniffing each 
item over every 5 minute period. Percent time per novel object was calculated as (total time 
investigating novel object)/(total time investigating both objects).  
3.2.4 Morris water maze 
In the initial platform training, mice were placed in a 3 gallon bucket of room 
temperature water level with a plastic platform and time until they climbed onto the platform was 
noted. This training was repeated twice a day 1 hour apart for 3 days using opaque water due to 
nontoxic white tempera paint on the second and third days. After each trial, animals were 




morning or afternoon throughout training, with both groups balanced with respect to genotypes. 
Once animals were trained to find a platform, 2 days of visual platform training began. 
The platform was connected to a brightly colored pole and flag then submerged in an 8 foot 
diameter pool of room temperature opaque water. The walls of the room containing the pool 
were uniquely decorated to provide color, pattern, and textural extra-maze cues, and the tester’s 
location was concealed with curtains. Mice were placed into the pool at one of 8 randomly 
chosen entrance points using 3 pathways to the pool to prevent association with any one location 
or the location of the tester, however the platform was never moved. Three times a day for two 
days, mice were manually timed and automatically tracked with AnyMaze Software (Stoelting) 
and a camera (Logitech) until they located the visible platform and remained on it for 30 
seconds.  
Next in the hidden platform training, the platform marker was removed and animals were 
timed and tracked until they located the unmarked platform and remained for 30 seconds. After 3 
trials a day for 5 days of hidden platform testing, the two probe trials occurred. One hour after 
the last hidden trial, the platform was removed and mice were automatically tracked while 
swimming for 1 minute. This probe was repeated 24 hours later. 
3.2.5 T maze 
In order to increase the reward of food, animals were weighed for 3 days then food 
restricted over the course of a week to achieve 80-90% of their starting weight. Animals were 
weighed daily and fed accordingly to maintain this weight. As noted above, mice were 
individually housed with igloo and nesting enrichment for the duration of this test. 
The T maze apparatus has one start arm 38cm long by 10cm wide with two choice arms 




high. Sliding doors separated the beginning of the start arm, as well as each choice arm. Extra 
food pellets (BioServ) were placed beyond each choice arm in order to mask any olfactory cues.  
Mice were allowed to explore the entire maze for 10 minutes on the first day of 
habituation. On the second and third days of habituation, food pellets were placed into each dish 
and were replenished once the mouse ate all 3 pellets. 
On two days of forced alternation training, mice were released from the start zone and 
allowed to explore the only open arm which did not have food (pseudorandomized left and right 
across 10 trials), then prodded back to the start zone. During a 5 second intratrial delay this arm 
was closed off and the opposite, goal arm opened with a food pellet in the dish at the end of the 
goal arm. Mice were allowed to explore the opposite, goal arm and eat the food, then returned to 
the start zone. This was repeated 10 times with an intertrial delay of 40 seconds for 2 days. On 
these and all other sessions, the animals were videotaped and manually timed and scored.  
Next animals advanced into choice training. The goal arm of the maze was closed off 
with a food pellet in the dish, but no food pellet in the open arm. Each mouse was timed until it 
reached the empty food dish of the open arm, then returned to the start zone for 5 seconds. The 
center area of the maze was wiped with 70% ethanol to remove olfactory cues and both arms 
were opened. The mouse was then released and the choice of arms (goal or non-goal) and time to 
the food dish were recorded. Once the animal’s body entered one arm, the door to the other arm 
was closed. There was a 40 second intertrial delay. This was repeated 10 times daily, 
pseudorandomized for the goal arm. If mice developed a strong turn bias, goal arms were biased 
toward the avoided side and 5 extra trials were added daily until the bias was corrected.  
Training continued until each mouse reached criterion of 7 out of 10 correct choices on 3 




memory testing. The intratrial delay was increased to 10, 20, or 30 seconds with 4 trials of each 
delay time pseudorandomized across the session. 
3.2.6 Prepulse inhibition 
On the first day, mice were weighed and then placed into the restraining startle chamber 
of the PPI box (Hamilton Kinder). The Startle Monitor software was programmed to deliver a 5 
minute habituation period, then 6 blocks of pseudorandomized trials with 10-20 second 
randomized intertrial delays. Each block was comprised of the following 7 trials: no sound, 40ms 
120dB burst (the startle stimulus), or a 20ms prepulse of 74, 78, 82, 86, or 90dB 100ms prior to 
the 120dB startle stimulus. Background noise of approximately 70dB was consistent throughout 
the experiment. After each stimulus, the equipment recorded force transduced over 65ms and the 
maximum force (startle) was reported. Percent PPI of a startle response was calculated as: 100 – 
[(startle response on acoustic prepulse + startle stimulus trials / startle response alone trials) × 
100]. 
 To determine startle threshold, 24 hours following PPI animals were weighed and 
returned to the startle chamber. After a 5 minute habituation, 13 auditory stimuli were presented 
5 times each in pseudorandomized order with 10-20s intertrial delays. Tested stimuli were 70, 
74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114 and 118dB over a background noise of 70dB. 
Maximum startle was sensed and reported as above. 
3.2.7 Auditory testing 
Two pairs of WT and HOM 5-7 week old female animals were brought to Elizabeth 
Olson’s laboratory at Columbia University Medical Center for auditory testing. Mice were 
anesthetized with ketamine (13 mg/kg) and urethane (1.5 mg/g). The analgesic buprenorphine 




the animal was sacrificed with an overdose of urethane or sodium pentobarbital. During the 
experiment, animal body temperature was maintained at ~ 37° C using a thermostatically 
controlled heating blanket. A tracheotomy was performed to maintain a patent airway. The left 
pinna was removed. To measure the compound action potential (CAP) thresholds, the bulla was 
opened with great care.  
Acoustic stimuli were generated and collected digitally using Tucker Davis Technologies 
(TDT) System III. Stimulus and acquisition programs were written in Matlab and TDT Visual 
Design Studio. The sampling frequency of the TDT system was 200 kHz.  Data were stored 
following removal of the first 4096 points of the response waveform to avoid the transient, and 
time-averaging the remaining waveform, typically in 50 time-locked segments. Responses were 
later analyzed by Fourier transform in Matlab.  
The ear was acoustically stimulated via a 40 – 1377 tweeter (Radio Shack). The tweeter 
and a probe-tube microphone (Bruel and Kjaer model 4134) were coupled together via a T tube 
and coupled to the ear canal.  The probe-tube microphone served as the ear canal pressure 
monitor. The transfer function of the probe-tube microphone was accounted for when setting the 
sound pressure level (SPL, decibels relative to 20 Pa peak) and analyzing the data. With a 1 
second data acquisition time, the microphone noise level (with probe-tube) was ~ -10 to 25 dB 
SPL up to 50 kHz. The noise level was determined by the average FFT value of the six adjunct 
points at frequencies below and above the stimulus. The level of distortion products produced by 
the system (mainly the driver) has been discussed previously (Dong and Olson 2006; Dong and 
Olson 2008). With current settings, system distortion was ~ 60 dB smaller than the 80 dB SPL 
primaries. Therefore, system distortion was not a concern in the results.  System distortion was 




Sound-evoked CAP recordings (.5 to 80 kHz) were made from a silver wire electrode 
firmly connected to the cochlear bony shell at the round window. The reference electrode was 
connected to the neck muscle and the animal was grounded. To get the CAP waveform, anti-
phase single tone (1 second duration) stimulus were used and averaged 30 times to remove the 
cochlear microphonic responses. 5 uV peak-to-peak criteria was used to determine the threshold 
sound pressure level to each stimulation. 
Two equal-intensity tones (1-2s duration) with fixed f2/f1 = 1.05 or 1.25 were used in 
DPOAE measurements. The primary frequencies were swept from 1 to 60 kHz in 500 Hz steps. 
3.2.8 Fear conditioning 
On the first day of fear conditioning, animals were individually habituated in rectangular 
cages with wire rack tops for 5-10 minutes. They were then placed into the sound-attenuated fear 
conditioning chambers (Med Associates) and videotaped and monitored via FreezeFrame 
software (Coulbourn). Paper towel scented with lemon extract was placed inside each chamber to 
create an odor. After 3 minutes of habituation, a 30 second tone of 85 dB and 2kHz was 
delivered then a 0.7mA shock was delivered for 2 seconds immediately after the tone ceased. 
This pairing of tone and shock was repeated 1 minute later. 
Twenty-four hours after conditioning, animals were re-exposed to the same context. They 
were habituated in the same rectangular cages, placed into the same chambers with lemon scent, 
and tracked for 6 minutes. Two hours later, animals were tested for cued conditioning. In order 
to create a novel context, they were habituated in triangular cages with plastic lids, then placed 
into the chambers but with plastic, colored floor and wall inserts and a vanilla scent. After 3 
minutes in this “novel” chamber, the tone played for 3 minutes. 




freezing/motion threshold was manually set for each animal on each trial. Animals were 
balanced with respect to genotype for time of day (morning vs. afternoon) and 4 available testing 
chambers. 
3.2.9 cFOS activation after fear conditioning 
Fear conditioning was executed as described above on 2-4 animals per session. Following 
cued conditioning assessment, animals were left in the chambers for 90-120 minutes. Each 
animal was then taken directly to anesthesia and perfusion with PBS and 4% PFA. After 
overnight post-fixation, brains were sliced 60um thick on a vibratome and every other section 
was stained with rabbit anti-cFOS 1:5000 (Calbiochem), mouse anti-NeuN 1:300 (Millipore), 
and TOPRO 1:2500.  
These slides were then viewed at 20x on a confocal microscope to permit manual 
counting of cFOS+ cells in the dentate gyrus, CA3, and CA1 subregions of the hippocampus as 
well as the lateral, basolateral, and central nuclei of the amygdala. Regions of interest were 
defined using a mouse atlas to set anatomic boundaries and analyzed from Bregma -1.3 to -1.9 
(Paxinos and Franklin 2004). The dentate gyrus is a clearly demarcated structure. Dorsal CA1 
hippocampus was defined from the end of the blades of the dentate gyrus to the end of the mossy 
fiber pathway. Dorsal CA3 began at the end of the mossy fiber pathway and terminated at the 
midline. The basolateral nucleus of the amygdala was defined as the lower half of the region 
within the forking of the external capsule while the lateral nucleus was the upper half. The 
central nucleus was medial to the lateral/basolateral nucleus. 
3.2.10 Data analysis 
 All data was analyzed and graphed using Prism 5 (GraphPad). For all paradigms one way 




genotype and time effects. Bonferroni correction post-hoc testing was then used to compare 
genotypes for significance. On novel object recognition and T maze paradigms, one sample t 
tests were used to compare mean percentages against 50% (chance) performance. Chi
2
 tests were 
used to assess expected vs. observed numbers of mice on startle and T maze tests. 
3.3 Results 
3.3.1 Generation of mouse model 
Rapgef6 animals were generated and shared by the Kataoka lab (Yoshikawa et al. 2007). 
Briefly, exon 21 that encodes the GEF enzymatic domain was deleted via homologous 
recombination of a floxed allele that was excised via crossing with a Cre expressing mouse line 
(see Methods for details) (Figure 3.1A). The Kataoka laboratory published proof of trap insertion 
and Cre-assisted deletion (Figure 3.1B-D). We confirmed by replication the absence of the 
expected protein bands on Western blot from homozygous knock out (HOM) animal brain 
samples (Figure 3.1E). 
 In an effort to more closely emulate the deletion in the patient with schizophrenia, we 
also attempted to generate knock out lines with a knock out cassette trap inserted into intron 1 or 
8 of Rapgef6. Although the location of the traps could be validated via PCR and sequencing on 
both ES cells and mouse tissue, Northern blot results were inconclusive on Rapgef6 expression 
due to either inadequate probe specificity or low RNA concentration (data not shown). 
Heterozygous knock out (HET) mice were born from the intron 1 ES cell injections, but HET x 
HET matings never yielded HOM pups as validated by qPCR, PCR, and Western blot results 
(data not shown). Timed matings were established to check if HOM embryos were dying prior to 
birth, but no HOM animals were detected from E15.5 onward. Since sequencing results 




the trap integration leading to either failure of the trap to block expression or a duplication of the 
gene locus that prevented complete knock out. 
 
Figure 3.1 Rapgef6 knock out mouse model 
3.3.2 Open field 
 Two cohorts of littermate males were allowed to explore an open field chamber for 60 
minutes on the first day and 30 minutes on the second. Since the two cohorts did not significantly 
differ in total distance traveled (P=0.3 on day 1, P=0.1 on day 2), the data sets were combined. 
Data was analyzed in 1 minute bins for effects of genotype and test time, or averaged across each 
test day for effect of genotype. On day 1 of testing, there was no significant effect of genotype on 
total distance (P=0.15), margin distance (P=0.15), or center distance (P=0.63) although there was 




was no significant effect of genotype on time spent in the margin or center zone (P=0.89) there 
was a significant effect of test time (P<0.0001) as well as a significant interaction of genotype 
and test time, indicating the genotypes varied in their response over time (P=0.005) (Figure 
3.2D,E). Entries into the center zone were not significantly affected by genotype (P=0.36) but 
were influenced by test time (P<0.0001) (Figure 3.3A). Rearing, an indicator of locomotion and 
exploration, was significantly different by genotype (P=0.018) and test time (P<0.0001) as well 
as an interaction between time and genotype (P=0.001) (Figure 3.3B). Post-hoc testing 
demonstrated significantly increased (P<0.05) rearing in HET animals over WT at 57 minutes 
and in HOM over WT at 27 and 55 minutes. 
When measurements were averaged over the hour of testing on day 1, there was no 
significant difference in total distance (P=0.17), center distance (P=0.73), margin or center time 
(P=0.64) (Figure 3.2A-E), or center entries (P=0.47) (Figure 3.3A). There was a significant 
effect of genotype on margin distance (P=0.014) with HET animals traveling more distance than 
WT (Figure 3.2B). Additionally, rearing rates were significantly affected (P=0.008) with HOM 
and HET animals increased over WT (Figure 3.3B).  
 On day 2 of testing, there was a significant effect of both test time (P<0.0001) and 
genotype (P=0.029) on total distance with HOM more active than WT at 30 minutes (Figure 
3.4A). There was only a significant effect of test time (P<0.0001) but not genotype (P=0.13) on 
margin distance, while both test time and genotype were significant for center distance 
(P<0.0001, P=0.017 respectively) (Figure 3.4B,C). Margin and center times were significant for 
neither test time (P=0.15) nor genotype (P=0.24) (Figure 3.4D,E). Center entries were affected 
by test time (P<0.0001) and genotype (P=0.049) with HOM entries greater than WT at 29 
minutes (P<0.01) (Figure 3.5A). Rearing, which was significantly different by genotype over test 



















Figure 3.5 Open field results day 2
 
time, was only affected by test time (P<0.0001) but not genotype (P=0.09) (Figure 3.5B). 
 Upon averaging measurements across day 2, there was no significant effect of genotype 
on margin distance (P=0.13), or center or margin time (P=0.24) (Figure 3.4B,D,E). Total 
distance was dependent on genotype (P=0.029) with HET mice traveling more than WT, as was 
center distance (P=0.017) for which HOM and HET animals traveled more in the center than WT 
(Figure 3.4A,C). Center entries was affected by genotype (P=0.049) with no post-hoc 
comparisons significant though HOM and HET were elevated over WT (Figure 3.5A). Finally, 
rearing was significant (P=0.0003) and increased in HOM and HET over WT (P<0.001 and 
P<0.01, respectively) (Figure 3.5B). 
3.3.3 Novel object recognition 
 When mice were exposed to two identical objects at opposite ends of an empty cage, 




spent investigating either object out of the total time of investigation (Figure 3.6A). These mean 
percent time values were not significantly different from 50% chance (P=0.999, P=0.45, P=0.81 
for WT, HET, HOM respectively). One hour later, there was no effect of genotype on the time or 
percent time (P=0.91, P=0.31 respectively) spent investigating the novel object (Figure 3.6B). 
There was a significant increase in time spent with the novel object for all genotypes (P=0.002, 
P=0.015, P=0.0008 for WT, HET, HOM) (Figure 3.6D). Finally, three hours later, there was no 
genotype difference in time (P=0.4) or percent time (P=0.57) with the second novel object, yet 
all genotypes persisted in investigating the second object more than chance (P=0.0005, P=0.03, 
P=0.01 for WT, HET, HOM respectively) (Figure 3.6C,E). 
3.3.4 Morris water maze 
 During two days of three trials per day of visible platform training, mice learned to swim 
to a submerged platform with a large, brightly colored flag marking its location. There was no 
significant effect of genotype on the latency to reach the platform (P=0.46) or the distance swum 
prior to reaching the platform (P=0.58), although all genotypes significantly improved over trials 
(P<0.0001 for both measures) (Figure 3.7A,B). 
 The flag was then removed and animals trained to reach the hidden platform for 2 or 3 
trials per day for 5 days. Again there was no significant effect of genotype on the latency to 
reach the platform (P=0.87) or the distance covered prior to reaching the platform (P=0.98), with 
all genotypes showing improvement across trials (P<0.0001 for both measures) (Figure 3.7C,D). 
 One hour after the last hidden trial, the platform was removed and the mice were tracked 
for 60 seconds. Analysis demonstrated a significant preference (P<0.0001) with an increase in all 
genotypes to spend more time in the NW quadrant that previously contained the platform 




Figure 3.6 Novel object recognition
 
 














Figure 3.9 Morris water maze 24 hour probe 
 
genotypes (Figure 3.8A). When the specific location of the platform was considered, there was 
no significant effect of genotype on platform location crossings (P=0.20) (Figure 3.8B). In view 
of the hyperactivity noted in HOM and HET animals on open field, the total distance covered 
and swim speed were calculated, but there was no significant effect of genotype (P=0.89 
distance, P=0.88 swim speed) (Figure 3.8C,D). 
 Twenty-four hours later, the same test was re-administered and there was a significant 
increase in time spent in the NW quadrant (P<0.0001) (Figure 3.9A). On post-hoc comparison, 




SW (P<0.05), but HET animals did not. Platform location crossings were not significantly 
different (P=0.68), nor were distance swum (P=0.15) nor speed (P=0.14) (Figure 3.9B-D). 
3.3.5 T maze 
 Mice were considered to have learned the T maze task to criterion when they could 
correctly choose the goal arm 7/10 times for 3 consecutive days. The number of days of training 
required to reach this criterion was not affected by genotype (P=0.55) (Figure 3.10A). While 
more HOM animals failed to reach criterion by 12 days of training, this was not significant via 
ANOVA (P=0.69) or Chi
2
 analysis (P=0.68). Upon reaching criterion, all genotypes were 
equally successful at the task (P=0.19) (Figure 3.10B). 
 During the 3 days of working memory testing with increasing intratrial delays, there was 
no effect of genotype on performance (P=0.78), although there was an expected effect of 
intratrial delay time (P=0.007) with performance decreasing significantly as delays increased 
(Figure 3.10D). At each delay value, all genotypes performed above chance (10s delay P<0.0001 
for all genotypes; 20s delay P<0.0001 WT, HET P=0.0002 HOM; 30s delay WT P=0.0001 HET 
P=0.025 HOM P<0.0001) (Figure 3.10E-G). 
 Some animals developed a turn bias during the testing phase. This perseverance was 
evaluated by calculating the percent of left turns for each set of trials, then computing the 
absolute percent difference from 50% which represents both chance and the correct number of 
left turns. There was no significant effect of genotype on turn bias (P=0.92) (Figure 3.10C).  
 Given the open field hyperlocomotion phenotype in HET and HOM animals, time to 
reach the forced run and choice arms were compared during the three testing days, separated by 
intratrial delay time to avoid confounding of working memory effects on speed. No genotype 










Figure 3.11 T maze speed
 
 
arm was different (P=0.0003) with HET (P<0.001) and HOM (P<0.5) mice faster than WT 
(Figure 3.11A,B). There was no difference by genotype for time on the forced (P=0.53) or choice 
(P=0.16) arms with a 20s delay (Figure 3.11C,D). During the 30s delay trials, there was no 
genotype effect for time during the sample arm (P=0.93) but there was on the choice arm 
(P=0.04) with HET and HOM animals trending to be faster than WT although post-hoc testing 




3.3.6 Sensorimotor gating 
On the initial day of PPI testing, mice were exposed to a 120dB startle stimulus in order 
to determine baseline startle without prepulses. This baseline response was not affected by 
genotype (P=0.22), however there were 4 out of 17 HET and 5 out of 16 HOM mice that 
generated less than 2N of force while every WT animal generated more than 2N (Figure 3.12A). 
While this was not significant on Chi
2
 testing by genotype (P=0.11), failure to startle excludes 
animals from PPI analysis. This reduction in startle to tone was not a result of diminished size 
since there was no genotype difference in weight (P=0.27) (Figure 3.12B). Interestingly, WT 
animal weight did not significantly correlate with force generated in response to a 120dB tone 
(P=0.31, Spearman r=0.31), both HET and HOM weights were correlated (P=0.046, r=0.49 and 
P=0.044, r=0.51 respectively) (Figure 3.12C). 
While the distribution of non-startling compared with startling animals was not 
significantly affected by Chi
2
 testing (P=0.11), it clearly influenced auditory startle since there 
was a highly significant effect of both genotype and tone volume (P<0.0001 for both) with 
significant post-hoc comparisons(P<0.05 HOM< WT at 110dB, P<0.01  HOM< HET at 118dB) 
(Figure 3.13A), yet with the most severely affected mice removed (3 HET, 4 HOM) the effect of 
genotype diminished but remained significant (P=0.04) while the effect of volume was 
unaffected (P<0.0001) and there were no longer any significant post-hoc comparisons (Figure 
3.13B). Even without the most affected mice, genotype remained a significant factor and HOM 
animals still startled less and thus the most affected animals were not driving the entire statistical 
significance. 
On PPI testing, when all animals were considered, there was a very significant effect of 










Figure 3.13 Auditory startle across pulse tones 
 
prepulse volume of 74dB (Figure 3.14A). When the non-startling animals were excluded, 
prepulse volume was still significant (P<0.0001) and genotype remained significant to a lesser 
degree across all volumes (P=0.002) with no significant post-hoc comparisons at specific 




3.3.7 Auditory testing 
 Wei Dong, a postdoctoral candidate in Elizabeth Olson’s laboratory at Columbia 
University, conducted auditory testing to determine if deafness were responsible for the reduced 
auditory startle. Two pairs of WT and HOM females were tested for distortion product 
otoacoustic emissions (DPOAE) and compound action potential (CAP) thresholds. CAP 
threshold reflects the minimum sound pressure level to cause a gross nerve action potential of a 
small group of neurons tuned to a single frequency.  DPOAEs have been used for probing the 
active process of the cochlea. These animals were not tested for startle or PPI; the focus of 
auditory testing was to determine a baseline change in hearing since the tones used in 
determining PPI may cause auditory damage. 
The amplitude of the outer hair cell response on DPOAE testing was not different across 
a range of paired primary tone frequencies in HOM compared with WT animals (Figure 3.15A). 
Not all animals survived the continuous anesthesia thus only one HOM had its compound action 
potential (CAP) threshold measured. This HOM animal was compared against other C57Bl/6 
WT mice tested previously in the lab, with no difference in CAP threshold across sound 
frequencies noted (Figure 3.15B). 
 3.3.8 Fear conditioning 
Two cohorts of mice completed fear conditioning as the terminal experiment in the 
behavioral battery. The prior protocols were open field and novel object recognition for both 
cohorts, but the first cohort also learned the water maze while the second did not. As the results 
were different from each cohort, it is possible the differences stem from prior behavioral training 











Figure 3.15 Auditory function testing
 
 
For the first cohort, during the initial 3 minutes of habituation to the conditioning 
chamber binned into 1 minute intervals, there was no significant effect of genotype (P=0.26) and 
a trend toward significance of test time (P=0.06) but there was a significant interaction of 
genotype and test time (P=0.02) (Figure 3.16A). When freezing response was averaged across 




their response to the first unconditioned stimulus tone (P=0.34), the first shock (P=0.32), or the 
second tone (P=0.10) or shock (P=0.66). 
On returning to the same context 24 hours later for 6 minutes, there was a nonsignificant 
trend for effects of genotype (P=0.06) but not test time (P=0.31) with HOM animals trending to 
freeze less in the context (Figure 3.16B) When contextual conditioning was analyzed as an 
average across the test time, genotype remained a trend (P=0.06). Two hours later, in a novel 
context for the first 3 minutes of cued testing, there was no effect of genotype (P=0.58) but 
surprisingly animals froze more across test time (P<0.0001); taken as an average across time, 
freezing response was still not affected by genotype (P=0.58) (Figure 3.16C). Once the 3 minute 
long tone began, all animals froze less as test time progressed (P<0.0001) but without regard to 
genotype (P=0.67), nor was this significant on analysis averaged across test time (P=0.67) 
(Figure 3.16D). During the initial 30s of the cued stimulus, there was no genotype effect 
(P=0.46). 
For the second cohort, there was also no significant effect of genotype (P=0.27) or of test 
time (P=0.06) but there was a significant interaction of genotype and test time (P=0.005) on 
freezing during initial habituation (Figure 3.17A). The averaged freezing response showed no 
effect of genotype (P=0.27). Again, genotype did not influence how the mice responded to the 
first tone (P=0.56) or shock (P=0.71), or the second tone (P=0.44) or shock (P=0.36). 
Upon contextual testing, there was an effect of genotype (P=0.016) but not test time 







(Figure 3.17B). When averaged across the test time, genotype remained significant (P=0.016) 
and HOM animals froze less than WT on post-hoc testing (P<0.05). In the novel context there 




(P<0.0001) with HET and HOM animals freezing less than WT in the final minute (P<0.05) 
(Figure 3.17C).Taken as an average across time, freezing response was still affected by genotype 
(P=0.03) with no post-hoc comparisons significant. During the continuous tone, the effect of 
genotype on freezing was also significant (P=0.003); although all animals froze less as test time 
progressed as expected (P<0.0001), HOM animals froze less than WT at each time point (P<0.05 
or <0.001) (Figure 3.17D). This effect remained significant on averaged analysis (P=0.003). 
Despite the strong effect across the entire 3 minute tone, during the initial 30 seconds of the cued 
stimulus, there was no genotype effect (P=0.24). 
When freezing in the novel context is affected, one recommendation is to subtract the 
averaged freezing rate in the novel context from the cued response (see Discussion for further 
explanation). Upon performing this calculation, the previously significant effect of genotype 
became only a trend (P=0.066) (Figure 3.18A). 
As mentioned before, there was a significant difference between the two cohorts 
independent of genotype for contextual (P=0.04) and cued (P=0.0002) conditioning. No post-hoc 
comparisons of contextual learning were significant, but WT from cohort 2 tended to freeze 
more than WT from cohort 1 while the reverse was true for HET mice (Figure 3.18B). On post- 
hoc testing of cued learning, WT from cohorts 1 and 2 were significantly different from each 
other in the last 2 minutes (P<0.001) while HOM and HET mice did not differ across cohorts 
(Figure 3.18C). Thus the WT animals were most different between the two cohorts and drove the 
majority of the discrepancy between the cohorts. 
3.3.9 cFOS analysis of amygdala and hippocampus activation 
To investigate the activation of the amygdala and hippocampus during fear conditioning, 














Figure 3.18 Fear conditioning normalization and comparison
 
expression was assessed as a measure of neural activity. cFOS is an early component of the 
synaptic plasticity pathway and its expression is significantly upregulated in the amygdala, 
hippocampus, and cortex within 90 minutes after fear conditioning (Ressler et al. 2002). 
Moreover, cFOS staining pattern is also a reliable measure of neural activation and the number 
of cFOS positive neurons positively correlates with fear learning (Radulovic et al. 1998; Tronson 
et al. 2009).  
As there were so few animals, analysis of behavioral outcomes from fear conditioning 
were not significant (data not shown), but there was an overall trend toward more freezing in the 
animals that experienced fear conditioning (FC) as opposed to controls without shocks (CTRL). 
Of the control animals, HOM mice tended to freeze less on all measures consistent with prior 




 In the lateral amygdala (LA), there was a significant effect of condition (P=0.0001), but 
only a trend for WT and HOM but not HET to be higher after fear conditioned than in controls 
(Figure 3.19A). This suggests fear conditioning has a positive effect on cFOS activation in the 
LA, but no conclusions can be drawn about genotype effects of cFOS activation in this brain 
region during conditioning. 
 Downstream in the basolateral amygdala (BLA), there was a significant effect of 
condition (P<0.0001) with significantly increased cFOS protein levels in WT after conditioning 
(Figure 3.19B). HOM control cFOS levels were higher than WT, but this pattern did not persist 
after conditioning. Since WT cFOS activity increased with conditioning but HET and HOM did 
not, this suggests HET and HOM mice did not activate the BLA in response to conditioning. 
 In the central amygdala (CE), there was no significant effect (P=0.73) of conditioning or 
genotype (Figure 3.19C). If there was an effect of these factors on cFOS levels, this study was 
underpowered to detect it. 
 In the hippocampus, cFOS staining levels in the dentate gyrus (DG), CA3, and CA1 
regions were all significantly affected by fear conditioning (P<0.0001, P=0.0004, P=0.02 
respectively). Unexpectedly, in the DG cFOS neural activation tended to be lower in conditioned 
as opposed to control animals though no post-hoc comparisons were significant (Figure 3.19D). 
Among both conditioned and control mice, HOM had reduced cFOS activity compared to WT, 
with a downward trend in HET. Thus HET and HOM animals have consistently less DG activity, 
but this was unassociated with fear conditioning. 
 WT conditioned mice had significantly higher cFOS levels than WT control mice in the 
CA3 (Figure 3.19E). This pattern did not extend to conditioned HOM or HET, which were 











appear to be impaired on CA3 activation after fear conditioning. 
 Finally in the CA1 WT animals had significantly more cFOS activity after conditioning, 
but this did not extend to HET or HOM animals (Figure 3.19F). Similar to the CA3, HET and 
HOM CA1 activation is also impaired during fear conditioning. 
3.4 Summary of findings 
Rapgef6 knock out mice demonstrated hyperactivity and anxiolysis on open field testing 
with increased rearing in HET and HOM animals on both days, increased margin distance in 
HETs on day 1, but increased total distance in HET and HOM on day 2 as well as increased 
center distance and center entries in HOMs on day 2. Rapgef6 HET and HOM animals did not 
show impairment in spatial learning or working memory since novel object recognition, water 
maze, and T maze findings were not significant. Despite normal audition, HET and HOM 
animals showed a variable penetrance for lack of startle response to 120dB. The remaining HOM 
animals with a startle response evidenced impaired startle across quieter tones. Prepulse 
inhibition was reduced in HET but not HOM animals, both with and without inclusion of the 
non-startling mice. Finally, the cohort of mice that were handled more had a trend toward 
impaired contextual fear conditioning, with a subsequent cohort handled less showing impaired 
freezing to contextual and cued conditions, but also generalizing this reduced fear to a novel 
context complicates interpretation of the data. cFOS activation studies following fear 
conditioning indicate a baseline hyperactivity in HOM BLA and hypoactivity in HOM DG, and 
impaired HET and HOM activation of the BLA, CA3, and CA1 after conditioning. 
In summary, we have described evidence for hyperactivity, reduced anxiety, reduced 
startle and sensorimotor gating, and impaired fear conditioning in the context of normal spatial 




impaired across several tested domains of innate and learned fear, that hippocampal function 
relative to fear but not spatial learning is also affected, and that mPFC-dependent working 
memory is intact. 
3.5 Discussion 
3.5.1 Behavioral domains and endophenotypes 
As we are trying to develop a model that can be used to either inform or test new 
therapeutics, we started from strong human genetic findings and then determined the behavioral 
phenotype available for potential pharmacologic rescue. Given the high comorbidity of 
schizophrenia with other neuropsychiatric disorders, we cast a wide net for behaviors that are 
affected in other schizophrenia models plus unexpected phenotypes arising from pleiotropy. 
After completing the described behavioral assays, there are several questions that remain to be 
investigated. 
3.5.1.1 Locomotion and exploration 
 Open field with laser tracking is an accurate way to measure locomotion and quantitate 
exploratory behavior such as rearing and anxiety behavior such as center avoidance (Bailey and 
Crawley 2009). Any drug or mutation which impairs motor ability or arousal will diminish 
locomotion, but open field center time or distance was increased by GABA agonists (barbiturates 
and benzodiazepines), serotonin receptor partial agonists and selective serotonin reuptake 
inhibitors, and dopamine receptor agonists (Brookshire and Jones 2009; Prut and Belzung 2003). 
Mice modeling the 22q11 deletion as a rare but recurrent genetic cause of schizophrenia were 
also hyperactive on open field similar to Rapgef6 mice, although male mice with the 22q11 
deletion had increased anxiety and center avoidance (Stark et al. 2008). Conversely, deletion of 




Rearing in the open field is considered a form of nonspecific attention and exploration 
that is influenced heavily by dopamine and serotonin levels (Aspide et al. 2000). Rearing rates 
were increased by dopamine and serotonin receptor agonists interacting in the ventral striatum 
(Berridge 2006; Ikemoto 2002), but decreased in dominant negative E or N cadherin mutant 
mice (Edsbagge et al. 2004), deletion of dopamine D2 and D3 receptors (Vallone et al. 2002), 
and in the neurofibromatosis mouse model, where LDopa rescued the phenotype (Brown et al. 
2010). Thus both rearing and overall locomotion are likely linked to schizophrenia and other 
neuropsychiatric diseases via the dopaminergic and serotonergic systems. Since Rapgef6 KO 
mice had increased locomotion and rearing, this suggests that dopamine release or dopamine 
receptor expression are increased in the striatum, possibly analogous to findings in humans with 
schizophrenia (Abi-Dargham et al. 1998). While Rapgef6 is expressed in the striatum, there is no 
published evidence that it regulates dopaminergic function, so this hypothesis would have to be 
tested further. 
3.5.1.2 Spatial and working memory 
Novel object recognition (NOR) is a useful way to assess spatial hippocampal memory 
because it does not require positive or negative reinforcement, thus it is still informative in 
animals with altered reward circuitry or pain sensitivity (Sousa et al. 2006). Since neither of 
these two pathways was analyzed in this mouse model, NOR is an important addition to the 
maze results in demonstrating intact spatial memory. NOR is, however, sensitive to attention or 
activity phenotypes (Amann et al. 2010). Despite open field hyperactivity our KO animals did 
not differ from WT demonstrating there was no activity-related bias. NOR is known to rely on 
schizophrenia-related neurotransmitter systems such as glutamate receptors NMDA-R2b and 




parahippocampal cortex (Dere et al. 2007).  
 The Morris water maze tests hippocampal spatial memory. Moreover it also includes 
visible platform testing to assess visual perception and offers a chance to measure speed and 
locomotion independent from the open field (Sousa et al. 2006). C57Bl/6 mice excel at this task, 
so perhaps there is a ceiling effect masking a mild deficit, such as HET animals performing 
below WT at 24 hours, which would not be apparent in a background strain so proficient at the 
task (D'Hooge and De Deyn 2001). Among schizophrenia models, Disc1 KO animals 
demonstrated normal water maze and novel object recognition testing (Kvajo et al. 2008). 
Despite clinical findings of hippocampal volume change (discussed in Chapter 4), mouse models 
of schizophrenia do not typically have water maze deficits. 
 T maze utilizes spatial as well as working memory. It is not considered the most accurate 
test of working memory, however, since it only involves one choice point, as opposed to an 8 
arm maze or a more complicated delay paradigm, thus there may be a possible deficit on more 
complicated testing that has not yet been excluded (Sharma et al. 2010). Working memory tasks 
are known to rely on the medial PFC based on chemical lesion studies (Kellendonk et al. 2006), 
but also involve monosynaptic output from ventral CA1 to medial PFC (Wang and Cai 2006). 
Among schizophrenia models, Disc1 animals demonstrated specific deficits in working memory 
as measured on T maze and a delayed non-match to position task (Koike et al. 2006; Kvajo et al. 
2008), while 22q11 and Dgcr8 models had an impairment in T maze acquisition (Stark et al. 
2008). The striatal D2 receptor overexpression mouse model also had impaired working memory 
on the T and 8 arm radial mazes (Kellendonk et al. 2006). 
3.5.1.3 Startle and prepulse inhibition 




it is a measure of sensorimotor gating. The startle reflex is generated by a circuit from the 
cochlear root neuron to the nucleus reticularis pontis caudalis, then output via the facial and 
spinal motor neurons; this pathway is modulated in PPI by the striatum, pallidum, and 
hippocampus (Geyer and Dulawa 2003). PPI has been probed in most models of 
neuropsychiatric disorders because the protocol is highly analogous in humans and mice and 
individuals with schizophrenia and other disorders have PPI deficits yielding face validity 
(Powell et al. 2009). It is hypothesized that impaired sensory gating may contribute to positive 
symptoms such as hallucinations (Dulawa and Geyer 2000). Mice mimicking both the 22q11 
deletion and heterozygous deletion of Dgcr8 had impaired PPI with normal startle (Stark et al. 
2008). Other genes within the 22q11 region also influence PPI; Gnb1L and Tbx1 deletion both 
impaired PPI, but PPI was increased in deletion of 7 other genes in the region (Arguello et al. 
2010). Disc1 KO mice were not affected (Kvajo et al. 2008) but Neuregulin1 KO mice showed 
PPI reduction (Chen et al. 2008). Genetic models of additional neuropsychiatric disorders had 
decreased PPI such as knock outs of Reelin, NCam, proline dehydrogenase, and Fabp7 (Amann 
et al. 2010).  
Since PPI using auditory stimuli is dependent on hearing, any PPI or startle deficits merit 
auditory analysis. On compound action potential threshold measurements, the HOM mouse 
demonstrated no difference from other C57Bl/6 WT mice in activity in the cochlear nerve, 
implying no impairment in hearing threshold. During distortion product otoacoustic emissions 
testing, HOM animals did not differ from WT. This indicates the entire auditory afferent and 
efferent pathway, from the basilar membrane to the auditory cortex and back to the outer hair 
cells, remained intact and functional in HOM animals. Because the lack of startle response was 




tested mice does not rule out abnormal hearing in specific mice that lacked startle 
response.  Auditory tests on startle-deficient animals should be done to probe this possibility 
further. 
Beyond audition, the decrease in startle response in HOMs likely affected the calculation 
of PPI. While startle and PPI were initially considered to be independent (Paylor and Crawley 
1997), recent experiments proved that changes in startle create artifacts when calculating PPI 
since startle response is part of the equation (Dulawa and Geyer 2000). Percent PPI (%PPI), 
which was used in this analysis, is considered the most accurate measurement since %PPI is 
somewhat independent of startle and significant %PPI results are still considered meaningful 
even if startle is also significantly different (Csomor et al. 2008). Experts agree that animals 
without any baseline startle cannot yield an interpretable %PPI, which is why our analyses were 
performed with and without non-startling animals. Since %PPI is a ratio, the lower the startle the 
higher the %PPI, both mathematically and experimentally (Csomor et al. 2008). This explains 
why HOM animals had normal %PPI despite reduced startle because PPI was biased upward by 
the startle value. Meanwhile, HET animals had decreased %PPI and no change in startle. There 
was possibly a reduction in PPI in HOM mice that was normalized up by the necessary 
calculations. 
Several mouse models suggest that the dopamine, glutamate, and norepinephrine 
pathways might be involved in reduced startle. Clozapine and ketamine both increased startle 
and reduced PPI, implicating dopamine and glutamate NMDA receptors in startle and PPI 
modulation (Csomor et al. 2008). Similar to ketamine studies, deletion of the glutamate NR1 
NMDA receptor subtype lead to increased startle and reduced PPI (Duncan et al. 2006). 




overexpressing the receptor increased PPI (Sallinen et al. 1998). These findings suggest the 
possibility that glutamate NMDA or norepinephrine α2C receptor activity may be elevated or 
dopamine systems may be depressed in the Rapgef6 mouse. 
Data supporting amygdala impairments in this animal are discussed below and it is 
possible that amygdala hypofunction could explain the reduction in PPI. Lesion studies have 
shown that the basolateral amygdala (BLA) is important for proper PPI to occur, possibly by a 
pathway from the BLA to the nucleus accumbens or ventral pallidum, but that BLA lesions do 
not affect startle (Decker et al. 1995; Wan and Swerdlow 1997). Lesion of the medial amygdala 
leads to anxiolysis, increased startle, and reduced PPI that are hypothesized to be the result of 
diminished unconditioned fear and anxiety (Vinkers et al. 2010). This phenotype is reminiscent 
of the hyperactivity, anxiolysis, and PPI changes in our mouse, providing further support for a 
possible amygdala dysfunction as discussed below. 
3.5.1.4 Anxiety and fear conditioning 
Within the amygdala, thalamic and cortical sensory input to the lateral nucleus (LA), 
where the plasticity of fear learning is thought to occur, continues to the basolateral nucleus 
(BLA), and then outputs through the central nucleus (CE) and on to freezing centers in the 
brainstem (Johansen et al. 2011). Traditionally, contextual fear conditioning is thought to involve 
the hippocampus and amygdala, while cued conditioning is dependent on the amygdala alone 
(Maren 2008). Hippocampal lesion studies, however, demonstrate that the HPC is not essential to 
contextual conditioning, especially if it is lesioned prior to conditioning (Gerlai 2001). While 
fear conditioning is not a canonical endophenotype of schizophrenia, it is certainly relevant to 
other neuropsychiatric disorders. Moreover, there is growing interest in the amygdala in 




amygdala volume and function in schizophrenia (Exner et al. 2004; Fahim et al. 2005; White et 
al. 2008). Among schizophrenia mouse models, both contextual and cued fear conditioning were 
impaired in 22q11 deletion animals but not in Dgcr8 or Disc1 animals (Kvajo et al. 2008; Stark 
et al. 2008). 
Our results demonstrated a trend toward impaired contextual conditioning in one cohort, 
with impaired contextual and cued conditioning as well as reduced fear generalization in a 
second cohort. Since HPC function is normal on spatial testing and the amygdala is necessary for 
both contextual and cued learning, the results point to the likely possibility that amygdala 
dysfunction caused this phenotype. These behavior results are strengthened by cFOS analysis 
demonstrating impaired HET and HOM activation of the amygdala (BLA) and hippocampus 
(CA3, CA1) following conditioning. These cFOS activity results are in agreement with findings 
in the literature of an increase in CA1, BLA, and LA activity after fear conditioning (Radulovic 
et al. 1998; Reijmers et al. 2007; Tronson et al. 2009). Baseline hypoactivity noted as reduced 
cFOS staining in HOM dentate gyrus suggests that the dentate would be an appropriate region to 
study since neurogenesis promotes contextual fear conditioning (Drew et al. 2010; Saxe et al. 
2006). Meanwhile, baseline hyperactivity in HOM BLA suggests there may be dysregulation of 
BLA input, perhaps analogous to the increase in baseline synaptic cortico-amygdala activity 
despite fear impairment in the Rap1 mouse model (Pan et al. 2008). 
The cFOS results should be qualified by noting that changes in baseline cFOS expression, 
or even expression after conditioning, may be due to effects of Rapgef6 on other aspects of cFOS 
regulation than neural activity. For instance, changes in growth factors or even in Rap1 can alter 
cFOS directly and these pathways should be altered following Rapgef6 deletion (Sakoda et al. 




case the overlapping nature of the regulatory pathways involved complicate the data 
interpretation. More direct analysis via electroporation or confirmation through other non-Rap1 
regulated genes should be pursued.  
While one study suggested there was no impact of the order of prior tests on fear 
conditioning (McIlwain et al. 2001), the only other study of inter-test interaction found that 
handling mice in order to perform tests lead to impaired contextual and increased cued fear 
conditioning, among other effects (Voikar et al. 2004). Mouse models of post-traumatic stress 
disorder found that stress increased fear learning and impaired extinction (Long and Fanselow 
2012). Since the only difference between the two fear conditioning test cohorts was that the first 
cohort was subject to the stress and handling of the water maze, resulting in first cohort WT 
freezing levels lower than second cohort WT, these results do not correspond with PTSD models 
of stress but do align with handling effects on contextual fear conditioning. Notably, differences 
in handling failed to affect HOM animals on any fear measures or HET animals on contextual 
fear conditioning. This data suggests HOM and HET animals are resistant to the negative effects 
of stress and handling, perhaps due to amygdala hypofunction. 
The second cohort displayed reduced freezing in the novel contest prior to the cued test in 
HOM relative to WT. This generalization of HOM contextual fear to the novel context is known 
to impact subsequent cued freezing measurement. Studies showed subtracting novel context fear 
from cued fear was the most appropriate mathematical method to correct for such differences, 
however the best overall solution would be to extinguish any novel context fear through 
habituation until this phenomenon is abolished, and then measure cued fear (Jacobs et al. 2010). 
We used this subtraction method, yielding a loss of significance on the second cohort cued 




Several other phenotypes can affect fear conditioning. If audition or pain threshold were 
impaired this would affect fear conditioning. Analysis above demonstrating all mice had the 
same response to the initial tone and after the first shock argues against impaired hearing or pain 
threshold. Changes in locomotion, anxiety, and exploration can all alter freezing and thus the 
output measured as fear (Maren 2008). Given Rapgef6 KO mice have increased activity and 
decreased anxiety, this baseline phenotype might contribute to the reported reduction in fear 
conditioning by causing HET and HOM mice to freeze less in all stages of the test.  
Acetylcholine receptor agonists injected into the nucleus accumbens led to impairments 
in startle and contextual fear conditioning and increased locomotion (Cousens et al. 2011). The 
startle deficit is hypothesized to contribute to the fear impairment in this animal as a result of 
pharmacologically strengthened input from the hippocampus and amygdala onto the nucleus 
accumbens. Similarly, abnormal activity in the Rapgef6 mouse HPC and/or amygdala, as 
evidenced by the behavior and cFOS activity data, may lead to the reduced startle and fear 
conditioning phenotypes observed here. 
3.5.2 Evidence for neuropsychiatric model validity 
The behavioral phenotype described in this chapter supports the utility of Rapgef6 
deletion as a model of neuropsychiatric disease, particularly schizophrenia. Our mouse 
demonstrated endophenotypes associated with schizophrenia including impaired PPI, 
hyperactivity, and amygdala dysfunction on fear conditioning and cFOS staining analysis. 
Reduced anxiety and fear learning could also represent imbalance in these affective circuits and 
thus a way to learn more about anxiety-related pathways in a mouse model of diminished 




3.5.3 Correlation with Rapgef and Rap mouse models  
 There are several ways in which these behavior results align with other Rap and Rapgef 
family mouse models. Rapgef3 or 4 individual deletions had no behavioral effect on their own, 
suggesting there is a great potential for compensation or redundancy within this gene family that 
could account for the mild phenotype seen here. Rap1 KO resulted in normal water maze 
performance, reduced cued fear, and reduced novel context fear similar to our mouse, which 
suggests Rapgef6 KO also shares the reduced cortico-amygdala plasticity demonstrated in Rap1 
deletion. Rap1 KO increased basal cortical activation of the lateral amygdala, which may be 
analogous to increased BLA cFOS activity in the Rapgef6 mouse. The MRas KO animal also had 
normal water maze performance, however our mouse had multiple behavioral deficits that were 
unaffected by MRas deletion. Although MRas was a major determinant of Rapgef6 localization 
in lymphocytes, our data suggested MRas and Rapgef6 behavioral phenotypes differ and 
therefore MRas may not direct Rapgef6 activity in neurons. 
 Unlike the Rapgef6 KO animal, constitutively active Rap2 caused hyperactivity, impaired 
water maze performance, and normal fear conditioning. The Rapgef3/4 double mutant had 
impaired water maze performance as well. MRas deletion led to normal fear conditioning. Thus 
deletion of Rapgef6 overlapped phenotypically with Rap1 deletion, but not as closely with Rap2, 
MRas, or Rapgef3/4 models. Despite biochemical predictions, behavioral analysis suggests 
neural Rapgef6 may be independent of MRas and activating Rap1 more than Rap2. 
3.6 Future directions 
3.6.1 Behavioral paradigms 
To completely rule out auditory dysfunction as a possible confounder on PPI studies, PPI 




normalization in PPI to a tactile stimulus would reinforce the current findings. 
As mentioned above, explicit testing of pain threshold is important to validate the fear 
conditioning results since if HOM animals did not feel the shock to the same extent as WT then 
they could not be equally conditioned. This assessment could be achieved with hot plate 
thresholding.  
Rapgef6 KO animals demonstrated hyperactivity and anxiolysis on open field testing. 
This finding could be further explored in two directions, to examine more anxiety phenotypes 
and to quantify stimulant-induced hyperactivity. A more thorough assessment of anxiety would 
include the light/dark box assay and elevated plus maze testing, both of which measure anxiety-
like preference for a dark or protected environment over the desire to explore a bright or exposed 
location. Just as patients with schizophrenia given stimulants demonstrated a significant increase 
in activity, so too can animals be tested by stimulant administration to explore the positive 
symptoms of schizophrenia; this phenomenon is thought to involve increased dopamine release 
from the striatum (Ujike 2002). 
In order to better understand the fear conditioning impairments in this model, there are a 
variety of protocols that can dissect different aspects of the conditioning process to localize the 
specific deficit. First, as mentioned above, the confounding effect of decreased fear in the novel 
context on cued fear measurement could be resolved using novel context habituation. Next, 
habituation to both cue and context, as well as extinction and revival conditioning, could help 
determine if the decrease in fear conditioning persists across time and over multiple trials. Such 
experiments would further probe amygdala and hippocampal function, as well as prefrontal 
cortex regulation of extinction (Knapska and Maren 2009). Altering the strength of conditioning 




the fear conditioning deficit can be overcome, as was seen in the Rap1 knock out mouse. Finally, 
the cFOS activation paradigm used in this experiment was focused on cued conditioning, but this 
could be altered to analyze contextual conditioning to determine if amygdala and hippocampal 
activation deficits persist, or to evaluate any possible dysfunction of the PFC in fear conditioning 
and extinction (Knapska and Maren 2009; Morrow et al. 1999). 
3.6.2 Genetic manipulations 
It could be informative to cross the Rapgef6 knock out onto other backgrounds or various 
mutations. Since individuals with schizophrenia likely carry a variety of both private and 
common risk variants contributing to the etiology of the disorder, a mouse model of one variant 
may be insufficient to fully recapitulate the human disorder (Girirajan et al. 2012). Crossing 
together models of different risk alleles can help determine if there is genetic redundancy of the 
two genes within the same pathway or epistatic interactions between different genes contributing 
to a larger phenotype (Beckers et al. 2009). Consider Rapgef3 and Rapgef4, each of which when 
individually knocked out had no behavioral phenotype but a double mutation did due to 
redundancy (Yang et al. 2012). Perhaps combining our Rapgef6 knock out with either of these 
mice would reveal a reduction in compensation and a worsening of the behavioral phenotype. 
Moreover, different genetic backgrounds contribute to epistasis in subtle ways that are 
frequently overlooked. Even though it is clear that backgrounds vary widely in their baseline 
behavioral phenotypes, not much effort has gone into determining what genetic factors cause 
these differences or how they contributes to mutant model phenotypes. Concerning the Rapgef6 
mouse, crossing onto backgrounds with different fear or startle thresholds could help reveal these 
phenotype differences. For example, C57Bl/6 is known to be a moderate background on anxiety 




2008), but given Rapgef6 KO animals have reduced fear and anxiety they may be reaching the 
lower limit of test sensitivity and could be interesting to study on a more anxious background. 
3.6.3 Pharmacologic interventions 
As mentioned in the introduction, Rapgef3/4 agonist 8CPT can increase PPI without 
altering startle and strengthen fear conditioning by mimicking an increase in cAMP (Kelly et al. 
2009) and 8CPT also compensates in vitro for Rapgef6 knock down effects on cell connectivity 
(Dube et al. 2008). While Rapgef6 does not depend on cAMP, it would still be interesting to 
evaluate whether activating Rapgef3/4 could lead to behavioral compensation and thus rescue of 
PPI and fear impairments in the Rapgef6 KO animal. This would be an interesting compliment to 
the suggestion above that crossing Rapgef knock out animals could diminish compensation and 
thereby aggravate behavioral phenotypes.  
3.6.4 In the next chapter 
In the subsequent chapter, we will consider neural morphology in brain regions 
associated with execution of these behavioral phenotypes in an attempt to correlate behavioral 





Chapter 4: Morphology Findings 
4.0 My role 
 I performed all experiments described here except for the Western blots, the design of the 
primers for cloning, and FACS which was performed by the Columbia University Medical 
Center FACS core. 
4.1 Introduction 
4.1.1 Alterations of neural morphology in schizophrenia 
 In a biologically based hypothesis, the symptoms of schizophrenia are due to alterations 
in circuits resulting from changes in neural morphology and connectivity. In order to identify 
these changes, there are numerous analyses of schizophrenia neural morphology and connectivity 
at the postmortem cellular and in vivo volumetric and functional imaging levels. Postmortem 
studies are complicated by many factors including the duration of illness, medication history, and 
time until tissue preservation. Although these methods are limited for technical reasons, 
postmortem analysis may still inform our understanding of schizophrenia pathophysiology. 
There are findings of prefrontal cortex specific impairment. In one study of the dorsolateral 
prefrontal cortex (dlPFC) there was a 23% reduction in layer III pyramidal neuron dendritic 
spine density in brains from individuals with schizophrenia compared to controls, and a 16% 
reduction compared to individuals with non-psychotic psychiatric disorders (Glantz and Lewis 
2000). This finding was apparently specific to the dlPFC as it was not observed in samples of 
visual cortex. Further analysis of the same brains found that spine density, soma size, and 
dendritic length in layers V and VI of dlPFC were unaffected by diagnosis, but spine density in 




only (Kolluri et al. 2005). Layer III receives mediodorsal thalamic and intracortical input 
suggesting there may be a reduction in activity from these regions.  
In the amygdala, postmortem analysis found no changes in volume, neural density, or 
soma size in two studies (Berretta et al. 2007; Chance et al. 2002). Microarray analysis 
demonstrated alterations in genes involved in presynaptic function, myelination, and signaling, 
suggesting there may be more subtle dysregulation (Weidenhofer et al. 2006). 
There are a variety of findings in postmortem hippocampus studies. Staining for the 
dendritic marker MAP2 identified an increase in dendritic length throughout the hippocampus 
and subiculum in schizophrenia cases, though this may be due to an increase in MAP2 
expression (Cotter et al. 2000). The mossy fiber synapses from the dentate gyrus to the CA3 had 
reduced spine density onto smaller CA3 spines, known as thorny excrescences (Kolomeets et al. 
2005; Kolomeets et al. 2007). Moreover, staining for immature neurons with Ki-67 found 
reduced adult neurogenesis in the dentate gyrus of patients with schizophrenia but not depression 
(Reif et al. 2006). The number of hippocampal inhibitory interneurons was reduced by multiple 
experimental techniques though pyramidal neuron number was unaffected (Benes et al. 2007; 
Konradi et al. 2011). Combined with studies of reduced dentate glutamatergic receptor 
expression, hippocampal morphology alterations and clinical findings of impaired hippocampal 
function contribute to a hippocampal hypothesis of schizophrenia in which reduced dentate 
glutamatergic release may dysregulate hippocampal circuitry, affecting pattern and associative 
memory and thus yielding psychosis and cognitive symptoms (Tamminga et al. 2010). 
Changes in morphology may be connected to alterations in neural migration and 
extracellular matrix in schizophrenia. A number of studies of postmortem neuronal density, as 




regions (Connor et al. 2011). This abnormality may be the result of reduced migration, altered 
neurogenesis or apoptosis balance, or cortical inflammation. Evidence in favor of altered 
migration came from analysis of the extracellular matrix, in which pro-migration factors such as 
Reelin, chondroitin containing molecules, and the Neuregulin1-ErbB pathway were affected in 
schizophrenia (Guidotti et al. 2000).  
 In vivo analyses of brain volume and function have yielded a variety of results depending 
on the experimental technique, sample size, and patient sample type (first episode psychosis, 
chronic, unmedicated, or longitudinal schizophrenia). One recent meta-review of meta-analyses 
concluded that there is sufficient evidence to confirm a reduction in whole brain volume, 
increase in lateral ventricular size, and volume reductions in subregions of the frontal and 
temporal lobes, most significantly within the superior temporal gyrus, anterior cingulate cortex, 
parahippocampus, hippocampus, and amygdala, as well as reduced midline thalamic volume 
(Shepherd et al. 2012). Additionally, there was also a reduction in corpus callosum cross-section 
area and in frontal and temporal connectivity.  
 Postmortem changes do not inform how the disease begins neurobiologically. Clinical 
and in vivo imaging results suggest that many of these anatomic changes are already present at 
the time of first psychosis and that symptoms can present as early as adolescence or childhood, a 
time when loss of synapse density, termed synaptic pruning, normally occurs (Keshavan et al. 
1994). In the 1980s, long before much supporting data was available, neuroscientists first 
proposed that schizophrenia may be a neurodevelopmental disorder due to increased synaptic 
pruning in adolescence (Keshavan et al. 1994). More recent studies of gene expression, imaging, 
and epidemiology all support the idea that synaptic dysfunction is a common endpoint for many 




effects of schizophrenia risk alleles on neural morphology and spine density, critical factors that 
determine synaptic function, is therefore important in order to assess whether there is evidence 
for neurodevelopmental dysfunction that contributes to adult symptoms and pathophysiology. 
4.1.2 Importance of neural development and morphology in circuits 
 Neurons transmit information as a direct consequence of their connectivity. Thus neural 
migration and form determine neural function as cells can only influence what they can reach. 
Cortical projection neurons migrate linearly from the ventricular zone through deeper structures 
toward the pia, while inhibitory interneurons migrate radially from the ganglionic eminences. 
Though cell-autonomous signaling contributes to migration, extrinsic signal pathways such as 
Reelin, Notch, and Semaphorins for projection neurons and Neuropilins, Semaphorins, and 
Robos for interneurons are essential to migration targeting (Huang 2009; Nakajima 2007). 
Neural morphology is important at two levels; the outgrowth of the axonal and dendritic 
arbors and the density and shape of spines. While traditionally neuroscience has been focused on 
axon guidance as a means to understand connectivity, there is growing interest in dendritic 
guidance and spine dynamics as two novel determinants of cellular function. Moreover, we now 
understand that dendritic morphology, beyond putting neurons in contact with each other, also 
shapes neurotransmission by affecting integration of synaptic input en route to the soma 
(Whitford et al. 2002). Analyzing neural morphology in vivo and in vitro is therefore an 
important aspect in understanding neural function. 
 Most neurons, such as cortical pyramidal neurons, are polarized, with an apical dendritic 
arbor and a basal axon. Even though the dendrites and axons tend to grow in opposite directions, 
they respond to the same trophic molecular cues using similar receptors. Experiments show that 




Netrin, and Slits via Neuropilin, frazzled/DCC, and Robo receptors, respectively (Kim and Chiba 
2004). Other important extrinsic signals include IGF, BDNF, NT3, and NT4; these factors have 
varying effects within different cortical layers, apical vs. basal dendritic arbors, and across brain 
regions (McAllister et al. 1995; Niblock et al. 2000). These divergent growth responses seem to 
result from differential cytosolic signaling pathway activity in distinct cellular subdomains, 
whether at the level of timed expression (axons develop before dendrites), sequestration of 
different signal pathways through cytoskeletal and motor protein polarization, differences in 
local protein synthesis, or diffusion barriers such as the initial axon hillock. Extrinsic signals that 
are shared between axons and dendrites likely evolved to increase cell connectivity and synaptic 
convergence by guiding pre- and postsynaptic processes toward each other (Kim and Chiba 
2004). 
 Careful in vivo analysis demonstrated that all cortical neurons start with the same basic 
morphology before diverging into layer- and region-specific morphology patterns; therefore 
neurons have intrinsic growth pathways that are genetically predetermined which are later 
modified by extrinsic signals such as those mentioned above to determine their mature form 
(Whitford et al. 2002). Intrinsic signals are hypothesized to derive from elevated levels of Notch, 
Numb, and β-catenin (Whitford et al. 2002). Using in vitro culture systems permits analysis of 
these intrinsic patterning signals that guide polarization since extrinsic signals are not available 
unless experimentally added. Hippocampal neural culture in particular is a widely used robust 
technique to study neural morphology development because cultured neurons undergo four 
reproducible stages of neurite growth and axon specification (Bradke and Dotti 2000).  
 The last major force shaping neural morphology is electrochemical synaptic activity. 




the maintenance of dendritic arbors. Calcium influx during neural activity is hypothesized to 
activate various targets including Creb, CaMKIV, and eventually lead to activation of Rho 
GTPases that modify actin structure to influence dendritic branches (Wong and Ghosh 2002).  
We will describe morphology analysis both in vivo and in vitro in an effort to understand 
effects of Rapgef6 on intrinsic, extrinsic, and activity driven neural morphological development. 
4.1.3 Morphological role of Raps and Rapgefs  
Nothing is currently known about the role of Rapgef6 in neural morphology, however its 
effect on cell adhesion pathways may alter neural development. In lymphocytes, Rapgef6 was 
brought to the membrane by MRas to mediate TNFα signal transduction, leading to Rap1 
activation which then stimulated RapL, Riam, and integrins such as LFA1 to promote cell-cell 
adhesion (Yoshikawa et al. 2007). Rapgef6 also increased cadherin and catenin-dependent 
adherens junction maturation as well as E-cadherin expression in epithelial cells (Dube et al. 
2008). In vitro epithelial migration via Jam-a activating Afadin could not promote β1-integrin 
adhesion unless Rapgef6 was present to activate Rap1a (Severson et al. 2009). Rapgef6 bound 
Bag3, an actin-associated protein at the leading edge of migrating cells, and was sufficient for 
the effect of Bag3 on promoting cell motility and adhesion via integrin recycling (Iwasaki et al. 
2010). Integrins and cadherins are essential to radial and tangential neural migration in the brain, 
as well as neurite outgrowth via adhesion to extracellular matrix (Clegg 2000; Suzuki and 
Takeichi 2008). β1-integrin was especially key in radial glia development and thus radial neural 
migration (Graus-Porta et al. 2001). Given its role in promoting cell-cell and cell-extracellular 
adhesion, we expect that Rapgef6 could play a significant role in neural adhesion and migration 
as well as morphology. 




related developmental processes such as adhesion and migration. Rapgef1 deletion was 
embryonic lethal due to failure of vasculogenesis, so initial studies focused on embryonic 
fibroblasts, which displayed increased motility and reduced cell spreading in culture, suggesting 
reduced cell adhesion (Ohba et al. 2001). Further experiments proved Rapgef1 was essential in 
fibroblast focal adhesion formation involving paxillin and β1-integrin (Voss et al. 2003). A 
Rapgef1 hypomorph mouse model displayed increased cells in the neuroepithelium due to failure 
of progenitors to stop symmetric mitosis rather than asymmetric division to yield neurons (Voss 
et al. 2006). Neurons that did develop failed to migrate appropriately in vivo because radial glia 
were abnormally oriented and also did not migrate in vitro in slice culture or cell culture (Voss et 
al. 2008). It appears that Reelin activated Rapgef1 to activate Rap1 and that this pathway is 
critical in the development of proper neural cytoarchitecture (Voss et al. 2008).  
Rapgef2 promoted neurite outgrowth in PC12 cells in response to NGF stimulating TrkA 
receptors by activating Rap1 and the MEK-ERK-MAPK pathway (Hisata et al. 2007). Knock 
down of both Rapgef1 and Rapgef2 caused a reduction in NGF induced neurite outgrowth in 
these experiments. More evidence for the role of Rapgef2 in promoting neural growth came from 
the cortical delayed knock out mouse which had widespread neuronal migration abnormalities 
including heterotopias (mislocalized, functional neurons) and failure of white matter tracts 
(Bilasy et al. 2009). Axons that were normally destined to decussate across the corpus callosum 
were instead bunched near the midline (Bilasy et al. 2011). 
Rapgef3/4 activation increased β1-integrin mediated cell adhesion via Rap1 and the 
MAPK pathway (Bos 2006; Roscioni et al. 2008). In vitro, Rapgef3/4 activation via specific 
agonist 8CPT caused reduced spine area, increased spine motility, reduced synaptic AMPA 




individual deletion of Rapgef3 or 4 had no effect on neural morphology, behavior, or 
electrophysiology, a double Rapgef3/4 knock out mouse had no change in spine density but a 
reduction in CA1 EPSC frequency and LTP as well as behavioral changes discussed previously 
(Yang et al. 2012).  
Rap1, the downstream target of Rapgefs, is well documented to promote cadherin 
mediated cell-cell junctions and integrin mediated cell-extracellular matrix adhesion by 
activating RapL, Riam, and Rac (Bos 2005; Retta et al. 2006). In vitro, inhibiting Rap1 via a 
dominant negative transcript diminished increases in dendritic complexity after neural 
depolarization, suggesting Rap1 was essential in activity-induced neurite outgrowth (Chen et al. 
2005). Rap1 activity permitted long term depression by facilitating removal of synaptic AMPA 
receptors (Xie et al. 2005; Zhu et al. 2002). Via Cdc42, active Rap1b directed axon polarity in 
vitro (Schwamborn and Puschel 2004), and in slice culture Rap1 was required for maintaining 
neural polarity and orientation during migration as a downstream effector of Reelin (Franco et al. 
2011; Jossin and Cooper 2011). 
In contrast to the growth promoting effects of Rap1, in vitro constitutively active Rap2 
caused a retraction of the axonal and dendritic arbors and a reduction in spine density (Fu et al. 
2007). Rap2 activation also depotentiated synapses by facilitating the removal of AMPA 
receptors from the synapse in vitro (Zhu et al. 2005). This finding extended in vivo to a 
constitutively active overexpression Rap2 mouse that had reduced spine density in CA1 
pyramidal neurons and increased hippocampal long term depression (Ryu et al. 2008). 
MRas is thought to be upstream of Rapgef6 (Gao et al. 2001). MRas activation by growth 
factors in fibroblasts increased filopodia and actin organization (Matsumoto et al. 1997). Despite 




effect on neural morphology in the hippocampus or cortex in vivo or in culture (Nunez 
Rodriguez et al. 2006). 
The role of Rapgefs in integrin-mediated cell adhesion is conserved across species. 
Drosophila Rapgef homolog Dizzy promoted cell protrusion and migration in a process 
presumed to involve integrin activation (Huelsmann et al. 2006). Rapgef1 homolog C3G was 
critical for muscle cell adhesion via integrins (Shirinian et al. 2010). 
In summary, Rapgef1 and 2 family members were involved in promoting cell adhesion 
and migration as well as neurite outgrowth, while Rapgef3/4 had no effect on morphology in 
vivo. Rapgef target Rap1 promoted axon polarity and neurite outgrowth, while Rap2 inhibited 
axon and dendrite outgrowth in vitro and spine dynamics in vivo. MRas increased neurite 
outgrowth in vitro, but had no effect in vivo. All of these effects appeared to be mediated via 
integrins, cadherins, and consequent actin restructuring. Since Rapgef6 activates Rap2 more than 
Rap1 (Kuiperij et al. 2003), it may have a growth restricting effect, thus the knock out phenotype 
may include increased neurite growth. This hypothesis is complicated, however, since Rapgef6 
activity appeared to promote lymphocyte adhesion, implying that while Rap2 is biochemically in 
vitro the most important effector, biologically the overall impact may be dominated by Rap1 
effects. 
4.2 Methods 
4.2.1 Western blot 
Following lethal anesthesia with carbon dioxide, mouse brain regions were excised 
according to the standard mouse brain atlas (Paxinos and Franklin 2004). Crude synaptosomal 
preparations were made by homogenizing in buffer containing 5 mM Hepes/10% sucrose (pH 




12,000 × g. The pellet was resuspended in the same buffer, then the protein concentration was 
determined using a DC protein assay kit (BioRad). The protein homogenate was mixed with 
NuPage LDS loading dye (Invitrogen) with reducing reagent and boiled for 10 minutes, then 
loaded onto a 4-12% gradient polyacrylamide gel and run and transferred onto a nitrocellulose 
membrane according to the manufacturer’s instructions (Invitrogen).  
Rapgef6 protein is predicted to be 177.9 kDa. Antiserum was generated in rabbits against 
the C-terminal synthetic peptide CLEPRDTTDPVYKTVTSSTD, then affinity purified against 
this peptide to isolate antibodies (Yoshikawa et al. 2007). Primary antibody rabbit anti-Rapgef6 
was used at 1:100. 
4.2.2 Cresyl violet staining 
 5 week old Rapgef6 littermates were lethally anesthetized with carbon dioxide and 
perfused with PBS and 4% paraformaldehyde (PFA), then the brains were post-fixed, cut into 
40um sections on a vibratome, and mounted. After washing in 0.5% TritonX and water, the 
slides were immersed in cresyl violet with neutral red for 4 minutes, then dehydrated in ethanol 
and xylene and mounted. 
4.2.3 In vivo knock out morphology 
 Rapgef6 animals were crossed with the Thy1-M-GFP mouse line, which expresses GFP 







 matings were lethally anesthetized with carbon dioxide at 10-12 weeks, 
perfused with PBS followed by 4% PFA, and the brains extracted. The brains were sliced 100µm 
thick on a vibratome, washed 3x5min in PBS, and stained with TOPRO 1:2500 in PBS for 10 
minutes.  Finally the slices were mounted in ProLong Gold. 




(Paxinos and Franklin 2004). The dorsal hippocampus CA3 was defined by the flexure of the 
mossy fiber pathway to its end. Dorsal CA1 began at the end of the mossy fiber pathway and 
terminated at the midline. Both of these were imaged from approximately Bregma coordinates -
1.3 to -1.9. Medial PFC was imaged from Bregma +2 to +1.5, with pre- and infralimbic 
subregions defined as the upper and lower halves of the tissue medial to the forceps minor of the 
corpus callosum. The lateral/basolateral nuclei of the amygdala were defined as the region within 
the forking of the external capsule from Bregma -1.1 to -1.9. 
For dendritic arbors, only neurons in the middle of the tissue with intact arbors were 
imaged. In the mPFC and HPC, the basal dendritic arbors were identified by their distinctive 
morphology and placement relative to structural landmarks, for instance HPC basal arbors lie 
outside the mossy fiber and Schaeffer collateral pathways.  
4.2.4 Morphology imaging and analysis 
 For in vivo and in vitro analysis, slides were imaged on a confocal microscope (Zeiss) at 
20x optical zoom for neurites and 63x optical zoom for spines to capture images of fluorescent 
neurons. For spines, images were taken after the first branchpoint along primary dendrites. A 
maximum intensity projection image was generated from the 3D image stack. This image was 
saved as a TIFF for analysis. In assessing neurites, images were loaded into the NeuronJ plug-in 
for ImageJ, where the neural processes were manually traced and labeled. NeuronJ automatically 
calculated the length and number of each neurite subtype, while branchpoints were manually 
counted after neurite tracing. For spine assessment, spines were manually counted and measured 
using LSM software (Zeiss) if there was a visible neck connecting to the dendrite. Spine 
morphology was assessed according to head shape and neck measurements as previously 




 For Sholl analysis, neurite tracings were saved and a macro was written in ImageJ to 
generate concentric circles 50µm apart, which was initiated over the center of the soma. 
Crossings of neurite tracings over circles were then manually counted. 
Data was analyzed by t test, one-way or two-way ANOVA with Bonferroni post-hoc 
testing in Prism (GraphPad). The genotype or knock down status was not known until after 
imaging and analysis was complete. 
4.2.5 In vitro hippocampal neural culture 
 Timed matings of either C57Bl/6 or Rapgef6
+/-
 mice were arranged and plugs were noted 
as day embryonic (E) 0.5. Pregnant females were lethally anesthetized with carbon dioxide at 
E17.5 and the embryos were extracted. Hippocampi were excised bilaterally under a dissecting 
microscope in HBSS/Hepes solution and placed on ice. The remainder of the brain was used for 
genotyping if necessary. The hippocampal tissue was digested in 1.2mL 0.025% Trypsin/EDTA 
(Gibco) for 10 minutes at 37
o
C, then the digestion was halted by adding 12µL FBS (Gibco) and 
incubating for 5 min at 37
o
C. The tissue was then triturated 20 times with a flame-polished glass 
pipette. After determination of cell density via hematocytometer counting, neurons were plated at 
a density of 4x10
8
 cells/mL onto polyornithine coated coverslips in plating medium (DMEM, 
10% FBS, penicillin, streptomycin), which was exchanged for NB (NeuroBasal Medium 
(Gibco), B27, glutamine, penicillin, streptomycin) after 4 hours of incubation.  Neuron cultures 
were maintained in a 37
o
C incubator with 5% CO2. The day of culture plating was counted as 
day in vitro (DIV) 0.  
4.2.6 In vitro knock out of Rapgef6 
 Neurons from Rapgef6
+/-
 timed mating cultures were transfected on DIV2 via incubation 




plasmid per coverslip of βactin-GFP. On DIV5 the coverslips were then fixed for 20 minutes in 
4% PFA. For spine analysis, cultures were transfected at DIV7 and fixed at DIV21. As the GFP 
fluorescence was sufficient for imaging, the coverslips were then washed 3 x 5 minutes in 1x 
PBS, incubated with TOPRO 1:2500 in PBS for 10 minutes, then washed again in PBS 3 times 
and mounted with ProLong Gold. Retained embryonic brain tissue from the cultures was 
genotyped for Rapgef6. 
4.2.7 Assessment of shRNA efficacy 
 shRNAs directed against mouse Rapgef6 with turbo-GFP coexpression were purchased 
(OpenBiosystems). These shRNAs were transfected into N18 cells via Lipofectamine2000 
(Invitrogen), 8µg DNA per 6cm plate. As transfection efficiency was quite low, Rapgef6 levels 
could not be determined via Western blot, staining and quantification, or qPCR on an entire 
culture. Instead, transfected cells were isolated through FACS sorting for GFP expression, then 
subjected to qPCR. N18 cells were transfected for 48 hours, then trypsinized, washed, and 
resuspended in 10% FBS in PBS. Fluorescent cells were sorted at the Columbia University 
FACS core on a FACSCalibur machine, then RNA was extracted via Qiazol (Qiagen). Following 
reverse transcription PCR (Ambion), cDNA was combined with the customized primer set and 
probes below directed toward exon 1 of Rapgef6 using the TaqMan reagents and GAPDH 
control (ABI).  
Table 4.1 Rapgef6 qPCR primers 
qPCR Primer and Probe sets Sequence 
Forward primer Rapgef6 exon 1 GGCAGGCACTGAGGAAGAAG 
Reverse primer Rapgef6 exon 3 AAGCATTTGATTGCCACTGTATC 




4.2.8 In vitro knock down of Rapgef6 
For Rapgef6 shRNA knock down neurite experiments, neurons from C57Bl/6 timed 
matings were transfected at DIV2 with either 1.2µg/well of scrambled or shRNA87843. Neurons 
were fixed in 4% PFA at DIV4 or DIV5. For spine experiments, the cultures were transfected at 
DIV7 and fixed at DIV21. To enhance the fluorescent signal from the turbo-GFP on the shRNA 
construct, all DIV2-transfected coverslips were stained with rabbit anti-tGFP 1:7500 (Evrogen), 
as well as mouse anti-Tau1 1:3000 (Chemicon), while DIV7-21 neurons were stained with rabbit 
anti tGFP 1:7500 and mouse anti-PSD95 1:100 (Millipore). 
4.2.9 Rapgef6 expression vectors 
 Rapgef6 human and mouse cDNA was purchased (Open Biosystems). PCR primers were 
designed to incorporate unique restriction enzyme cut sites as well as the hemaglutinin (HA) 
exogenous tag at the 3’ end. Additional primers were designed to amplify PCR product that for 
ligation in order to delete the GEF domain (RAPGEF6∆GEF), analogous to the mouse deletion.   
PCR products were amplified using these primers, then isolated on an agarose gel, 
purified, ligated with T4 (NE Biolabs) into pcDNA vector, and transformed into competent XL 
Gold cells (Stratagene). Cells were grown with antibiotic selection and surviving colonies were 
isolated for growth followed by DNA extraction via mini prep (Qiagen). This DNA was sent for 
sequencing from the vector T7 region to verify the resulting plasmid orientation. Only vectors 
containing human RAPGEF6 or RAPGEF6∆GEF were successfully cloned. 
 The Kataoka lab gifted plasmids of human RAPGEF6 with 5’ FLAG and eGFP tags 
under the CMV promoter (pFLAG-CMV2-RAPGEF and pFLAG-CMV2-EGFP-RAPGEF), as 
well as hRAPGEF6 with the MRas binding RA domain (amino acids 749-779) deleted (pFLAG-




Table 4.2 Rapgef6 cloning primers 
Species End Primer Name Primer Sequence 








Human 3’ 3’ hRAPGEF6 
HindIII   
GCTAAGCTTAGACTGCTGAAACTTGTTCATTTTC 
 
Mouse 5’ 5’ XhoI 
mRAPGEF6 
TATCTCGAGACCATGAACTCGCCCGTGGACCC 




Mouse 3’ 3’ mouse exon 
21 deletion  
TTTGTGCTGCCTTGACTCAATGATTCATGGAGAAATG
TCATATCTTTC 




Human 3’ 3’ hRAPGEF6 
deletion 
TCTTGGTCAAGGTACCATATGCGGATAGCTGGCTTTC
CTTAACTA (used with 5’XhoI-hRAPGEF6) 
Human 5’ 5’ hRAPGEF6 
deletion 
TAGTTAAGGAAAGCCAGCTATCCGCATATGGTACCT
TGACCAAGA (used with 3’hRAPGEF6-HindIII) 
 
4.2.10 In vitro overexpression neural morphology 
 C57Bl/6 hippocampal cultured neurons were transfected at DIV2 with pcDNA-GFP, 
RAPGEF6-GFP, or RA-RAPGEF6-GFP, then fixed at DIV4 or DIV5 and stained with rabbit 
anti-GFP 1:1000 (Invitrogen), mouse anti-Tau 1:3000, and chicken anti-Map2 antibodies 
(Abcam). GFP
+
 neurons were then imaged and analyzed as above. 
4.2.11 N18 overexpression morphology 
 N18 cells were grown on glass coverslips in DMEM (Gibco) with 10% FBS, penicillin, 
and streptomycin. When cells were 50-75% confluent, they were transfected via Lipofectamine 
with plasmids containing either βactin-GFP, human RAPGEF6, or RAPGEF6 with the GEF 
domain deleted (RAPGEF6∆GEF). Twenty-four hours later, N18 cells were fixed with 4% PFA, 




These slides were imaged on a fluorescent microscope (Nikon) using SPOT software (Diagnostic 
Instruments). Resulting images were then qualitatively assessed for the morphology of green 
cells based on whether cells were round or a simple spindle shape, had short, uncomplicated 
processes, longer processes, or highly complex processes, blind to transfection status. Four 
independent rounds of transfection were analyzed and the percent of cells of each morphology 
category were compared  
4.3 Results 
4.3.1 Localization of Rapgef6 
The Allen Brain Atlas (www.brain-map.org) predicted that Rapgef6 mRNA is expressed 
at very low levels diffusely throughout the mouse cortex, with higher expression in the 
hippocampus particularly within CA3. We sought to verify this finding at the protein level using 
antibodies to detect and quantify Rapgef6 via Western blot and immunohistochemistry. 
Commercial antibodies (Santa Cruz, AbCam) were nonspecific for Rapgef6 detection. 
The Kataoka laboratory generously gifted a custom-made antiserum raised against the C 
terminus that reliably detected the absence or presence of Rapgef6 in HOM or WT mice on 
Western blot. However Western blots using this antibody detected additional numerous smaller 
bands in both HOM and WT mouse extracts. These bands likely represent cross-reactivity of the 
antibody with other family members or proteins; therefore its usefulness is limited for 
immunohistochemistry or immunocytochemistry. 
By careful dissection, we isolated various brain regions and did comparative Western 
blotting. Two isoforms of Rapgef6 were expressed in the hippocampus, striatum, and at a lower 
level in the cerebellum (Figure 4.1A). Brain expression seemed to be higher than in the spleen, a 




Atlas prediction of low brain expression. Developmentally, Rapgef6 was expressed in pups as 
early as P10 and DIV8 neurons in culture, as well as in the N18 neural-like cell line. Rapgef6 
levels were higher in synaptosomal preparations than in whole brain extracts, suggesting it may 
be localized at the membrane in spines. Within the hippocampus, Rapgef6 was expressed at 
relatively equal levels in the dentate gyrus, CA3, and CA1 (Figure 4.1B). While hippocampal 
expression appeared to be higher than that of the prefrontal cortex (Figure 4.1B), amygdala 
expression was higher still (Figure 4.1C). 
Figure 4.1 Rapgef6 protein expression on Western blot
 
4.3.2 Knock out neural morphology in vivo 
Cresyl violet staining of brains demonstrated that Rapgef6 HOM and HET animals were 
not grossly different from WT littermates in their neural architecture (Figure 4.2). No 




Basal dendritic arbors of CA3 and CA1 subregions of the hippocampus were analyzed 
(Figure 4.3A). In CA3, there was no effect of genotype on total dendritic length (P=0.27), nor on 
the number of segments (P=0.48) or branchpoints (P=0.45) (Figure 4.3B-D). While the number 
of primary segments was not different (P=0.15), the primary segment length was significantly 
reduced in HET (P<0.05) with a trend in HOM (Figure 4.3E,F). There was no effect of genotype 
on secondary, tertiary, or quaternary dendrite lengths (P=0.90, P=0.17, P=0.98 respectively). 
Figure 4.2 Repgef6 mouse cresyl violet staining
 
On Sholl analysis of CA3, there were no significant differences in crossings close to the 
soma although there was a trend toward reduced HET and HOM crossings (Figure 4.4). From 
450µm from the soma onward this trend reversed; there was a significant effect of genotype at 
450µm, 650µm, and 700µm (P=0.04, P=0.003, P=0.002 respectively) with a trend at 500µm and 




HOM>WT P<0.05 and HOM>HET P<0.01 at 650, HOM>WT and HET P<0.01 for both at 700). 
At the next step of the trisynaptic pathway in CA1, there were no significant effects of 
genotype on morphology. Total basal dendritic length (P=0.49), number of dendritic segments 
(P=0.31), number of branchpoints (P=0.83), and primary dendritic number (P=0.81) and length 
(P=0.14) were all equivalent among genotypes (Figure 4.5). Higher order secondary through 
quaternary branch lengths were also unaffected (P=0.83, P=0.19, P=0.87 respectively).  
Sholl analysis of CA1 neurons did not yield any differences by genotype (Figure 4.6). 
Crossings close to the soma (P=0.67, P=0.78, P=0.77, P=0.53, P=0.53, P=0.8 at 0µm to 250µm) 
were, unlike CA3, no different by genotype from those far from the soma (P=0.42, P=0.31, 
P=0.5, P=0.23, P=0.66, P=0.74 at 300µm to 550µm). 
CA3 basal dendritic spine density was significantly affected by genotype (P=0.007) 
(Figure 4.7A). HOM spine density was reduced about 20% relative to both WT and HET density 
(P<0.05 for both). In comparison, CA1 basal spine density did not differ by genotype (P=0.15) 
(Figure 4.7B). 
In the basolateral amygdala of these animals, spine density was counted along the apical 
and basal dendritic trees of pyramidal neurons (Figure 4.8A). Neither basal (P=0.46) nor apical 
(P=0.71) dendritic spine density were affected by genotype (Figure 4.8B,C). Dendritic 
morphology could not be assessed due to technical limitations. 
Finally, the pre- and infralimbic subregions of the medial prefrontal cortex layer V 
pyramidal neurons were analyzed for basal dendritic morphology (Figure 4.9A). Basal dendritic 
length (P=0.5), number of segments (P=0.58), and branchpoints (P=0.62) were all not  
significantly affected by genotype (Figure 4.9B-D). Primary dendritic number (P=0.11) and 






















Figure 4.6 CA1 Sholl analysis of in vivo knock out 
 

















Figure 4.10 mPFC Sholl analysis of in vivo knock out
 
 
effect of genotype at 0µm (P=0.03) and 700µm (P=0.01) from the soma where post-hoc testing 
demonstrated an increase in HET crossings over WT at the soma and a decrease in HET 
compared to WT at 700µm (P<0.05 for both) (Figure 4.10). 
4.3.3 Knock out neural morphology in vitro 
Cultures of Rapgef6 HET x HET embryos at E17.5 yielded hippocampal neurons for 
analysis of early neural morphology at DIV5. Total axon length and dendritic length were both 
not significantly affected by genotype (P=0.10, P=0.79) (Figure 4.11A,B). Dendritic complexity 




also not different (Figure 4.11C,D). Similar to CA3 neurons in vivo, there was an effect of 
genotype on primary dendrite number (P=0.002) and length (P=0.048); on post-hoc testing HET 
primary dendrites were less numerous (P<0.001) and shorter (P<0.05) than WT, with a trend in a 
reduction in HOM (Figure 4.11E,F). Secondary and higher order branches were not significantly 
different by genotype. 
 





Figure 4.12 Rapgef6 shRNA knock down validation
 
 
On analysis later in development at DIV21 of dendritic spines, there was no significant 
effect of genotype on spine density (P=0.62) (Figure 4.11G). 
4.3.4 Validation of Rapgef6 shRNA 
 N18 cells transfected with GFP expressing shRNAs directed against Rapgef6, as well as 
scrambled shRNA, were enriched via FACS for GFP and cDNA was generated. On qPCR, only 
shRNA87843 (sh43) was significantly effective at reducing Rapgef6 expression by 
approximately 45% compared to scrambled (P=0.015) (Figure 4.12).  
4.3.5 Knock down neural morphology in vitro 
shRNA43 validated above was then used to examine the effects of acute Rapgef6 knock 
down on WT hippocampal neural morphology in culture. Two time points of knock down were 
analyzed, DIV2-4 and DIV2-5. DIV2-4 neurons did not significantly differ by transfection. Axon 
length (P=0.52) and branchpoints (P=0.76) (Figure 4.13A,B), as well as dendritic total length 
(P=0.73), number of segments (P=0.38), and branchpoints (P=0.37) (Figure 4.13C-E) were no 
















Figure 4.15 Knock down in vitro spines
 
 
Transfection from DIV2-5, however, yielded significant results. Axon length was 
significantly reduced 25% by shRNA43 (P=0.012) but not branchpoints (P=0.34) (Figure 
4.14B,C). shRNA43 also led to a significant, consistently 35-40% reduction in total dendritic 
length (P=0.006), branchpoints (P=0.02), and segments (P=0.01) compared to scrambled shRNA 




significantly different, nor were higher order dendritic branches (Figure 4.14G,H). 
Dendritic spines analyzed at DIV21 were also affected by Rapgef6 knock down. Spine 
density was increased 40% by shRNA43 (P<0.0001) (Figure 4.15B). When spines were assigned 
morphologies (Chakravarthy et al. 2006), there were no morphology-specific changes in spine 
length (mushroom P=0.43, long P=0.18, stubby P=0.9, thin P=0.96, filopodia P=0.2), but there 
was an overall 8.5% increase in total spine length (P=0.0006) (Figure 4.15C,D). Given that 
mushroom spines are the most mature subtype, the width and area of these spines was also 
measured, but there was no difference (P=0.48, P=0.99 respectively) (Figure 4.15E,F). 
4.3.6 Overexpression in vitro neural morphology 
 Human RAPGEF6 clones of both the intact cDNA (RG6) and a form with the RA 
domain that interacts with MRas for localization deleted (RA) were generated in the Kataoka lab 
with eGFP tags. These proved more convenient for morphology analysis than HA-tagged clones 
produced in our lab. As for knock down analysis, neurons were transfected at DIV2 and analyzed 
at DIV4 and 5. 
 On DIV4 there were no differences between RG6, RA, or control GFP transfected 
neurons (Figure 4.16). Axon length (P=0.41) and branchpoints (P=0.16), as well as dendritic 
length (P=0.94), segments (P=0.62), and branchpoints (P=0.42) were all equivalent between 
conditions. 
 Similarly, on DIV5 there were no significant effects of transfected plasmid on 
morphology (Figure 4.17). Axon length (P=0.34) and branchpoints (P=0.94) were unchanged by 
overexpression of RAPGEF6 or mutant RAPGEF6, as were dendritic length (P=0.87), number of 















Figure 4.17 Rapgef6 overexpression in vitro morphology DIV2-5
 
 
4.3.7 Overexpression N18 morphology 
N18 cells are derived from neuroblastoma tissue and are widely considered neural-like in 
their cellular responses. Initial tests of the effect of RAPGEF6 overexpression involved 
transfecting GFP, human RAPGEF6, or RAPGEF6 with the GEF domain deleted (∆GEF) into 
N18 cells and qualifying the resulting morphology. There were very striking and overall 
significant effects of transfection (P<0.0001) (Figure 4.18A,B).  
When analyzed by transfection plasmid, among GFP+ control N18 cells there was a 
significant difference of morphology (P<0.0001) with more small processes cells than 
round/spindle (P<0.001), large processes (P<0.0001), or complex (P<0.0001). The number of 





Figure 4.18 Rapgef6 overexpression N18 morphology
 
significant difference (P<0.0001) consisting of more complex cells than round (P<0.0001), small 
(P<0.0001), or large (P<0.0001). There were also more small (P<0.01) and large (P<0.05) 
processes than round cells. When the nonfunctional RAPGEF6 mutant was transfected the effect 
on morphology was still significant (P=0.0002), but post-hoc testing was less significant with 
more small processes than round (P<0.001) or complex (P<0.001) and more large than round 
(P<0.05). 
Analysis in terms of the morphology category demonstrated the same significant 




(P<0.001) and ∆GEF (P<0.05) than RAPGEF6 transfected cells. Among cells with small 
processes (P<0.0001), the same finding held with a higher percentage found in GFP (P<0.001) 
and ∆GEF (P<0.001) than RAPGEF6 transfected cells. Cells with large processes were 
differentially distributed (P=0.0003) with more in ∆GEF transfected cells than GFP (P<0.01) or 
RAPGEF6 (P<0.001). Complex cell morphology differences between transfected plasmids was 
highly significant (P<0.0001); these cells were most populous in RAPGEF6 transfected cultures 
than GFP or ∆GEF (both P<0.0001). Overall, RAPGEF6 transfection shifted cell morphology 
toward a more complex state, while ∆GEF transfection had an intermediate effect on complexity. 
4.4 Summary of findings 
In vivo, Rapgef6 KO resulted in a reduction in CA3 spine density and primary dendrite 
length with an increase in cell complexity far from the soma. No significant changes were noted 
in CA1 arbors or spines, mPFC layer V neural basal arbors, or amygdala spine density. In vitro 
knock out neurons demonstrated only a reduction in primary dendrite number and length. These 
knock out findings were far more subtle than in vitro knock down neural and N18 
overexpression findings, which strongly supported a role for Rapgef6 in promoting neurite 
outgrowth. In vitro hippocampal neuron knock down led to dramatic reductions in axon length 
and dendritic length and dendritic complexity, as well as an increase in spine density. While in 
vitro neural overexpression had no effect, overexpression in N18 cells of mutant hRAPGEF6 
mildly increased neurite complexity, while hRAPGEF6 overexpression strongly increased N18 
neurite outgrowth and complexity.  
In vivo there was moderate evidence that Rapgef6 promoted hippocampal primary 
dendrite growth and spine density, yet in vitro Rapgef6 strongly promoted neurite outgrowth, 





4.5.1 Localization of Rapgef6 
While Allen Brain Atlas suggested Rapgef6 expression was limited in the brain, we 
detected Rapgef6 protein throughout the brain particularly in the amygdala, prefrontal cortex, 
and all regions of the hippocampus. These localization results suggested that these brain regions 
would be relevant to evaluate neural morphology and behavior effects of Rapgef6 deletion. 
4.5.2 Discussion of brain regions and results 
4.5.2.1 Hippocampus 
 Analysis of hippocampal neurons in vivo and in vitro from knock out mice confirmed a 
reduction in primary neurites in HOM neurons, but no other consistent effect on hippocampal 
neural morphology. Interestingly, we observed a reduction in spine density in CA3 HOM 
neurons in vivo but not in vitro. Experiments in wild type hippocampal cultures using shRNA 
against Rapgef6 were far more affected, probably due to a variety of effects discussed below. 
Surprisingly, despite reduced dendritic and axonal arbor growth, spine density was increased in 
knock down neurons. This may represent a compensatory change to normalize synaptic input 
along a shorter arbor.  
It is important to note, as mentioned later, that hippocampal neural morphology is rather 
different in vivo than in vitro thus analysis comparisons are not necessarily analogous. In vivo 
we imaged the basal dendritic arbor of CA1 and CA3 due to technical limitations that made the 
apical dendritic arbor inaccessible, but it is the apical arbors which participate in the trisynaptic 
HPC circuit while the basal arbors gather additional input from entorhinal cortex. Results 
reported here are therefore not as relevant to classic HPC function. Cultured neurons from HOM, 




neurons from knock down analysis. This growth discrepancy makes comparison between knock 
out and knock down cultures difficult.  
Abnormalities in the HPC have been confirmed in schizophrenia. Contrasting with our 
results, one postmortem study found an increase in dendritic length throughout the hippocampus 
(Cotter et al. 2000). Mossy fiber synapses from the dentate gyrus onto CA3 were reduced in 
density, similar to our in vivo reduction in CA3 spine density (Kolomeets et al. 2007). Though 
pyramidal hippocampal neurons were not affected in postmortem tissue, inhibitory interneuron 
number was reduced in schizophrenia (Konradi et al. 2011). Meta-analyses found bilateral 
volume reductions of up to 8% in first episode psychosis (Steen et al. 2006; Vita et al. 2006) and 
in individuals with chronic schizophrenia after correcting for illness duration (Adriano et al. 
2012). Since postmortem studies find a reduction in interneurons but not pyramidal neurons in 
the hippocampus, the reduction in volume may represent a decrease in dendritic arbors. 
Compared with the literature, our findings concur on reduced CA3 spine density but do not show 
evidence for either reduced hippocampal volume or increased dendritic arbors. 
In mouse models of schizophrenia there are many reports of altered hippocampal 
anatomy. Mice mimicking the 22q11 deletion had reduced mushroom spine density and width 
and decreased basal dendritic complexity in CA1 in vivo and HPC neurons in vitro (Stark et al. 
2008). This finding appeared to be partially due to deletion of Dgcr8 since its deletion alone 
decreased CA1 spine width and basal dendritic complexity in vivo and in vitro. Neonatal PCP in 
mice caused a reduction in spine density in the hippocampus as well as in other regions 
(Nakatani-Pawlak et al. 2009). In line with the synaptic overpruning hypothesis of schizophrenia, 
prenatal stress caused increased CA1 spine density and decreased CA3 spine density at 




Tellez et al. 2009). Our spine density results are in line with other schizophrenia mouse models. 
Behaviorally, the hippocampus is linked to spatial memory. In Chapter 3, this was tested 
via novel object recognition, Morris water maze, and T maze paradigms, all of which 
demonstrated no genotype dependent impairments. Contextual impairment was noted on fear 
conditioning, possibly suggesting hippocampal dysfunction, however it is possible this was due 
to amygdala dysfunction since cued conditioning was also affected. 
4.5.2.2 Prefrontal cortex 
In vivo, Rapgef6 had no effect on the basal dendritic arbor of layer V pyramidal neurons 
in the prefrontal cortex. Due to technical limitations, we were unable to image the apical 
dendritic arbor. Cortical culture was not performed. The basal dendritic arbor in the deep layers 
of PFC receives heavy dopaminergic input from the ventral tegmental area that is hypothesized 
to modulate working memory (Krimer et al. 1997; Miller and Cohen 2001), thus the medial PFC 
is highly relevant to schizophrenia research. 
Dorsolateral PFC activity was decreased in individuals with schizophrenia during an n-
back working memory task upon meta-analysis, but these patients had an increase in activation 
of the anterior cingulate and left frontal pole indicating a malfunctioning cortical circuit (Glahn 
et al. 2005). Interventions hypothesized to mimic to schizophrenia including L-methionine 
administration and basolateral amygdala and hippocampal lesions all reduced PFC spine density 
(Marquis et al. 2008; Solis et al. 2009; Tueting et al. 2010). Among genetic models of 
schizophrenia, Dgcr8 deletion reduced layer II-IV neural density and layer V basal dendritic 
spine density, while Disc1 deletion caused diminished PFC volume and shorter apical dendritic 
length (Kvajo et al. 2008; Stark et al. 2008). Since we did not assess spine density, our findings 




The prefrontal cortex mediates working memory and attention control. We tested 
working memory using the T maze and did not find any effect of Rapgef6 deletion. 
4.5.2.3 Amygdala 
There was no effect of Rapgef6 deletion on apical or basal dendritic spine density in the 
lateral/basolateral amygdala pyramidal neurons in vivo. The lateral nucleus dendritic arbors 
receive processed sensory information about conditioned and unconditioned stimuli, initiating 
Hebbian plasticity, then this nucleus sends synapses onto the dendritic arbor of the basolateral 
nucleus neurons that are essential for fear conditioning (Johansen et al. 2011). We did not 
anatomically discriminate between the lateral and basolateral nuclei, thus it is possible there may 
be a change in one nucleus that is masked by contributions from the other. 
Amygdala activation compared between neutral and negative emotional stimuli was 
reduced in individuals with schizophrenia bilaterally in a meta-analysis, although amygdala 
response to negative stimuli alone was not different (Anticevic et al. 2012). Moreover, 
postmortem microarray analysis demonstrated altered expression in schizophrenia amygdalae of 
multiple genes involved in presynaptic function, myelination, and signaling (Weidenhofer et al. 
2006). Amygdala morphology is not routinely assessed in rodent models of schizophrenia, 
however anxiety and depression models such as serotonin transporter deletion demonstrated 
reduced PFC arbors and increased amygdala pyramidal neuron spine density (Wellman et al. 
2007). 
We examined amygdala behavioral function directly in fear conditioning and indirectly in 
anxiolysis measures and unlearned fear in the open field paradigm. Both measures of amygdala 





4.5.2.4 Overexpression of Rapgef6 
Overexpression of hRAPGEF6 and a mutant with the membrane targeting RA domain 
deleted to prevent MRas interaction had no detectable effect on neural morphology in vitro. In 
the course of overexpression experiments, we had difficulty achieving measurable levels of 
Rapgef6 protein expression. Furthermore, biochemical studies suggested Rapgef6 may be 
autoinhibitory (Kuiperij et al. 2003) and difficult to express unless the C terminus was truncated 
(Kuiperij et al. 2006). It is possible that overexpression results were falsely negative due to poor 
protein expression below the threshold of morphological effects. 
N18 cells derived from mouse neuroblastoma are commonly used as an in vitro model of 
neural-like survival, morphology, and other cellular pathways. While nascent N18 cells are 
round or spindle shaped, many manipulations cause an increase in cellular complexity due to 
tubulin rearrangement (Morgan and Seeds 1975; Seeds and Maccioni 1978), reflecting a 
neuronal phenotype. Based on this, we used N18 cells as a preliminary assessment of the role of 
hRAPGEF6 overexpression on morphology and found a strong effect upon increased neurite 
growth and complexity. Curiously the GEF deleted mutant increased neurite outgrowth 
somewhat over control transfection suggesting either an off-target effect of plasmid transfection 
or a dominant negative effect of the catalytically dysfunctional protein. N18 cells were more 
successfully transfected with hRAPGEF6 and qualitatively appeared to express the construct 
more effectively when stained for RAPGEF6, therefore N18 cells may have been a more 
successful expression system than primary neural culture and thus yielded more significant 
morphology results. 
4.5.3 Differences between in vitro and in vivo systems 




developmental stage, growth signaling, and cell autonomous or non-autonomous conditions. In 
vitro axon specification is different from in vivo, where extracellular cues limit axon 
development to only one process (Whitford et al. 2002). Activity-dependent changes in 
morphology are completely different in vitro where connectivity is grossly disorganized and 
altered compared to in vivo. Neurons in vitro are restricted in their development and connections, 
lacking in native extracellular matrix and extrinsic signals. But transfection in vitro is an 
effective way to test cell-autonomous effects.  
Next, as mentioned in the introduction, neural growth is regulated by extrinsic and 
intrinsic signaling. Culture systems mostly rely on intrinsic directions because native extrinsic 
signals and activity-based triggers are disrupted by tissue digestion. Comparisons of in vivo and 
in vitro axon polarization demonstrate different signaling programs at work in each system. In 
vitro there is an intrinsically programmed growth of several neurites, one of which stochastically 
becomes the axon (Bradke and Dotti 1999; Bradke and Dotti 2000). In vivo, one process grows 
initially in an oriented polarization repulsed by extracellular cues such as Sema3A (Polleux et al. 
1998). Thus in vitro systems highlight effects of or changes to internally programmed cell 
growth, whereas in vivo systems elucidate changes in extracellular influences (Whitford et al. 
2002).  
Third, in vitro and in vivo differ in the role of cell non/autonomous effects. Although 
knock out cultures are genetically homogeneous, transfection of shRNA or overexpression vector 
leads to expression heterogeneity since only a fraction of neurons take up and express the 
plasmid. As a result, cells in culture reflect mostly cell autonomous functions since they are 
isolated among unaffected neighboring cells, while neurons in tissue are also subject to non-




technical differences between culture and tissue may help explain why we found different results 
in each experimental preparation. 
There is also a biological distinction between knock down and knock out experiments, 
most importantly concerning temporal (acute as opposed to chronic expression changes) and off-
target effects. Knock down by shRNA is by nature far more acute and less successful in reducing 
protein levels than a constitutive knock out such as we used for Rapgef6. Because shRNA works 
so acutely, there may not be time for compensatory effects, such as those discussed below, to 
arise as they normally would in vivo across development in the chronic absence of a protein. 
Additionally, shRNA can have off-target effects potentially due to reduction of unintended gene 
expression. Supporting this conclusion, analysis of morphology after transfection with a control 
shRNA demonstrated reduced dendrites and spine density (Alvarez et al. 2006). However spines 
were increased in our findings therefore suggesting this may not be a typical off-target effect. 
Methods to identify or eliminate off-target effects include repeating results with additional 
targeted shRNAs and rescuing knock down with overexpression of an shRNA-resistant cDNA to 
prove results are indeed target gene dependent. 
Two sources of compensation are most likely to diminish any phenotype resulting from 
Rapgef6 deletion in vivo. First, there may be remaining isoforms unaffected by either the shRNA 
or deletion of exon 21. The Genome Browser does not report any meaningful predicted isoforms 
unaffected by our interventions, nor is it likely that an isoform missing the catalytic domain 
would be functional, however it is possible that unreported isoforms exist. Next, there may be 
compensation by redundancy from other gene family members. For instance, Rapgef3 and 4 
presumably compensate for each other in vivo since mouse models showed there was no 




Rapgef6 suggesting it might be the most likely redundancy candidate, although it is also possible 
that Rap1 or Rap2 are also upregulated to compensate for Rapgef6 knock out. 
Due to these and other technical issues, it is not uncommon for mouse models to yield 
discrepancies between in vitro and in vivo results or for in vivo morphology to poorly predict 
functional behavioral findings. For example, in the stathmin deletion animal, there were no in 
vivo morphology changes in the amygdala to correlate with reduced fear conditioning, however 
electrophysiology demonstrated reduced long term potentiation in the lateral amygdala, 
indicating altered function in the absence of morphological changes (Shumyatsky et al. 2005).  
4.5.4 Primary dendrite morphology 
We demonstrated a reproducible finding of decreased primary dendritic number and 
length in the setting of unchanged total dendritic length and complexity in vivo and in vitro. This 
was also found to be the case for another novel schizophrenia candidate gene mouse model in 
our lab (B. Xu, in press). There is little known about the mechanism of primary dendrite 
reduction, but it has been shown that excess BDNF and NT4 worked via Rac1 and Rho 
(GTPases similar to Raps) to specifically increase primary dendrites more than the total dendritic 
arbor (McAllister et al. 1995). Perhaps Rapgef6 activation is also functionally downstream of 
one of these trophic factors leading to diminished primary dendrite growth. Presumably changes 
in the primary dendritic arbor could influence synaptic integration in a manner detectable by 
electrophysiology assays. 
4.5.5 Role of Raps and Rapgefs compared to Rapgef6 
In comparison with other family members’ effects on neural morphology, Rapgef6 
deletion is far less deleterious. As mentioned above, this lack of effect may be similar to the 




2012). Overexpression of constitutively active Rap2 caused reduced CA1 spine density in vivo 
which is similar to the reduction in CA3 spine density we observed (Ryu et al. 2008), however 
this is a contradictory result as Rapgef6 deletion should tend to reduce Rap2 activity. MRas 
overexpression in vitro increased PC12 neurite outgrowth whereas MRas deletion caused no 
morphology changes in vivo or in vitro (Nunez Rodriguez et al. 2006; Sun et al. 2006); this is the 
most analogous situation to our model in terms of results and biology given that MRas localized 
Rapgef6 to the membrane in lymphocytes and hypothetically in neurons. Overall our results 
suggest that while Rap2 is biochemically predicted to be the stronger target of Rapgef6, the 
neural process growth promoting effect of Rapgef6 expression and inhibiting effect of its 
deletion on neurites suggest that the neurite promoting activity of Rap1 may be the more relevant 
Rapgef6 target in neurons. 
4.5.6 Morphology results in light of behavior phenotype 
As mentioned above, the behavioral findings do not correlate with the minimal neural 
morphology changes observed. There were changes in hippocampal morphology but only a 
possible correlating behavioral deficit on contextual fear, whereas amygdala functional deficits 
on fear conditioning and perhaps impacting anxiolysis and startle did not correlate with 
amygdala pyramidal neuron spine changes. There may still be changes at the synaptic or 
circuitry wiring level that our analysis did not detect, or in second messenger pathways such as 
those mediated by GTPases, to explain these behavioral results. Possible experiments to detect 




4.6 Future directions 
4.6.1 Electrophysiology 
Electrophysiology assessment of the entire hippocampus would be helpful to determine 
whether there is a functional impact of reduced CA3 spine density. This change may lead to 
diminished transmission through CA3 neurons, or there may be effects we cannot predict based 
on the reduced cFOS results and potential synaptic changes in the apical dendritic arbor that 
were not assessed for morphology. Amygdala electrophysiology of cortical and thalamic inputs 
to the lateral nucleus would be useful to see if there is further functional overlap between our 
Rapgef6 mouse and the Rap1 KO mouse that had reduced fear conditioning and altered cortico-
amygdala synaptic strength (Pan et al. 2008) and to support the significance of the cFOS finding 
suggestive of reduced amygdala activation. Whole cell responses and firing properties from 
neurons in culture could permit assessment of whether synaptic integration is altered as a result 
of primary neurite morphological changes. 
4.6.2 Morphology and cellular techniques 
There are many experiments by which we could try to assess integrin and cadherin 
function in the absence of Rapgef6. First, we could determine expression via qPCR or Western 
blot since knock down of RAPGEF6 decreased integrin and cadherin expression (Dube et al. 
2008; Severson et al. 2009). Since key functions of these pathways include cell migration and 
adhesion, we could assess these parameters in neurons. Neural migration can be quantified in ex 
vivo slice cultures with video capture of the movement of GFP+ neurons, or through 
incorporation of BrdU or electroporation of GFP into newly generated neurons at various time 
points in development. When combined with cortical layer-specific immunohistochemistry, these 




binding to various integrin substrates (Denda and Reichardt 2007).  
In order to further assess the discrepancy between in vitro knock down and knock out 
results, we should validate and transfect additional shRNAs to recapitulate the knock down 
finding for Rapgef6 specificity. We should also demonstrate Rapgef6 specificity by rescuing the 
knock down phenotype with shRNA-resistant Rapgef6 overexpression, however initial rescue 
trials were unsuccessful due to difficulty with both overexpression and cotransfection. Impairing 
synaptic activity dependent growth by culturing neurons in TTx could determine whether the 
increase in spine density upon in vitro knock down is a compensatory response to upregulated 
activity onto a shorter arbor, as opposed to a cell autonomous effect. 
As Rapgef6 was increased in gliogenesis and decreased in neurogenesis on microarray 
(Kempermann et al. 2006) and the dentate gyrus had reduced cFOS activation, we could assess 
these processes in the knock out mouse. BrdU injections followed by staining and cell counting 
would identify alterations in dentate gyrus adult neurogenesis, perhaps finding increased 
neurogenesis given Rapgef6 might inhibit this pathway. Gliogenesis may be reduced on BrdU 
counts, or we could assess overall glia density via specific staining and cell counting. BrdU 
studies would also permit analysis of neural and glial migration. 
In vivo, it would be interesting to try to rescue the spine deficit in CA3 with Rap1 and 
Rap2 overexpression or 8CPT administration via slice culture. Alternatively, BDNF could be 
used to attempt a rescue of primary dendrite growth in knock out cultures or on slice culture. 
This would help to determine what ligands are upstream of Rapgef6 signaling in the brain. 
4.6.3 Testing Rapgef6 activity 
We attempted to quantify Rap1-GTP activity both in vitro and in cellular extracts using a 




consistently detect changes in Rap activity in our samples. Further optimization of this assay 
would be incredibly useful in order to determine if the absence of Rapgef6 leads to a predicted 
decrease in Rap1 or Rap2 activity, thereby providing direct evidence for a functionally 
significant affected pathway. 
In order to determine the binding partners of Rapgef6 in neurons, we could attempt 
coimmunoprecipitation (coIP) followed by mass spectroscopy identification. We attempted to 
validate TNIK as a potential binding partner through coIP assays but were unable to get reliable 
results (Hussain et al. 2010). Other potential coIP targets could be JamA, Bag3, and Afadin using 
brain homogenates since these are known binding partners outside the brain (Dube et al. 2008; 
Severson et al. 2009). 
In order to determine if other Rapgefs are compensating for the loss of Rapgef6, we could 
run qPCR to measure increased expression of other Rapgef family members or downstream 
target Raps. qPCR might be more sensitive than protein level analysis since protein upregulation 
may be mild. Microarray analysis from brain regions of KO animals could detect changes in 
Rapgef or Rap genes and altered expression of other interacting genes, perhaps identifying novel 
Rapgef6-dependent pathways. 
4.6.4 In the next chapter 
 We will next reconsider all of the experimental findings together and discuss the overall 





Chapter 5: Summary and Conclusion 
5.1 Summary of results 
 In human genetic studies, we discovered CNVs impacting RAPGEF6 and RAPGEF2. 
Behavioral analysis of a mouse modeling Rapgef6 deletion determined that amygdala function 
was the most impaired behavioral domain as measured by reduced fear conditioning and 
anxiolysis. More disseminated behavioral functions such as startle and prepulse inhibition were 
also reduced, while locomotion was increased. Hippocampal-dependent spatial memory was 
intact, as was prefrontal cortex function on a working memory task. Neural activation as 
measured by cFOS levels demonstrated a reduction in hippocampal and amygdala activation 
after fear conditioning. In vivo neural morphology assessment found CA3 spine density and 
primary dendrite number were reduced in knock out animals but additional hippocampal 
measurements were unaffected. Furthermore, amygdala spine density and prefrontal cortex 
dendrites were not changed. Considering all levels of analysis, the Rapgef6 mouse was most 
impaired in hippocampal and amygdala function. These brain regions are particularly significant 
for schizophrenia research, as discussed further in section 5.2.  
5.1.1 RAPGEF6 is a genetic and functional schizophrenia candidate gene 
 Though schizophrenia is up to 81% heritable (Sullivan et al. 2003), attempts to identify 
causal mutations have yielded very few penetrant, non-private, replicated loci. Though it was 
statistically unlikely to find two mutations affecting the same small gene family, we discover two 
CNVs affecting RAPGEF family members within an Afrikaner population: a de novo deletion of 
exons 2-11 of RAPGEF6 in a sporadic case of schizophrenia and an inherited duplication 




mother (Xu et al. 2008; Xu et al. 2009). Whole exome sequencing of the same population 
identified two additional inherited mutations in RAPGEF2 (Xu et al. 2012). Moreover, 
RAPGEF6 is within the chromosome 5q31 locus implicated in schizophrenia by multiple 
karyotype, linkage, and association studies (Bennett et al. 1997; Chen et al. 2006b; Lewis et al. 
2003). Together, these genetic results converge on the RAPGEF family with particularly strong 
evidence for RAPGEF6 as a candidate gene in the development of schizophrenia. 
 There are no published studies on the direct role of RAPGEF6 in the nervous system, 
therefore we focused on other RAPGEF family-dependent pathways with neural relevance. One 
mouse study found Rapgef6 expression was positively correlated with astrocyte gliogenesis and 
negatively correlated with adult neurogenesis (Kempermann et al. 2006). The role of Rapgef6 in 
these processes remains unclear. In vitro knock down and overexpression experiments 
demonstrated that RAPGEF6 activated Rap2 more than Rap1, was localized to the membrane by 
MRas, and promoted cadherin and catenin dependent cellular junctions (Dube et al. 2008; Gao et 
al. 2001; Kuiperij et al. 2006; Severson et al. 2009). A mouse model with Rapgef6 deleted had 
no gross anatomical abnormalities, but immune B cells failed to activate integrin signaling for 
cellular adhesion to the extracellular matrix in response to TNFα (Yoshikawa et al. 2007). Since 
integrins and cadherins are also key elements in neural migration and neurite outgrowth (Clegg 
et al. 2003; Suzuki and Takeichi 2008), these findings suggest that Rapgef6 may also participate 
in neural development and morphology. 
 The other members of the Rapgef family and their downstream targets, Rap1 and Rap2, 
have key roles in the nervous system, implying Rapgef6 may be neurally important as well. 
Rapgef1 was activated by neurotrophins and Reelin in neuroepithelial development and neural 




in cortical heterotopia and failure of cortical axons to decussate at the midline within rostral 
commissures (Bilasy et al. 2011; Bilasy et al. 2009). SNPs within RAPGEF3 were associated 
with depression (Middeldorp et al. 2009), while SNPs within RAPGEF4 were associated with 
autism (Bacchelli et al. 2003). Introduction of Rapgef3/4 agonist 8CPT into the hippocampus 
improved contextual fear conditioning in wild type mice (Ma et al. 2009). Although deletion of 
either gene independently produced no demonstrable phenotype, deletion of both Rapgef3 and 
Rapgef4 caused impairments in spatial memory and social interaction as well as a reduction in 
hippocampal long-term potentiation (Yang et al. 2012). Rapgef5 was downregulated during 
neural differentiation (Rebhun et al. 2000).  
There are multiple conflicting reports of Rap1 and Rap2 effects on neural development 
and synaptic function in vitro. In animal models, targeted cortical deletion of Rap1 caused cued 
fear conditioning impairments and disturbed cortico-amygdala synaptic function (Pan et al. 
2008). Constitutively active Rap2 led to hyperactivity, spatial memory deficit, and decreased 
contextual fear extinction on behavioral assessment with reduced CA1 spine density and 
increased hippocampal long-term depression (Ryu et al. 2008). Postmortem brain analysis found 
that Rap1 expression was reduced in individuals with schizophrenia and depression (Yuan et al. 
2010), while Rap2 expression was reduced in the anterior cingulate in patients with 
schizophrenia (Funk et al. 2012). Rapgef and Rap family members are involved in a variety of 
neurodevelopmental, synaptic transmission, and behavior phenotypes. Overall, the convergence 
of genetic data and phenotypes in the literature suggest that Rapgef6 is both a positional and 










5.1.2 Rapgef6 deletion mice demonstrated hyperlocomotion and reduced anxiety 
 We acquired the Rapgef6 deletion mouse model, in which the exon coding for the GEF 
catalytic domain was deleted (Yoshikawa et al. 2007). We performed a comprehensive 
behavioral and morphological assessment to determine the effect of Rapgef6 deletion on 
neuropsychiatrically relevant phenotypes (Figure 5.1). HET and HOM animals were born at 
Mendelian frequencies and were grossly normal for motor abilities and lifespan. Cresyl violet 
staining confirmed that there were no obvious neuroanatomical changes, including no 
heterotopias, and the commissures and hippocampus were intact (Figure 4.2). 
 To understand basic motor function and locomotion, we first performed the open field 
test. On open field testing, HOM and HET animals were hyperactive and showed increased 
rearing, which is considered both a measure of activity and nonspecific attention (Figures 3.3-
3.5). Increased activity in the center of the field demonstrated a lack of anxiety-like behavior in 
HET and HOM animals (Figure 3.4). Dopamine stimulation can increase both locomotion and 
rearing (Berridge 2006; Brookshire and Jones 2009), suggesting that Rapgef6 mice may have 
increased striatal dopamine release or receptor expression, similar to findings in individuals with 
schizophrenia (Abi-Dargham et al. 1998). 
5.1.3 Rapgef6 deletion mice demonstrated mildly impaired hippocampal function and 
morphology 
 We sought to understand the role of Rapgef6 in the hippocampus. While characterization 
of spatial memory did not find many hippocampal-dependent behavioral deficits, there were 
subtle morphological changes in the hippocampus in vivo and in knock out hippocampal neurons 
in vitro, as well as striking reductions in hippocampal neural arbors upon knock down. Novel 




memory, were both unaffected in HOM animals (Figures 3.6-3.9) (Sousa et al. 2006). Contextual 
fear conditioning was impaired in HOM animals in the second cohort with a trend toward 
impairment in the first cohort (Figures 3.16, 3.17). Contextual conditioning involves the 
amygdala as well as hippocampus, although hippocampal function is not necessary (Gerlai 2001; 
Maren 2008).  
In line with mildly altered hippocampal performance on contextual fear conditioning but 
not spatial memory tasks, in vivo morphology of the basal dendritic arbor was not significantly 
altered in hippocampal area CA1 (Figures 4.5, 4.6). In CA3, the only significant changes were a 
reduction in the primary dendritic length in HET animals and an increase in dendritic complexity 
far from the soma on Sholl analysis in HOM neurons (Figures 4.3, 4.4). When spine density was 
measured, density was reduced in CA3 but not CA1 in HOM neurons (Figure 4.7). Similar to in 
vivo results, cultured hippocampal neurons had no significant changes in axon or dendritic 
measures except a reduction in primary dendrite number and length in HET neurons with a trend 
in HOM neurons (Figure 4.11). Spine density was not affected in vitro. As BDNF and NT4 are 
neurotrophic factors that increased primary dendritic outgrowth via GTPases (McAllister et al. 
1995), it is possible that Rapgef6 might be downstream of these ligands, accounting for the 
specific deficit in primary dendrites. Upstream Rapgef6 mediators are currently unknown in the 
brain. 
In contrast, hippocampal neurons transfected with shRNA to knock down Rapgef6 had 
reduced axon length as well as dendritic length and complexity but greatly increased spine 
density (Figures 4.14, 4.15). Discrepancies between knock out and knock down results are 




tissue conditions. Since in vivo morphology is more relevant to animal behavior and more 
analogous to human neuroanatomy, we emphasize in vivo results over in vitro findings.  
In order to better understand hippocampal function during a behavioral task, we analyzed 
cFOS immureactivity as a measure of neural activation after cued fear conditioning. cFOS 
activation demonstrated impaired CA3 and CA1 neural activation following cued fear 
conditioning recall. In the dentate gyrus, HOM animal cFOS levels were reduced regardless of 
conditioning (Figure 3.19). Though loss of Rapgef6 only subtly affected hippocampal 
morphology (and the trisynaptic pathway was not directly assessed), our cFOS results imply 
there may be synaptic dysfunction throughout the hippocampus during fear conditioning. If this 
phenotype extends to other behavioral tasks, then the hippocampus may by hypoactive and 
inefficient at processing and recalling memories in the absence of Rapgef6. 
In summary, spatial memory was intact and contextual fear memory impaired in the 
setting of reduced primary dendrites and CA3 spine density as well as decreased cFOS activation 
throughout the hippocampus. The small effect of Rapgef6 deletion on dendritic growth and spine 
formation in vivo may influence neurotransmission, leading to the deficit we observed in certain 
hippocampal behavioral functions. 
5.1.4 Rapgef6 deletion impaired amygdala function but not spine density  
 Both fear conditioning cohorts demonstrated impairments in contextual and cued fear 
learning to varying extents, although the two cohorts differed in their pretest training (Figures 
3.16-17). Fear conditioning is the canonical paradigm to probe amygdala function in learning 
and memory (Maren 2008). Anxiety as measured by open field testing and sensory motor gating 
as assessed by prepulse inhibition are phenotypes that are modulated by the amygdala and were 




amygdala lesion studies do not support a role for the amygdala in modulating baseline startle 
response, some mouse models report overlapping fear and startle deficits as amygdala dependent. 
For example, injection of acetylcholine receptor agonist into the nucleus accumbens led to 
deficits in startle and contextual fear conditioning as well as hyperlocomotion, a behavioral 
profile matching Rapgef6 deletion (Cousens et al. 2011). This suggests that analysis of 
acetylcholine signaling and the nucleus accumbens may help explain the mechanism of Rapgef6 
effects on the amygdala. Thus amygdala dysfunction was present in the Rapgef6 mouse across 
many behavioral paradigms including learned and unlearned fear. 
 We investigated the pathology leading to this behavior result by examining spine density 
in the amygdala. Spine density on the basal and apical dendritic arbors of lateral and basolateral 
pyramidal neurons was not affected in vivo upon Rapgef6 KO (Figure 4.8). Yet there was a 
significant failure of Rapgef6 HET and HOM animals to activate cFOS in the basolateral nucleus 
following fear conditioning (Figure 3.19). There are other examples of mouse models, such as 
the Stathmin knock out, with fear deficits, normal amygdala morphology, but altered amygdala 
neurotransmission (Shumyatsky et al. 2005). Given the strong behavioral phenotype of fear 
impairment with cFOS evidence for amygdala hypoactivity, either the morphology study was 
underpowered to detect spine density changes or the pathophysiology lies at the level of synaptic 
transmission strength.  
5.1.5 Rapgef6 deletion did not affect prefrontal cortex  
 Although Rapgef6 is expressed in the prefrontal cortex, we found no evidence for 
dysfunctional behavior or morphology in this brain region. Rapgef6 KO animals had no 
significant deficits on the T maze protocol assessing prefrontal cortex dependent working 




dendritic arbor of layer V pyramidal neurons in the medial prefrontal cortex found no significant 
genotype differences (Figures 4.9-10). Our paradigms may have missed the pathology, for 
example a more complicated maze task or analysis of layer II/III neural morphology might be 
affected. Alternatively, while Rapgef6 is widely expressed it might be redundant in certain 
circuits but necessary in others, such as the amygdala. 
5.2 Validity of Rapgef6 deletion as a model of schizophrenia 
 The evidence summarized above demonstrates the validity of this mouse as a 
schizophrenia model. At the genetic level, recent research has validated the finding that rare 
CNVs are significantly associated with schizophrenia etiology (Malhotra and Sebat 2012). We 
identified a rare CNV affecting RAPGEF6 and chose to model the deletion because the 
convergent genetic data at this gene locus make it a strong candidate for schizophrenia risk.  
 At the behavioral and morphological levels, the Rapgef6 KO mouse demonstrated many 
but not all of the archetypal schizophrenia endophenotypes amenable to rodent modeling. The 
Rapgef6 mouse demonstrated impairment in fear, anxiety-like behavior, and prepulse inhibition, 
an increase in locomotion, and diminished activation in the hippocampus and amygdala all of 
which are clinically relevant to neuropsychiatric disease. KO animals were hyperactive and this 
may represent psychomotor agitation in patients (Powell and Miyakawa 2006). Both locomotion 
and rearing rates have been positively linked to dopamine function, suggesting these mice may 
have dopaminergic imbalances in striatal circuits (Berridge 2006; Brookshire and Jones 2009). 
Prepulse inhibition deficit is a well-recognized and defined schizophrenia endophenotype 
(Powell et al. 2009). Such sensory disturbances might form the basis for hallucinations and 
delusions (Dulawa and Geyer 2000). HET animals had decreased prepulse inhibition, while 




  Schizophrenia patient meta-analyses found amygdala volume was significantly reduced 
(Shepherd et al. 2012) and amygdala function was diminished in fMRI studies during emotional 
tasks (Anticevic et al. 2012). Although postmortem analysis found no change in amygdala 
volume on histological analysis, amygdala gene expression results found altered synaptic and 
signaling pathways in patients (Berretta et al. 2007; Chance et al. 2002; Weidenhofer et al. 
2006). These results have led to the proposal that amygdala dysfunction may underlie negative 
schizophrenia symptoms (Pietersen et al. 2007). Reduced anxiety on the open field test and 
diminished cued and contextual fear conditioning, in light of reduced basolateral amygdala cFOS 
activation, strongly suggest that there is amygdala dysfunction in Rapgef6 animals which is not 
captured by our spine density analysis but which may be relevant to schizophrenia 
pathophysiology. 
 Studies of the hippocampus in individuals with schizophrenia consistently yield 
reductions in volume, even in first episode psychosis (Adriano et al. 2012; Steen et al. 2006) and 
impairments in hippocampal memory tasks that contribute to cognitive symptoms (Tamminga et 
al. 2010). Postmortem, patient brains had decreased interneurons and fewer mossy fiber synapses 
(Kolomeets et al. 2007; Konradi et al. 2011). While we found that Rapgef6 KO mice had no 
significant changes on spatial memory tasks such as novel object recognition or the Morris water 
maze, they showed impairment in contextual fear conditioning, aligning with less cFOS 
activation in the CA3 and CA1 after fear conditioning and less cFOS in the dentate gyrus 
independent of conditioning. CA3 spine density and primary dendrite number were also reduced 
in vivo.  
 We did not find evidence for working memory deficits or structural changes in layer V of 




schizophrenic patients, limiting reduced spine density findings to layer II/III only (Glantz and 
Lewis 2000; Kolluri et al. 2005). Similarly, functional studies confirmed reduced PFC activation 
during working memory tasks (Glahn et al. 2005) and diminished working memory performance 
across a range of testing paradigms (Lee and Park 2005). These domains appear to be unaffected 
by Rapgef6 deletion. 
 In comparison with other rare mutation models of schizophrenia, the Rapgef6 mouse 
demonstrates a certain degree of phenotypic overlap. 22q11 mice were hyperactive but had 
increased anxiety (Stark et al. 2008). While no schizophrenia models had impaired baseline 
startle, PPI was reduced following deletion of 22q11 and Dgcr8 but not Disc1 (Koike et al. 2006; 
Stark et al. 2008). Of those three models, only the 22q11 model displayed fear conditioning 
impairments, but all three had working memory deficits on the T maze and other tasks (Koike et 
al. 2006; Kvajo et al. 2008; Stark et al. 2008). Disc1 mice had dysmorphic adult-born neurons in 
the dentate gyrus, while 22q11 and Dgcr8 mice had reduced CA1 arbors and spine densities in 
vivo, and this held true in vitro for the 22q11 mouse as well (Kvajo et al. 2008; Mukai et al. 
2008; Stark et al. 2008). Considering other neuropsychiatric disease models, we have not yet 
identified any mouse with reduced startle and impaired PPI in the setting of normal audition. Our 
results overlap somewhat, but not entirely, with the amygdala deficit in Rap1 cortical deletion 
mouse (Pan et al. 2008). As described above, our behavior results resemble those of nucleus 
accumbens injection of acetylcholine receptor agonist (Cousens et al. 2011). Thus the Rapgef6 
mouse model possessed a unique behavioral and morphological phenotype. 
Deletion of Rapgef6 possibly subtly reduces neurotrophic signaling and neural adhesion 
for connectivity, leading to small changes in synapse number in CA3 and diminished synaptic 




possibly between, these regions negatively impacts fear-related learning as well as unlearned fear 
or anxiety. The hyperlocomotion and reduced startle observed in this mouse may represent a 
disinhibition of exploration and a lessening of reflexive fear responses in the setting of reduced 
anxiety. Alternatively, these phenotypes may indicate that connectivity changes extend to the 
dopaminergic system. Comparison with other animal models suggests that acetylcholine and 
norepinephrine function could also be affected in this model and should be examined in order to 
better understand the pathology.  
Our aim in analyzing this Rapgef6 model is to contribute to our understanding of 
schizophrenia pathogenesis and the development of novel treatments that target disease 
mechanisms. Our model is based on human genetics results, leading to etiologic validity. 
Rapgef6 KO mice demonstrated schizophrenia related endophenotypes such as hyperactivity, 
impaired prepulse inhibition, diminished fear conditioning and anxiety, and cFOS functional 
reductions in hippocampal and amygdala activity, yielding face validity. As these phenotypes are 
not specific to schizophrenia, this mouse may also inform our comprehension of anxiety 
disorders through the role of the amygdala in generating learned and unlearned fear, or 
interactions between the amygdala and hippocampus. Whether this mouse is useful for 
therapeutic testing and predictive validity remains to be seen. 
In conclusion, this model contributes to our understanding of schizophrenia in a specific 
domain. Though the prefrontal cortex and hippocampus are major research targets in 
schizophrenia, we do not find changes in the prefrontal cortex and hippocampal deficits are 
minimal. Strikingly, the major phenotypes in this mouse model are reduced anxiety and fear 
learning, indicating the amygdala is the structure most affected by Rapgef6 deletion. Rapgef6 




findings of decreased amygdala size and function in patients with schizophrenia. Amygdala 
dysfunction could contribute to negative schizophrenia symptoms. Therefore, this model 
provides evidence about the involvement of the amygdala in negative symptoms, as opposed to 
the positive or cognitive symptoms typically targeted in animal systems. 
5.3 Model limitations 
 There are several reasons why the rodent phenotype of Rapgef6 deletion was less severe 
than we had predicted based on other mouse models of the Rapgef family. First, the effect of the 
RAPGEF6 CNV in the patient with schizophrenia may have been modulated by additional, 
unidentified mutations. Such phenotype modulation is known as the two-hit hypothesis for rare 
mutations (Coe et al. 2012). There is direct evidence that having additional rare CNVs correlated 
with worsening developmental delay phenotype from the recurrent 16p12.1 deletion (Girirajan et 
al. 2010). This result can be interpreted more broadly to suggest that other rare or even common 
alleles may modify the phenotypic outcome caused by a large scale rare mutation. As discussed 
below, these extra hits could be modeled by crossing our line with other modifying mutations, 
either identified from patients or based on candidate interacting genes. For example, we could 
reduce compensation by crossing into deletion or hypomorph lines of other Rapgefs or Raps. 
There may be a variety of additional mutations or risk alleles not assessed in the CNV study that 
contribute to the human phenotype but are not currently modeled in the mouse. 
 Furthermore, the mouse mutation and genetic background may contribute to reduced 
penetrance. This mouse mutation does not exactly mimic the human CNV in terms of which 
gene regions were deleted; instead the mutation in the mouse models the effect of a catalytically 
dead protein that Western blotting demonstrates is not expressed (Yoshikawa et al. 2007). 




human or mouse genomes after the respective deletions, it is possible there are unidentified 
isoforms in each species that partially compensate for the deletion effects. Concerning the 
genetic background, this mutation was generated in 129Sv oocytes and then backcrossed onto the 
C57Bl/6 background (Yoshikawa et al. 2007). As mentioned in Chapter 3, inbred strains have 
varying phenotypes at baseline, with C57Bl/6 considered moderate on anxiety measures and 
strong on maze tasks (Crawley 2008; D'Hooge and De Deyn 2001). Crossing the Rapgef6 
deletion onto another background would be interesting as a method for dissecting the effects of 
the deletion from the background. For example, a more anxious background might ameliorate the 
fear conditioning phenotype, while a background with worse hippocampal function might 
uncover spatial memory deficits. Thus, the accuracy of how the mutation mimics the human 
genetic findings and the subtle genome-wide influences of background strain may limit 
schizophrenia-related endophenotype expression. 
 Interestingly, the phenotypes of HET and HOM animals did not always align. For 
example, while both genotypes had reduced neural activity on cFOS analysis, HET animals did 
not demonstrate reduction in CA3 spine density or some behavioral deficits. Therefore there is 
dissociation between the phenotypes by genotype, implying the behavioral and morphological 
deficits following complete Rapgef6 deletion may not be entirely due to neural activity changes. 
Alternatively, compensation mechanisms are more likely to occur in complete deletion as 
opposed to the heterozygous state. This could explain why on certain phenotypes HET but not 
HOM animals were significantly affected. A careful comparison of genotype results helps inform 
potential mechanisms in this mouse model. 
Finally, the evolutionary differences in brain development between humans and mice 




decades because there is high genetic homology between mice and humans as well as strong 
similarity between brain region specific gene expression profiles (Strand et al. 2007), however, 
this does not guarantee that individual genes will serve analogous purposes in development and 
function. Though human and mouse Rapgef6 proteins share 90% amino acid identity 
(blast.ncbi.nlm.nih.gov), it is possible they do not share the same expression pattern or 
functionality in both species, leading to differing phenotypes upon deletion. Moreover, we aim to 
model schizophrenia, a uniquely human disease state that is challenging to translate into animal 
models. While there are endophenotypes of cognitive and negative symptoms discussed above 
that can be accurately measured in both species, many symptoms are not amenable to modeling. 
Interspecies differences may be masking or invalidating phenotypes in our model. 
5.4 Future directions  
5.4.1 Human genetics 
 With neuropsychiatric genetics progressing at a rapid pace, it is likely that more 
mutations in RAPGEF gene family members will be discovered. We intend to monitor results 
from exome and genome sequencing as well as future CNV studies for additional mutations 
affecting this gene family. To date, CNV results suggest large scale mutations of RAPGEFs in 
schizophrenia are private and very rare as our laboratory was the only one to uncover such CNVs 
in the literature. While there were no de novo pathological mutations affecting RAPGEFs in 
published exome sequence data, there will be far more genetic data available shortly as more 
consortia and laboratories invest in sequencing technology. Identification of additional mutations 
would strengthen the association of this gene family with disease and thus bolster the etiological 
validity of Rapgef models. Moreover, smaller scale mutations could identify critical protein 




5.4.2 Animal behavior 
Although we have assessed the Rapgef6 deletion mouse for phenotypes related to 
locomotion, spatial and fear learning, and sensory processing, behavioral testing in this mouse 
line is far from exhausted. Additional behavioral phenotyping would clarify known deficits and 
possibly identify novel dysfunction.  
One of the domains to further explore is anxiety-like and fear behavior. While our open 
field results suggested reduced anxiety, more validated paradigms to pursue are the elevated plus 
maze and light-dark box (Bailey and Crawley 2009). Furthermore, the fear conditioning 
impairment could be more accurately assessed by adding habituation to remove the novel 
contextual fear generalization and extinction training to test prefrontal cortex contributions 
(Jacobs et al. 2010; Knapska and Maren 2009). Anxiety is an important behavioral trait to assess 
because there is high comorbidity between schizophrenia and anxiety disorders (Achim et al. 
2011). It would be useful to determine more accurately whether the Rapgef6 mouse phenotype 
also includes comorbid behavioral changes and the extent of amygdala dysfunction. 
There are no Rapgef6-specific agonists or antagonists we can use to alter function, nor 
are there any pharmaceutical options that target up- or downstream pathways that are specific to 
Rapgef6. There is a specific agonist of Rapgef3 and 4, the cAMP mimic 8CPT (Bos 2006). 
Administering this compound to Rapgef6 KO mice would test whether Rapgef3/4 can 
compensate to rescue behavioral deficits. Since 8CPT increased prepulse inhibition and fear 
learning in wild type animals and these domains are affected in Rapgef6 mice, it is likely such an 
intervention would be beneficial (Kelly et al. 2009). While a positive response would not prove 
that Rapgef3/4 and their associated pathways are affected following Rapgef6 deletion, it would at 




Given the two-hit hypothesis of neurodevelopmental disease, it might be useful to cross 
the Rapgef6 line with other modifying mutations (Coe et al. 2012). Additional rare CNVs were 
not identified in individuals harboring RAPGEF6 and 2 CNVs, however they may carry more 
common large scale mutations or rare single nucleotide variants that could interact with the 
RAPGEF loci to increase the genetic risk of schizophrenia. Modifying mutations would 
presumably affect genes that interact with RAPGEF6, thereby informing our understanding of its 
pathways. Alternatively, we could test compensation by crossing Rapgef6 KO animals with 
those lacking Rapgef3 or Rapgef4. A worsening of phenotype would indicate that other family 
members typically counterbalance the loss of Rapgef6 function. 
5.4.3 Cellular pathophysiology 
 Currently, we cannot explain which neurobiological alterations led to behavioral 
impairments in the Rapgef6 mouse model since neural morphology was not greatly altered and 
cFOS activation findings only apply to cued fear conditioning. We are still seeking the level of 
affected function. Our behavioral results were similar to the Rap1 mouse model that had 
increased cortico-amygdala synaptic transmission (Pan et al. 2008), in addition spine density was 
reduced in the hippocampus yet overall morphology was intact; therefore we predict the 
dysfunction occurs at the synaptic level. This hypothesis could be tested via slice 
electrophysiology recording in the hippocampus and amygdala. Furthermore, to test specific 
neurotransmitter systems such as dopamine and acetylcholine, which might be influenced by 
Rapgef6 based on comparison of our phenotype with the literature, we could employ specific 
receptor agonists and antagonists during slice electrophysiology. Schizophrenia does not have 
dramatic neuropathological findings, supporting the idea that it is a disease of circuit 




circuitry in schizophrenia-relevant regions such as the hippocampus and amygdala, that would be 
further evidence for etiological validity. 
Rapgef6 modulates cadherin and integrin signaling in lymphocytes, therefore we predict 
these adhesion pathways are also altered in neurons (Dube et al. 2008; Yoshikawa et al. 2007). 
Integrin and cadherin families are critical to neural migration and morphology (Clegg et al. 2003; 
Suzuki and Takeichi 2008). To assess these pathways, we could analyze cortical migration using 
BrdU or electroporation labeling or cortical layer immunohistochemistry. Functional impairment 
of cadherins and integrins can be easily quantitated via neural adhesion assays in vitro (Denda 
and Reichardt 2007). These experiments could determine whether integrin and cadherin 
expression and function are altered, providing clues to a mechanism by which Rapgef6 deletion 
leads to cellular phenotypes. 
5.5 Conclusion 
In conclusion, we have described human mutations affecting the RAPGEF family and 
have translated one of these mutations into a mouse model with Rapgef6 deleted. Behavioral and 
morphological experiments demonstrated deficits in the amygdala and hippocampus, brain 
regions implicated in schizophrenia pathophysiology at a variety of levels. The exact cause of 
Rapgef6 pathology has not yet been determined, but the dysfunction appears to be due to subtle 
spine density changes as well as synaptic hypoactivity. Continued investigation may yield a 
deeper understanding of amygdala and hippocampal pathophysiology as well as novel 
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